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SUMMARY
1. Four groups of rabbits were set up to investigate the separate and combined 
effects of hypertension and hypercholesterolemia on a number of cardiovascular 
parameters, including in vivo vascular reactivity, phosphoinositide metabolism in 
aortic tissue, and platelet [Ca^+]^  concentrations. The four groups were: a control 
group, a hypertensive group (perinephritis hypertension), a hypercholesterolemic 
group (0.3% cholesterol diet), and a hypertensive-hypercholesterolemic group.
2. As the basic pharmacology of one of the agonists used in this work, endothelin, 
was poorly understood at the time these studies were planned, prelim inary 
investigations into its effects in normotensive-normocholesterolemic animals were 
undertaken before em bark ing  on the m ain p ro ject. In add ition , some 
phosphoinositide studies were done using rat aorta.
Endothelin -1 caused a dose-related increase in phosphoinositide hydrolysis in 
both rat and rabbit aorta. In rat aorta, endothelin-1-induced phosphoinositide 
hydrolysis increased with stimulation time for the first 30 minutes, and thereafter 
plateaued. The endothelin-stimulated effects were attenuated with endothelium 
rem oval, or with ex tracellu lar Ca depletion. The endothelin -l-induced  
phosphoinositide hydrolysis was greater in rat aorta than in rabbit aorta.
In vivo endothelin-1 caused a short-lived depressor response followed by a long- 
lasting pressor response in the rabbit. The pressor response was dose-related, and 
could be attenuated by the calcium antagonist nifedipine.
3. The imposition of perinephritis hypertension caused an increase of about 40 
mmHg in mean arterial pressure in the operated rabbits, which stabilized after 6-7 
weeks, while feeding a 0.3% cholesterol diet induced a continual rise in plasma
cholesterol levels in the rabbits, which reached 30 mmol/L after 4 months.
In contrast to 0.3% cholesterol diet, perinephritis hypertension was a significant 
risk factor for cardiovascular deaths in the course of a 4-month study. There were 
significantly greater numbers of cardiovascular deaths in both the hypertensive and 
the hypertensive-hypercholesterolemic groups versus the control group (p= 0.038 
and 0 .009, respective ly ), but no s ig n ifican t d ifferen ce  betw een the 
hypercholesterolem ic and the control group, or between the hypertensive- 
hypercholesterolemic and the hypertensive group. However, it is noteworthy that 
when the hypertensive-hypercholesterolem ic group was com pared to the 
hypertensive group, 0.3% cholesterol diet tended to augment the cardiovascular 
deaths in these hypertensive animals.
4. The imposition of perinephritis hypertension enhanced the pressor responses to 
angiotensin n, and endothelin-1, as well as the depressor responses to acetylcholine, 
isoproterenol, and nitroprusside at 2-3, 6-7, and 13-16 weeks of study. The 
differences tended to increase with the duration of hypertension for the pressor 
responses, but not for the depressor responses. The patterns of changes in the 
duration of hypertension differed from one pressor agonist to another, suggesting 
that structural changes in the vessel wall were not the sole explanation for enhanced 
vascular reactivity. Similar conclusions held for the depressor agonists. In contrast, 
the imposition of 0.3% cholesterol diet had no effect on the in vivo vascular 
reactivity at any time point of the study, whether given to normotensive or 
hypertensive animals.
5. Neither perinephritis hypertension nor 0.3% cholesterol diet caused any changes 
in the basal platelet [Ca^^j at the 17th week of study.
6. At the 18th week of study, perinephritis hypertension tended to enhance the 
noradrenaline-stimulated, but not the endothelin-stimulated phosphoinositide 
hydrolysis in rabbit aorta, but the difference was significant only at 10 '^  M 
noradrenaline for the hypertensive versus the control group. In contrast, 0.3% 
cholesterol feeding tended to decrease both noradrenaline- and endothelin- 
stimulated, phosphoinositide hydrolysis. The difference was significant at 10'^ M 
noradrenaline for the hypercholesterolemic versus the control group, as well as for 
the hypertensive-hypercholesterolemic versus the hypertensive group, and at 10“^  & 
10~^ M endothelin-1 for the hypertensive-hypercholesterolem ic versus the 
hypertensive group.
There was no difference in the basal [ H]-inositol phosphates formation between 
any experimental group and the control group, suggesting that neither perinephritis 
hypertension  nor 0.3%  ch o les te ro l d ie t for 18 weeks a ltered  the basal 
phosphoinositide metabolism in rabbit aorta.
7. Overall, in our study no significant additive effects of the two disease states were 
observed in any of the parameters examined. However, the number of biochemical 
responses, vessels and animals examined were limited, and further studies might 
identify sites of interaction between the two parameters.
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CHAPTER 1 
GENERAL INTRODUCTION
1
Chapter 1. General Introduction
1.1. Hypertension, hypercholesterolemia, and atherosclerosis: An overview
1.1.1 Atherosclerosis as the most important cause of cardiovascular morbidity and
mortality
Cardiovascular diseases are the most common cause of death in modem western 
countries. Atherosclerosis is the principal underlying cause of cardiovascular 
diseases; it has been estimated that atherosclerosis accounts for 85% of deaths from 
cardiovascular diseases (Fraser, 1986). Moreover, clinical manifestations of 
cardiovascular diseases, such as angina pectoris, myocardial infarction, sudden 
death, and stroke, are chiefly attributable to atherosclerosis (Kannel & Sytkowski,
1987).
It is now recogn ized  that a therosc lero tic  card io v ascu lar d iseases are 
"multifactorial" in etiology. Age, sex, hypercholesterolemia, hypertension, diabetes 
mellitus, obesity, cigarette smoking, oral contraceptives, sedantary lifestyle, Type A 
personality, family history, and menopause have all been proposed as "risk factors" 
for atherosclerotic diseases (Kannel & Sytkowski, 1987). Among them, the major 
risks w hich are also am enable to in terven tion  are hypertension , 
hypercholesterolemia, and cigarette smoking (Dal Palu & Zamboni, 1990; Stamler,
1988). The role of two of these factors, hypertension and hypercholesterolemia, will 
be discussed in more detail.
1.1.2. Hypertension as a risk factor for atherosclerosis
In the Framingham Study, the epidemiology of the potential cardiovascular risk 
factors of white Americans in a U.S. northeastern town was extensively followed for 
more than 20 years. The results from this study strongly indicated that hypertension 
is an important and independent risk factor for atherosclerosis (Dawber, 1980). The
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incidence of coronary, cerebral, or peripheral arterial diseases increased significantly 
with the rise of systolic as well as diastolic blood pressure. There was no critical 
point of exemption from the diseases, and even in the "normotensive" population, 
the relative risk increased progressively with the rise in blood pressure. "Blood 
pressure elevation" as a risk factor for atherosclerotic diseases has also been 
identified from various prospective studies worldwide, including Seven Countries 
(Finland, Greece, Italy, Japan, Netherlands, U.S.A., & Yugoslavia) (Keys, 1980), the 
Pooling Project (U.S.A.) (The Pooling Project Research Group, 1978), and several 
epidemiological studies from Australia (Welbom et al, 1969), Japan (Shimamoto et 
al, 1989), Norway (Holme et al, 1980), Puerto Rico (Garcia-Palmieri & Costas, 
1986), Sweden (Carlson & Bottiger, 1985), and United Kingdom (Reid et al, 1976).
In addition, when blood pressure is lowered by various anti-hypertensive drugs, 
there is a reduction in stroke and coronary events; this strengthens the status of high 
blood pressure as an important risk factor (Collins et al, 1990).
1.1.3. Hypertension in the pathogenesis of atherosclerosis
In human autopsy studies from worldwide sources, it has been reported that 
blood pressure is positively and significantly correlated with the severity of 
atherosclerotic lesions (Robertson & Strong, 1968; Solberg & Strong, 1983).
In animal studies, hypertension can induce a host of changes conducive to 
atherosclerosis, such as endothelial-cell shape changes (Chobanian, 1990), reduced 
endothelium-dependent vascular relaxation (Luscher, 1988; Vanhoutte, 1989), 
enhanced endothelial permeability (Chobanian, 1983), adherence of monocytes, 
lymphocytes, and granulocytes to the endothelial surface (Chobanian, 1990), 
macrophage accumulation and smooth muscle cell migration into the intima 
(Chobanian, 1990), intimal thickening (Chobanian, 1990), hypertrophy, hyperplasia, 
hyperploidy of smooth m uscle cells in the m edia (Chobanian, 1990), and
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extracellular accumulation of connective tissue such as proteoglycans, collagen, and 
elastin in the media (Chobanian, 1990). One point of note from these studies is that 
while intimal and medial thickening are commonly observed in hypertensive 
animals, increased lipid accumulation or accelerated atherogenesis requires the co­
existence of hypercholesterolemia (Chobanian, 1983; Chobanian, 1990).
1.1.4. Hypercholesterolemia as a risk factor for atherosclerosis
The Framingham Study (Dawber, 1980), the Pooling Project (The Pooling 
Project Research Group, 1978), and the Seven Countries study (Keys, 1980) all 
strongly indicated that in addition to hypertension, hypercholesterolemia is a potent 
and independent risk factor for atherosclerotic diseases. Epidemiological studies 
from Australia (Welborn et al, 1969), Finland (Pelkonen et al, 1977), Israel 
(Goldbourt & Yaari, 1990), Japananese emigrants in Hawaii (Kagan et al, 1981), 
Norway (Holme et al, 1980), Puerto Rico (Garcia-Palmieri & Costas, 1986), Sweden 
(Carlson & Bottiger, 1985), and United Kingdom (Reid et al, 1976) are all consistent 
with the hypothesis that serum cholesterol levels are significantly correlated with 
card iovascu lar events. The c lin ica l h isto ry  of hom ozygous fam ilia l 
hypercho lestero lem ic patien ts also h igh ligh ts the im portance of 
hypercholesterolemia in the pathogenesis of atherosclerosis. These patients have six 
to ten times the normal concentrations of plasma low density lipoproteins (main 
carrier of plasma cholesterol), and often suffer severe coronary atherosclerosis and 
premature death in childhood, even in the absence of other major risk factors such as 
hypertension, diabetes mellitus, or cigarette smoking (Brown & Goldstein, 1986).
The impressive reduction of coronary events in hypercholesterolemic patients 
treated with cholesterol-lowering drugs in two major prospective studies ( The Lipid 
Research Clinics Coronary Primary Prevention Trial and The Helsinki Heart Study) 
also confirms the significant role of hypercholesterolemia in atherosclerosis (Lipid 
Research Clinics Program, 1984; Frick et al, 1987).
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1.1.5. Hypercholesterolemia in the pathogenesis of athersclerosis
In human autopsy studies from worldwide sources, it has been reported that 
plasma cholesterol was positively and significantly related to the severity of 
atherosclerotic lesions (Solberg & Strong, 1983). Results from in vivo coronary 
angiography also support this conclusion (Dahlen et al, 1986; Holme et al, 1981).
In animal studies, hypercholesterolemia has been reported to induce a host of 
changes in the blood vessels conducive to atherosclerosis, such as endothelial-cell 
shape changes, enhanced endothelial perm eability , leukocyte adherence, 
macrophage accumulation and smooth muscle cell migration into the intima, smooth 
m uscle cell proliferation  in the intim a and m edia, cholesterol deposition, 
extracellular matrix accumulation, foam cell accumulation, intimal thickening, and 
atherosclerotic plaque formation (Chobanian, 1990; Masuda & Ross, 1990a; Masuda 
& Ross, 1990b; Rosenfield et al, 1987a; Rosenfield et al, 1987b).
1.1.6. Hypertension and hypercholesterolemia as coexistent or interactive risk 
factors in atherosclerosis
Although the beneficial effect of a reduction in stroke events by means of 
lowering blood pressure in patients with hypertension is widely recognized, the 
outcome of treating mild to moderate hypertension is less obvious in terms of 
reduction in coronary events (MacMahon et al, 1986; Collins et al, 1990).
Results from clinical trials in mild-to-moderate hypertensive patients suggest:
(1) In a hypertensive population, lowering blood pressure results in a greater 
reduction in stroke events than in coronary events (MacMahon et al, 1986; Collins et 
al, 1990). One of the explanations proposed is that the incidence of hemorrhagic 
strokes, the direct complication of hypertension, can be reduced by lowering blood 
pressure, while it is more difficult to reduce the incidence of so-called indirect
5
com plications such as m yocardial infarction (Dal Palu & Zamboni, 1990). 
Moreover, the metabolic side effects of anti-hypertensive drugs might offset the 
benefits of blood pressure reduction for coronary risks. For example, (3-blockers are 
known to reduce the "protective" plasma high-density lipoprotein levels, and 
thiazide diuretics are known to increase plasma cholesterol levels (MacMahon et al, 
1986; Collins etal, 1990).
(2) The "Multiple Risk Factor Intervention Trial"— a large-scale study to investigate 
the effect of blood pressure lowering, diet counselling to reduce plasma cholesterol, 
and advice to reduce smoking, showed that measures to reduce cholesterol and 
smoking did result in a significant reduction of coronary heart disease, whereas anti­
hypertensive drug therapy did not (Multiple Risk Factor Intervention Trial Research 
Group, 1982).
It is particularly significant against this background that until recently, most 
efforts in combating atherosclerotic diseases have been directed towards blood 
pressure reduction. These studies suggest that a "multiple-risk-factorial" approach in 
combating atherosclerotic diseases should be considered. In the middle-aged and 
elderly population, generally there is a picture of several concomitant risk factors at 
play in atherogenesis. The relative risks are cumulative according to the number and 
extent of risk factors present in each patient (Kannel & Sytkowski, 1987). The 
possible interplay of risk factors such as hypertension and hypercholesterolemia in 
the atherosclerotic process warrants further investigation (Reid, 1988).
1.2. Changes in vascular function in hypertension, hypercholesterolemia, and 
atherosclerosis
1.2.1. Changes in vascular function in hypertension
The cause(s) of essential hypertension has been in question for several decades. 
Furthermore, the mechanisms by which primary or secondary hypertension in 
humans or animals progresses to the established, sustained state of hypertension,
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with elevated peripheral resistance as its hallmark, are far from clearly defined. Even 
in the established phase of hypertension, there are qualitative as well as quantitative 
differences between different types of hypertension in the vascular reactivity to 
various agonists. In this context, numerous researchers have investigated  
haem odynam ic and functional changes in the vasculature in and after the 
development of hypertension. In addition, haemodynamic and functional studies 
have been carried out with regard to hypercholesterolemia and atherosclerosis. 
Changes in vascular function can be categorized as follows:
(1) Changes in endothelial permeability.
(2) Changes in endothelium-dependent vascular relaxation or contraction.
(3) Changes in vascular smooth muscle reactivity to various agonists.
(1) Enhanced endothelial permeability may be observed in hypertensive animals 
before any structural lesions occur. In hypertensive animals, investigators have 
demonstrated increased vascular permeability to colloid particles (iron and carbon), 
small molecules such as horseradish peroxidase, plasma proteins including 
fibrinogen, red blood cells, and platelets (Wiener & Giacomelli, 1983). It has been 
proposed that the permeability change is due to the haemodynamic (wall shear) 
stress (Fry, 1973), the mechanically coupled enzymatic mechanisms for generating 
histamine (Huttner & Gabbiani, 1983), or the vasculotoxic effect of renin and 
angiotensin II (Wiener & Giacomelli, 1983).
(2) Changes in endothelium-dependent vascular relaxation or contraction
Ever since the seminal finding of Furchgott & Zawadzki (1980) that rabbit aortic 
strips in organ baths could respond to low concentrations of acetylcholine by "vaso­
relaxation" only in the presence of intact endothelium, the crucial role of the 
vascular endothelium not only as a passive barrier, but also as an active participant 
in the regulation and modulation of local vascular tone has become increasingly 
appreciated (Vanhoutte, 1989). Vascular endothelium or cultured endothelial cells
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can generate and release short-lived endothelium-derived relaxing factors. The major 
endothelium-derived relaxing factor is probably nitric oxide, which causes muscle 
relaxation by an increase in intracellular cGMP concentration (Furchgott, 1990; 
Vanhoutte, 1989). It has been reported that in cultured endothelial cells, the 
precursor of nitric oxide is L-arginine (Palmer et al, 1988). Estimated half-life values 
for endothelium-derived relaxing factor ranged from 6 to 50 seconds (Furchgott, 
1990). Endothelium-derived relaxing factor is generated and released ubiquitously in 
large vessels as well as resistance arteries, and veins. In addition to basal release, 
release of endothelium-derived relaxing factor can be stimulated by flow-induced 
increase  in shear stress, by vasoactive  horm ones (e.g. vasop ressin ), by 
neurotransmitters (e.g. acetylcholine and substance P), by autocoids that modulate 
local blood flow, especially during inflammation (e.g. histamine and bradykinin), 
and by substances involved in haemostasis (e.g. thrombin, serotonin, and adenosine 
diphosphate released from platelets). Endothelium-derived relaxing factor also 
possesses anti-aggregation and anti-adhesion activities toward platelets (Furchgott, 
1990; Vanhoutte, 1989).
There are numerous reports showing that the endothelium-dependent vascular 
relaxation is impaired in large vessels as well as in resistance arteries, from animals 
with primary or secondary hypertension, compared to controls from normotensive 
animals (Luscher, 1988; Sunano et al, 1989; Tesfamariam & Halpern, 1988; 
Lockette et al, 1986). The impaired relaxation was associated with a decreased 
cGMP production. (Shirasaki et al, 1988) Impaired endothelium-dependent vascular 
relaxation was also demonstrated in forearm resistance vessels from patients with 
essential hypertension (Linder et al, 1990; Panza et al, 1990).
In addition to the production of the endothelium-derived relaxing factor, the 
vascular endothelium can also release vasoconstrictor substances. So far there are a 
number of types of endothelium-derived contracting factors described by various 
groups (Anggard et al, 1990):
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(A) Hypoxia- or anoxia-induced endothelium -derived contracting factor in 
peripheral, coronary, and cerebral arteries. Its action is very rapid and readily 
reversible; it may be a superoxide anion or a closely related free radical species 
(Vanhoutte & Katusic, 1988).
(B) Endothelium-derived contracting factor induced by stretch, increased transmural 
pressure, high potassium, calcium ionophore A23187 and arachidonic acid. It has 
been reported that this type of contracting factor is sensitive to inhibitors of 
cyclooxygenase such as indomethacin and could be a prostaglandin or related factor 
(Anggard et al, 1990; Vanhoutte & Katusic, 1988).
(C) Endothelium-derived contracting factor generated by cultured endothelial cells. 
Yanagisawa et al (1988) were the first group to purify and determine the sequence of 
this peptide contracting factor. They called this 21-amino-acid peptide "endothelin"; 
it has been identified in human plasma and is believed to have pathophysiological 
relevance (Kohno et al, 1990). Three d istinct endothelin  genes have been 
demonstrated in humans and other mammals using gene probing techniques (genes 
for endothelin-1, -2, & -3). However, it appears that only endothelin-1 is expressed 
and released by endothelial cells (Yanagisawa & Masaki, 1989a). Endothelin-1 is a 
highly potent vasoconstrictor (EC^q values ranging 2x10“^  - 5x10"^ M), and its 
action is long-lasting (more than 30 minutes), difficult to wash out and resistant to 
antagonists of a-adrenergic, H j-histam inergic, serotonergic, and muscarinic 
receptors, and the inhibitors of cyclooxygenase or lipooxygenase (Yanagisawa et al,
1988).
(D) Recently, it has been reported that another endothelium-derived contracting 
factor exists. This factor is sensitive to indomethacin and may contribute to the 
endothelium-dependent contractile response to acetylcholine in aorta or arterioles 
from spontaneously hypertensive rats as compared to control normotensive rats 
(Luscher & Vanhoutte, 1986; Koga et al, 1989; Cordellini et al, 1990; Fortes et al,
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1990; Kato et al, 1990).
(3) Changes in vascular smooth muscle reactivity to various agonists.
In comparing the dose-response relationships of vascular beds to an agonist in 
hypertensive and normotensive men or animals, there are three aspects to be 
examined:
(A) The threshold concentration for a response in each group.
(B) The ED^q, the concentration at which half maximal response is achieved.
(C) The Emax, the maximal response achieved in each group.
It is customary to refer to (A) and (B) as "sensitivity", and (C) as "reactivity". In 
vessel strip studies in vitro, Emax can be obtained, while in clinical investigations or 
in studies conducted in vivo with conscious animals, Emax data are often not 
obtainable due to the high risk and ethical considerations.
In the established phase of hypertension (either primary or secondary in 
etiology), there are structural changes to the blood vessel wall which may account 
for the changes in ED^g and Emax in the dose-response curves (Folkow, 1982). On 
the other hand, changes in dose-response curves in response to some pressor or 
depressor substances, but not others, e.g., noradrenaline but not angiotensin II 
(M iyahara, 1966; H am ilton & Reid, 1983), or verapam il but not sodium 
nitroprusside (Hulthen et al, 1982; Robinson et al, 1982), argue for a "selective, 
functional factor" in the pathophysiology of hypertension. This point is also 
substantiated by in vitro vessel strip or perfused vascular bed studies. Changes in 
some specific receptor-mediated responses, e.g., a - or p- adrenoceptor-mediated 
responses, but not in other receptor-mediated or non-receptor-mediated responses, 
have been reported from various groups in hypertension of primary or secondary 
origin (Collis & Vanhoutte, 1977; Fink & Brody, 1979; Katovich et al, 1984; Aqel et 
al, 1986).
Thus there are different, but not mutually exclusive, grounds for support of
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"structural" as well as "functional" components contributing to the changes in 
vascular responses in hypertension (Friedman, 1983).
Furthermore, changes in vascular responses are not always the products of 
sustained hypertension. When they precede or parallel the developm ent of 
hypertension, these specific changes may have causative or ontological implications 
(Webb & Bohr, 1981; Lais & Brody, 1978).
There are many reports showing that the in vivo pressor responses to a -  
adrenoceptor agonists are enhanced in humans or animals with primary or secondary 
hypertension (Mendlowitz & Naftchi, 1958; Miyahara, 1966; Jie et al, 1986; Hicks 
et al, 1983; Finch & Haeusler, 1974; Hamilton & Reid, 1983). Results from in vitro 
studies are controversial in primary hypertension (Bhalla et al, 1989; Mulvany, 
1984), while most in vitro studies on secondary hypertension have reported an 
enhanced responsiveness (Finch, 1971; Collis & Alps, 1975; Katovich et al, 1984).
There are many reports showing that in the established phase of hypertension, in 
vivo as well as in vitro p-adrenoceptor-mediated cardiovascular responses are 
attenuated in both humans and animals (For review, see Feldman, 1987), while an 
increased vasoconstrictor response to serotonin has been observed in animals with 
primary as well as secondary hypertension (Cheng & Shibata, 1980; Mecca & 
Webb, 1984; Huzoor-Akbar et al, 1989; Turla & Webb, 1990).
To summarize, there are a host of functional changes in the vascular endothelium, 
as well as in smooth muscle cells, associated with hypertensive states.
1.2.2. Changes in vascular function in hypercholesterolemia and atherosclerosis
(1) Changes in endothelial permeability
In cholesterol-fed rabbits, enhanced entry of albumin has been demonstrated in 
the aortic intimal surface 2 weeks after starting a cholesterol-enriched diet. At this 
time, no lipid lesion was visible (Adams & Bayliss, 1977). Stemerman (1981) also
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found that hypercholesterolemia was associated with increased uptake of horseradish 
peroxidase even in the absence of endothelial loss. Increased permeability to plasma 
proteins such as albumin, fibrinogen, and most notably, cholesterol (visualized by 
[JH]-cholesterol uptake) in the pig aorta has been seen during dietary cholesterol 
challenge (Somer & Schwartz, 1971). Recently, Schwenke & Carew (1989) reported 
that in cholesterol-fed rabbits, as early as 4 to 16 days when the vasculature was still
1 o 1
morphologically normal, the uptake of [ I]-low-density-lipoproteins has been 
increased markedly in all segments of aorta, as compared to untreated controls. 
Moreover, the fractional degradation rate of [ I]-low-density-lipoproteins was 
also severely retarded, especially in lesion-prone sites such as the aortic arch and 
branch sites of the aorta.
(2) Changes in endothelium-dependent relaxation or contraction
The impairment of endothelium-dependent relaxation has been observed in vivo 
in human arteries or arterioles with hypercholesterolemia (Creager et al, 1990) as 
well as atherosclerosis (Ludmer et al, 1986; Cox et al, 1989), while the endothelium- 
independent relaxation in these vessels was largely preserved. Similar in vivo 
findings have been made in both large and resistance vessels in cholesterol-fed 
animals (Bossaller et al, 1987a; Yamamoto et al, 1988; Girerd et al, 1990). In vitro 
studies also highlighted the impairment of endothelium-dependent relaxation in large 
and resistance vessels from humans or animals with hypercholesterolemia or 
atherosclerosis (Bossaller et al, 1987b; Osborne et al, 1989; Guerra et al, 1989; 
Shimokawa & Vanhoutte, 1989; Merkel et al, 1990). Furthermore, some research 
groups have demonstrated that this impairment of endothelium-dependent relaxation 
in the arteries from hypercholesterolemic and atherosclerotic animals was mainly 
due to the decreased release or production of endothelium-derived relaxing factor 
(Guerra et al, 1989; Shimokawa & Vanhoutte, 1989; Sreeharan et al, 1986). 
Bossaller et al (1987b) also found that the impaired endothelium-dependent 
relaxation in the atherosclerotic arteries was associated with suppressed production
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of cGMP. The relaxation apparatus, in terms of relaxation to nitroprusside or other 
agonists acting directly on smooth muscle cells, was generally intact. In line with 
this, it was also shown that L-arginine, which is the precursor for the synthesis of 
endothelium-derived relaxing factor, i.e., nitric oxide, could partially or mostly 
reverse this impaired endothelium-dependent relaxation in the atherosclerotic 
arteries, suggesting that a decreased production of nitric oxide was involved (Girerd 
et al, 1990; Rossitch et al, 1991).
(3) Changes in vascular smooth muscle reactivity to various agonists.
While studies on the vascular pressor/constrictor or depressor/dilator responses to 
a -  or (3- adrenoreceptor agonists, or angiotensin II in hypercholesterolemic or 
atherosclerotic humans or animals have given controversial results (for more 
detailed discussion, see the Introduction Section of the "Pressor and Depressor 
Responses in Hypertensive and Hypercholesterolemic Rabbits" Chapter), there are 
more consistent reports on the altered responsiveness to serotonin and ergonovine. 
The in vivo vasodilator response to serotonin in hindlimb vascular beds was 
reported to be impaired and converted to vasoconstriction in atherosclerotic animals 
(Heistad et al, 1984; Lopez et al, 1989a). An augmented in vivo vasoconstrictor 
response to serotonin was also observed in cerebral, ocular, and mesenteric vascular 
beds (Faraci et al, 1989; Lopez et al, 1989b). Many in vitro studies also showed that 
there was an enhanced vasoconstrictor response to serotonin in both large and 
resistance vessesls from humans and animals with hypercholesterolem ia or 
atherosclerosis (Kalsner & Richards, 1984; Merkel et al, 1990; Chilian et al, 1990; 
Yokoyama et al, 1983).
An enhanced constrictor response to ergonovine has been observed in aorta from 
diet-induced as well as hereditary hypercholesterolem ic rabbits (Henry & 
Yokoyama, 1980; Yokoyama et al, 1983).
Thus, hypercho lestero lem ia  and a therosc lerosis  may both augm ent
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vasoconstrictor responses and attenuate vasodilator responses (Lopez et al, 1989a), 
and thereby have pathological implications in coronary or cerebral vasospasm 
(Shimokawa & Vanhoutte, 1989; Shimokawa et al, 1988).
To summarize, hypercholesterolemia and athersclerosis can induce a variety of 
functional changes in the vascular endothelium as well as smooth muscle cells, and 
may thus predispose the vasculature to occlusive or vasospastic diseases.
1.3. Changes in second messenger systems in hypertension, hypercholesterolemia, 
and atherosclerosis.
1.3.1. The second messenger systems involved in contraction-relaxation cycles and 
cellular proliferation processes of vascular smooth muscle cells
The contraction-relaxation cycles of vascular smooth muscle cells are mediated
9  i 9  .
chiefly by changes in intracellular Ca concentration ([Ca ]j) (Karaki, 1989). 
There are three main second messenger systems involved in the regulation of 
[Ca^+]^  and thereby the contraction or relaxation of vascular smooth muscle cells 
(Karaki, 1989). They are:
(1) The phosphoinositide hydrolysis system (i.e., inositol 1,4,5-trisphosphate and 
1,2-diacylglycerol system).
(2) The cAMP system.
(3) The cGMP system.
A gonists may stim ulate  the p roduction  of in o sito l trisphosphate  and 
diacylglycerol by way of phosphatidylinositol 4,5-bisphosphate hydrolysis, increase 
[Ca^+]p and cause the contraction of vascular smooth muscle cells. Firstly, inositol
9  I
1,4,5-trisphosphate causes an intracellular release of Ca from endoplasmic 
reticulum after binding to the receptor site in the latter, which in turn causes a short­
lived [Ca^+]j increase, and a phasic contraction of vascular smooth muscle cells 
(Somlyo et al, 1988). Secondly, 1,2-diacylglycerol activates protein kinase C in the 
membrane, which in turn brings about the tonic contraction of vascular smooth
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muscle and an increase of Ca influx through the cell membrane (Rassmussen et al,
1987; Khalil & Van Breemen, 1988).
Agonists may elevate cAMP levels in vascular smooth muscle cells by way of
receptor--G-protein—adenyl-cyclase activation. This decreases [Ca^+]j as well as the 
1+Ca sensitivity of contractile elements, and thus relaxes the smooth muscle 
(Karaki, 1989).
Agonists may elevate cGMP levels in vascular smooth muscle cells by way of 
receptor-activated (e.g., atrial natriuretic peptide), non-receptor-mediated (e.g.,
nitroprusside), or indirect endothelium-dependent (e.g., acetylcholine), activation of
9 +  9  +guanylate cyclase; this decreases [Ca as well as the Ca sensitivity of
contractile elements, and thus relaxes the smooth muscle (Karaki, 1989). Guanylate
cyclase activation by any of these pathways may also inhibit phosphoinositide
hydrolysis and smooth muscle contraction in rat aorta (Rapoport, 1986).
In addition to their crucial roles in the regulation of contraction and relaxation of
vascular smooth muscle cells, both the phosphoinositide hydrolysis and the cAMP
messenger systems may be involved in the regulation of cellular proliferation in
smooth muscle cells.
(1) The phosphoinositide hydrolysis system in cell proliferation
Studies on the biochemical changes induced by growth factors in a variety of
cells have pinpointed some of the key signals at the early phase of cell proliferation.
They include (A) increased phospholipase C activity and thereby increased
9 I
phosphoinositide hydrolysis, (B) an increase in [Ca^ ]j, (C) stimulation of the
, , /i.
Na /H antiport leading to cellular alkalization (an increase in cytosolic pH), (D)
Enhanced tyrosine-specific protein kinase activity (Taylor, 1986; Berridge, 1986). In
addition, as pointed out by Berk & Alexander (1989), growth factors for cultured
vascular smooth muscle cells such as noradrenaline, adrenaline, platelet-derived
growth factor, epidermal growth factor, and endothelin , are also capable of causing
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smooth muscle contraction by way of phosphoinositide hydrolysis (Thyberg et al,
1990). In line with the suggestion that phosphoinositide metabolism is involved in 
cell proliferation processes, it has been observed that there is a higher rate of 
phosphoinositide hydrolysis, together with a higher proliferation rate, in cultured 
vascular smooth muscle cells from spontaneously hypertensive rats as compared 
to Wistar-Kyoto rats, under basal as well as agonist-stimulated conditions (Paquet et 
al, 1989; Scott-Burden et al, 1989a; Paquet et al, 1990).
(2) The cAMP system in cell proliferation
Franks et al (1984) showed that the ability of cultured vascular smooth muscle 
cells to grow correlated with adenyl cyclase activity in the cell lines. Also, adenyl 
cyclase activity increased after the addition of growth stimuli, and this increase 
preceded the rise in [^H]-thymidine incorporation. In addition, cAMP has been 
reported to enhance cellular proliferation by epidermal growth factor or modulate the 
pro liferation  cycle (Olashaw & Pledger, 1988). Thus both the cAMP and 
phosphoinositide hydrolysis systems have been implicated in the regulation of cell 
proliferation, although potential interactions have yet to be elucidated (Nishizuka, 
1986).
Recently, Garg & Hassid (1989) reported that vasodilator drugs that generate 
nitric oxide, which activates guanylate cyclase and increases cellular cGMP levels, 
inhibited the mitogenesis and proliferation of cultured vascular smooth muscle cells, 
suggesting a possible role for the cGMP messenger system in the regulation of cell 
proliferation. Notably, in contrast to the cAMP and phosphoinositide systems, 
cGMP appeared to inhibit growth.
1.3.2. Changes in the phosphoinositide second messenger system in hypertension, 
hypercholesterolemia, or atherosclerosis.
Many investigations into the phosphoinositide second messenger system in 
hypertension have been undertaken, but the results are controversial. (For review, 
see Heagerty & Ollerenshaw, 1990, and "Chapter 6. Phosphoinositide Hydrolysis in
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Hypertensive and Hypercholesterolemic Rabbits" in this thesis.) These investigations 
can be broadly categorized into three types:
(1) Investigations into the content of phosphoinositides in the membrane, namely the 
am ount of pho sp h a tid y lin o sito l, pho sp h a tid y lin o sito l 4 -phosphate , and 
phosphatidylinositol 4,5-bisphosphate, in non-stimulated cells, measured after [^H] 
or [ P] radiolabelling.
(2) Investigations into the activity of membrane phospholipase C under basal, non­
stimulated conditions, measured as radioactivity of various inositol phosphates or
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diacylglycerol after radiolabelling the phosphoinositides with [H ]  or [ P], i.e., the 
basal rate of phosphoinositide hydrolysis.
(3) Investigations into the response of phosphoinositide hydrolysis to the challenge 
by agonists, namely the relative yield of inositol 1-monophosphate, inositol 1,4- 
bisphosphate, and inositol 1,4,5-trisphosphate or diacylglycerol after stimulation as 
compared to non-stimulated, basal states. This gives a measure of the activity of 
membrane phospholipase C in response to agonists.
(1) The content of phosphoinositides in the membrane
o  - 2 9
A higher con ten t of, or a h igher [ H] or [ P] inco rpora tion  in to , 
phosphatidylinositol 4,5-bisphosphate in primary hypertension has been reported in 
various tissues including vascular smooth muscle cells (Durkin et al, 1990; Resink et 
al, 1987), platelets (Dimitrov et al, 1986), and erythrocytes (Marche et al, 1985; 
B orisk ina et al, 1978). S im ilarly , a h igher con ten t o f rad io lab e lled  
phosphatidylinositol 4,5-bisphosphate in secondary hypertension was observed in 
erythrocytes from Goldblatt renal hypertensive rats (Boriskina et al, 1978). Some 
groups found that the higher content of phosphatidylinositol 4,5-bisphosphate was 
associated with the developing stage of hypertension (Durkin et al, 1990; Riozzi et 
al, 1987; Kiselev et al, 1981). In contrast, a decreased (Remmal et al, 1988) or 
unchanged (Ek et al, 1989; Koutouzov et al,1987; Riozzi et al, 1987) [ ^ P ]
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incorporation into phosphatidylinositol 4,5-bisphosphate in primary hypertension 
has also been observed.
(2) Basal, non-stimulated rate of phosphoinositide hydrolysis (or phospholipase C 
activity)
A higher rate of basal phosphoinositide hydrolysis or phospholipase C activity in 
vascular smooth muscle cells (Uehara et al, 1988; Resink et al, 1987), renal cortex 
and medulla (Kawaguchi et al, 1987), and erythrocytes (Tremblay et al, 1990) has 
been observed in primary hyertension. In secondary hypertension, a higher rate of 
basal phosphoinositide hydrolysis was also found in aorta (Jones et al, 1988) and 
cardiac atria and ventricles (Eid & de Champlain, 1988) In contrast, an unchanged 
rate of basal phosphoinositide hydrolysis in both primary (Ek et al, 1989; Paquet et 
al, 1989; Jeffries et al, 1988; Koutouzov et al, 1988; Feldstein et al, 1986; Zhu et al,
1990) and secondary hypertension (Nixon et al, 1990; Takata et al, 1989) has been 
reported. Thus, diverse results have been reported for basal phosphoinositide 
hydrolysis in hypertension.
(3) The effect of agonist stimulation on phospholipase C activity
Increased phosphoinositide hydrolysis in response to agonist stimulation in 
primary hypertension has been observed in various tissues including vascular 
smooth muscle cells (Huzoor-Akbar et al, 1989; Paquet et al, 1989), platelets 
(Koutouzov et al, 1987; Marche et al, 1989), and fibroblasts (Zhu et al, 1990) In 
secondary hypertension, an enhanced phosphoinositide hydrolysis response has also 
been shown in vascular smooth muscle cells (Jones et al, 1988; Takata et al, 1989), 
cardiac atria and ventricles. (Eid & de Champlain, 1988) Of note here, both Huzoor- 
Akbar et al (1989) and Jones et al (1988) found an enhanced contractile response 
with increased phosphoinositide hydrolysis in aortic strips from spontaneously 
hypertensive rats and aldosterone-salt hypertensive rats, respectively. On the other 
hand, a decreased phosphoinositide hydrolysis response in primary hypertension has 
been reported in aorta (Heagerty et al, 1986), renal cortex (Jeffries et al, 1988), and
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cultured neurons (Feldstein et al, 1986). No change in phosphoinositide hydrolysis 
responses was also observed in secondary hypertension in aorta (Nixon et al, 1990) 
and platelets (Limon et al, 1990).
Recently, in addition to the inositol phosphate pathway, the activity of protein 
kinase C has also been studied. It has been proposed that protein kinase C plays a 
significant role in long-term regulation of smooth muscle cell functions such as 
tonus maintenance and cellular proliferation (Rassmussen et al, 1987; Nishizuka, 
1986). An enhanced protein kinase C activity in primary as well as secondary 
hypertension was observed in vascular smooth muscle cells (Turla & Webb, 1987; 
Murakawa et al, 1988; Turla et al, 1990; Turla & Webb, 1991), platelets (Takaori et 
al, 1986), and erythrocytes (Kravtsov et al, 1988).
Thus there are many reports showing that the phosphoinositide messenger system 
is perturbed in both primary and secondary hypertension, although the picture may 
differ depending on the model or stage of hypertension, tissue examined, and 
agonists employed.
In con trast, little  is known about phospho inositide  m etabolism  in 
hypercholesterolemic or atherosclerotic states, although Winocour et al (1990) 
reported that the phosphoinositide hydrolysis response was significantly greater in 
diet-induced as well as genetically-determined hypercholesterolemic rats.
1.3.3. Changes in the cAMP system in hypertension, hypercholesterolemia, and 
atherosclerosis
In cardiovascular tissues such as heart and large as well as resistance vessels, 
there are many reports showing that the responsiveness of the cAMP system is 
decreased in the established phase of primary and secondary hypertension (Feldman, 
1987; Hamet & Tremblay, 1990). This decreased responsiveness can be manifested 
in any of the following ways:
(1) An exaggerated increase in tissue and extracellular cAMP levels at the
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developing stage of hypertension, followed by a progressive diminution in the 
established phase of hypertension (Hamet & Tremblay, 1990).
(2) Enhanced adenyl cyclase activity prior to the development of hypertension, 
followed by a decrease in activity in the hypertensive state. It has been suggested 
that this stage-dependent decrease in adenyl cyclase activity may involve G-protein 
interaction with the catalytic subunit of adenyl cyclase (Hamet & Tremblay, 1990; 
Bhalla & Sharma, 1982; Sharma et al, 1982).
(3) An decrease in the activity of cAMP-dependent protein kinase (Hamet & 
Tremblay, 1990; Coquil & Hamet, 1980).
(4) An increased activity of calmodulin, which exerts multiple effects including 
changes in the activity of adenyl cyclase, cAMP phosphodiesterase, the cation ion 
transport system, and cellular proliferation (Hamet & Tremblay, 1990).
As reviewed earlier, the cAMP system is involved not only in vasodilation and 
cardiac inotropism and chronotropism, but also in the regulation of the cellular 
proliferation process. Indeed, an increased cAMP level preceding and accompanying 
an increase in vascular DNA and protein content has been observed in spontaneously 
hypertensive rats (Chatelain et al, 1985) and coarctation hypertensive rats 
(Chatelain, 1983).
Perturbations of the cAMP system have also been noted in diet-induced 
atherosclerosis. In atherosclerotic rabbit aorta, an increased cAMP level was 
observed as compared to adjacent non-lesioned areas or the aorta from normal-diet 
rabbits (Augustyn & Ziegler, 1975). In contrast, in pigs on an atherogenic diet, a 
reduced cAMP level and adenyl cyclase activity together with an increased content 
of protein and cholesterol was seen in atherosclerotic lesions as compared to non- 
lesioned areas. Moreover, the cAMP level was negatively correlated with the content 
of protein and cholesterol (Lundholm et al, 1980).
1.3.4. Changes in the cGMP system in hypertension, hypercholesterolemia, and 
atherosclerosis
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cGMP-induced relaxation in vascular smooth muscle cells can be effected by 
endothelium-derived relaxing factor (nitric oxide) and nitro-vasodilators (e.g., 
nitroprusside), via soluble guanylate cyclase activation, or by atrial natriuretic 
peptide via particulate guanylate cyclase activation (Hamet & Tremblay, 1990).
Most studies showed that in hypertension, there is an impaired endothelium- 
dependent relaxation, whereas the endothelium-independent relaxation to nitro- 
vasodilators is generally preserved; this suggests that the cGMP-soluble guanylate 
cyclase relaxation apparatus is not impaired (Vanhoutte, 1989; Marshall & Kontos,
1990). Possible mechanisms for this impaired endothelium-dependent relaxation 
include: decreased release or production of endothelium-derived relaxing factor 
from the endothelium, the destruction of endothelium-derived relaxing factor by 
oxidants after its release in the extracellular space, or the release of endothelium- 
derived contracting factors from the endothelium (Marshall & Kontos, 1990; 
Vanhoutte, 1989).
On the other hand, increased vasorelaxant responses to atrial natriuretic peptide, 
which mediates its effects via cGMP-particulate guanylate cyclase, have been 
observed in primary hypertension (Hamet & Tremblay, 1990).
In hypercholesterolemia and atherosclerosis, most papers also indicate an 
impaired endothelium-dependent relaxation, with the endothelium-independent 
relaxation generally unchanged (Marshall & Kontos, 1990); it has been shown that 
the cGMP-soluble guanylate cyclase relaxation apparatus in response to exogenous 
nitric oxide or nitroprusside is largely intact, suggesting the lesion is outside smooth 
muscle cells (Guerra et al, 1989; Marshall & Kontos, 1990).
1.4. A comparison of hypertension and hypercholesterolemia in the development of 
atherosclerosis
In the previous discussion, it has been shown that both hypertension and
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hypercholesterolemia can cause (1) an increase in endothelial permeability, (2) the 
impairment of endothelium-dependent vaso-relaxation, (3) an alteration in vascular 
responses to agonists, (4) changes in the membrane phosphoinositide or cAMP 
messenger systems. There are numerous additional lesions common to the two 
disease states.
Hypertension and hypercholesterolemia have been reported to be associated with 
more "membrane lesions", such as changes in cell membrane fluidity (Naftilan et al, 
1986; Lurie et al, 1985), membrane lipid composition (Naftilan et al, 1986; Lurie et
9-i
al, 1985), Ca flux rates through cell membranes (Jones et al, 1973; Strickberger et 
al, 1988), and a-adrenergic receptor number (Michel et al, 1990; Nanda & Henry, 
1982).
Secondly, an increased content of calcium in the arterial walls has been observed 
in hypertensive as well as hypercholesterolemic humans and animals (Fleckenstein 
et al, 1987; Phair, 1988). It has been speculated that this calcium overload in the 
arterial tissue might have deleterious effects on the physiological functions of 
smooth muscle cells and aggravate the atherosclerotic processes.
Furthermore, lesions associated with one pathology may exacerbate abnormalities 
associated with the other disease state. Increased levels of low-density lipoproteins 
are associated with hypercholesterolemia. These low-density lipoproteins may act 
adversely at sites where hypertension-related defects have been reported. Such 
actions include:
(A) Injury to cultured endothelial cells (Henriksen et al, 1979).
(B) Activation of platelets with an increase in inositol 1,4,5-trisphosphate, 
diacylglycerol, and [Ca^+]^  (Knorr et al, 1988; Block et al, 1988). Activation of 
arterial smooth muscle cells, endothelial cells, lymphocytes, and fibroblasts via the 
phosphoinositide hydrolysis pathway has also been observed (Block et al, 1988).
(C) Inhibition of endothelium-dependent relaxation in aorta, possibly by reducing 
the production or release of endothelium-derived relaxing factor (Andrews et al,
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1987; Takahashi et al, 1990).
(D) Increases in [Ca^+]j, cellular alkalization, DNA synthesis, expression of proto­
oncogenes, phosphoinositide metabolism, and cell proliferation in cultured vascular 
smooth muscle cells (Scott-Burden et al, 1989b; Sachinidis et al, 1990; Libby et al, 
1985).
In epidemiological terms, the presence of hypertension and hypercholesterolemia 
is additive in increasing the relative risk of cardiovascular events (Kannel & 
Sytkow ski, 1987). In anim al studies, the presence of hypertension and 
hypercholesterolemia can aggravate each other in inflicting atherosclerotic lesions in 
arteries (Hollander et al, 1976; McGill et al, 1985.) Nevertheless, there are some 
differences in the picture of atherosclerotic lesions induced by hypertension and 
hypercholesterolemia, although proliferation of smooth muscle cells is one of the 
key common features. Firstly, the proliferative response in hypercholesterolemia is 
mainly confined to the intima, whereas the proliferative response in hypertension is 
in the media. Secondly, the intimal lesions in hypercholesterolemia are seen in large 
vessels, but not the small vessels, while the medial lesions in hypertension are seen 
in large as well as small vessels (Mulvany & Simonsen, 1989). Thirdly, in animal 
studies, lipid deposition seldom occurs in vascular walls in hypertensive animals 
without the presence of hypercholesterolemia (Chobanian, 1990). Finally, the 
vascular lumen in hypercholesterolemic animals tends not to be diminished despite 
the proliferative processes, while the structural remodelling process in chronic 
hypertension reduces the lumen diameter in hypertensive animals (Heistad et al,
1991).
1.5. Summary
1. Hypertension and hypercholesterolemia have been identified as major and 
independent risk factors for atherosclerotic diseases. In many subjects, more than
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one risk factor are often present, and the relative risk is cumulative. In clinical trials 
of treating mild to moderate hypertension, results suggest anti-hypertensive drugs 
can reduce the incidence of stroke and heart failure, but the outcome in terms of 
reducing coronary events is dubiously modest. On the other hand, major prospective 
studies of lowering plasma cholesterol in hypercholesterolemic patients showed 
impressive reductions in cardiovascular events, including coronary incidents.
2. In a wide range of animal species, experim ental hypertension and 
hypercholesterolemia can induce a host of atherosclerotic changes in the arterial 
intima and media. These include endothelial shape changes, enhanced endothelial 
permeability, impaired endothelium-dependent vascular relaxation, platelet and 
monocyte adherence, macrophage and lymphocyte accumulation, smooth muscle 
cell migration into the intima, smooth muscle cell proliferation, extracellular calcium 
and connective tissue accumulation, and intimal thickening. Hypercholesterolemia 
can also induce lipid accumulation and foam cell formation. In addition, changesd in 
vascular responses to vasoconstrictors as well as vasodilators are observed in both 
conditions.
3. Changes in [Ca^+]j are crucial signals for the activity of many cell types,
including vascular smooth muscle cells, platelets, and neurons. There are three major
94-second messenger systems involved in the regulation of [Ca in vascular smooth 
muscle cells and platelets: the phosphoinositide hydrolysis system, the cAMP 
system, and the cGMP system. Stimulation of the phosphoinositide hydrolysis 
system can increase [Ca^+]j in vascular smooth muscle cells and bring about muscle 
contraction, whereas activation of either the cAMP or the cGMP can decrease 
[Ca^+]j and bring about muscle relaxation. There are many reports showing that all 
three m essenger system s can be perturbed by hypertension as w ell as 
hypercholesterolemia. Moreover, changes in cell membrane characteristics such as 
fluidity, lipid composition, Ca^+ flux rates, and receptor number, can be observed in 
hypertension and hypercholesterolemia.
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4. P roliferation of vascular smooth muscle cells is the hallm ark of the 
atherosclerotic lesions induced by hypertension and hypercholesterolemia. Early 
changes in cultured cells in response to growth factor stimulation include increased 
phospholipase C activity and phosphoinositide hydrolysis, an increase in [Ca^+]p 
cellular alkalization, activated membrane Na+/H+ antiport, and enhanced tyrosine- 
specific protein kinase activity. These changes suggest that the phosphoinositide 
messenger system is involved in the regulation of cell proliferation processes. On the 
other hand, correlation of adenyl cyclase activity and DNA synthesis in cultured 
vascular smooth muscle cells also implicates the cAMP system in the regulation of 
cell proliferation.
5. The vascular endothelium has a crucial role in modulating local vascular tone 
and blood flow, in activating or degrading vasoactive hormones, in secreting 
endothelium-derived relaxing as well as contracting factors, and in maintaining a 
patent and thromboresistant circuit. In pathological states such as hypertension and 
hypercholesterolemia, it contributes to the atherogenetic processes by increasing 
paracrine growth-factors or decreasing growth-inhibitors for vascular smooth muscle 
cells.
Thus there is much evidence for increases in cardiovascular risk as well as for 
many potential sites of interactions when hypertension and hypercholesterolemia 
occur together. However, the relative importance of such interactions remains to be 
elucidated.
In this thesis, aspects of hypertension and hypercholesterolemia, both alone and 
in combination, will be investigated with the aim of identifying key areas of 
interaction.
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Chapter 2. Preliminary Study on the Pharmacology of Endothelin-1
2.1. Introduction
2.1.1. Endothelium-derived relaxing and contracting factors
Furchgott & Zawadzki reported in 1980 that the vasorelaxation response of 
isolated rabbit aorta to acetylcholine in organ baths depended on the presence of 
vascular endothelia cells, and this response was not mediated by prostacyclin or 
related substances (Furchgott & Zawadzki, 1980). Later on, the phenomenon of 
endothelium -dependent vascular relaxation has been found to be present 
ubiquitously in various vascular beds among several species including man. Both 
arteries and veins possess this capability (Vanhoutte, 1989). Reports from several 
sources strongly suggest that this "endothelium-derived relaxing factor" is nitric 
oxide, and its precursor is L-arginine. There may be some basal secretion of 
endothelium-derived relaxing factor in vascular beds, and this secretion can be 
stimulated by shear stress, hormones, neurotransmitter, or platelet products. 
Endothelium-derived relaxing factor is short-lived, with a half-life varying from 6 
seconds to 2 minutes, depending on the assay conditions. It stimulates soluble 
guanylate cyclase and increases cGMP levels in vascular smooth muscle cells, 
thereby bringing about vascular relaxation (Furchgott & Vanhoutte, 1989; Marshall 
& Kontos, 1990). There is growing evidence that the endothelium-dependent 
vascular relaxation is impaired in humans and animals with disease states such as 
hypertension, hypercholesterolemia, and atherosclerosis (Marshall & Kontos, 1990; 
Cooke, 1990).
In addition, "vasoconstriction" dependent on, or enhanced by, intact endothelium
has been observed in several vascular beds in response to various chemical and
physical stimuli such as noradrenaline, thrombin, hypoxia, increased transmural
pressure, and mechanical stretch (Yanagisawa et al, 1988). Several groups have
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identified a peptide substance from cultured endothelial cells which causes 
vasoconstriction (Hickey et al, 1985; Gillespie et al, 1986; O’Brien et al, 1987). In 
1988, Yanagisawa et al succeeded in purifying, determining the sequence, and also 
synthesising the peptide endothelin (Yanagisawa et al, 1988). This subsequently led 
to an explosive outburst of research throughout the world, investigating the 
pharmacological effects of endothelin in various tissues and its mechanisms of 
action.
So far, three types of endothelium-derived contracting factor have been 
identified, and endothelin is one of them (Anggard et al, 1990; Vanhoutte et al,
1991).
(1) Hypoxia- or anoxia-induced endothelium-derived contracting factor found in 
peripheral, coronary, and cerebral arteries. Its action is very rapid and readily 
reversible; it may be a superoxide anion or a closely related free radical (Vanhoutte 
& Katusic, 1988).
(2) Endothelium-derived contracting factor induced by stretch, increased transmural 
pressure, high potassium, calcium ionophore A23187 and arachidonic acid. It has 
been reported that this type of contracting factor is sensitive to inhibitors of 
cyclooxgenase such as indomethacin and meclofenamate, and could be a 
prostaglandin or related factor (Anggard et al, 1990; Vanhoutte & Katusic, 1988).
(3) Endothelium-derived contracting factor generated by cultured endothelial cells, 
namely endothelin (Yanagisawa et al, 1988). More detailed discussion on endothelin 
will be presented in the following sections.
2.1.2. Endothelins: subtypes, tissue autoradiography, receptors, and regulation 
Using gene probing techniques, Inoue et al (1989) revealed that there are three 
distinct endothelin-related genes in human, rat, and porcine genomes. Each of the 
genes predicts a 21-residue peptide, similar to but distinct from each other, named
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endothelin-1 (the original porcine and human endothelin), endothelin-2 (with two 
amino acid substitutions from endothelin-1), and endothelin-3 (with six amino acid 
substitutions), respectively. (Figure 2.1) It appears that vascular endothelial cells do 
not produce endothelin-2 or endothelin-3, and only endothelin-1 can be detected in 
endothelial cells or in the culture supernatant either at the peptide level or at the 
mRNA level (Yanagisawa & M asaki, 1989a). Further discussion of the 
characteristics of endothelin will be confined to endothelin-1.
Endothelin-1, an acidic 21-amino-acid peptide with two intrachain disulfide 
bridges, has a molecular weight of 2492. Structure-activity studies indicate that both 
the disulfide bonds, and the carboxyl-terminal residue L-tryptophan, are crucial to its 
potent vasoconstrictor activity (Yanagisawa & Masaki, 1989a).
Tissue autoradiography studies in humans, pigs, monkeys, guinea pigs and rats 
have shown that endothelin-1 binding sites are widely distributed, not only in 
arteries, veins, and heart (cardiac nerves, atria, ventricles, and coronary arteries, in 
decreasing order), but also in lung, kidney (cortical glomeruli and medulla, less in 
papilla), brain (especially the cerebellum), spinal cord, adrenal gland, liver, spleen, 
and the gastrointestinal tract (Lerman et al, 1990). MacCumber et al (1989) found 
that synthesis of mRNA occurred in close proximity to the binding sites of 
endothelin in many tissues, suggesting the role of a local hormone.
Results from radioligand binding studies suggested that there are at least two 
types of endothelin receptors: one is "endothelin-l-selective", and the other is "non­
isopeptide-selective" (Takayanagi et al, 1991). This suggestion was further 
strengthened by the findings that two distinct types of endothelin receptors could be 
obtained using cDNA cloning and expression techniques (Arai et al, 1990; Sakurai 
et al, 1990). Both receptors contain seven membrane spanning domains, with similar
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Endothelin-1
(Human/Porcine/
Dog/Rat)
Endothelin-2
(Human)
Endothelin-3
(Human/Rat)
Figure 2.1: Amino acid sequences of the endothelin family.
(Filled circles: amino acid residues different from those in endothelin-1.)
(Source of figure: Yanagisawa M & Masaki T. Molecular biology and biochemistry 
of the endothelins. Trends Pharmacol Sci 1989; 10: 374-378.)
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sequence and topology to other G-protein-coupled receptors. Northern blot analysis 
showed that mRNA for both receptors could be detected in brain, heart, lung, and 
kidney, but the "non-isopeptide-selective" receptor was not expressed in vascular 
smooth muscle cells (Sakurai et al, 1990; Arai et al, 1990).
It has been suggested that the production of endothelin seemed to be regulated at 
the level of messenger RNA transcription, since it was unlikely that endothelin was 
accumulated in endothelial granules and released in response to stimuli (Yanagisawa 
et al, 1988). Indeed, increases in messenger RNA for preproendothelin were 
observed within 1 hour of stimulation with agonists such as thrombin, adrenaline, or 
the calcium ionophore A23187. Increased secretion of endothelin-1 into the 
supernatant of incubating media for vessel strips or cultured endothelial cells has 
been reported when the media were stimulated with thrombin, angiotensin II, 
arginine-vasopressin, calcium ionophore A23187, glucose, transforming growth 
factor-pi, shear stress, or hypoxia (Emori et al, 1989; Boulanger & Luscher, 1990; 
Yamauchi et al, 1990; Ohlstein et al, 1990; Yoshizumi et al, 1989; Rakugi et al,
1990).
Yanagisawa et al (1988) proposed a possible route for endothelin biosynthesis. 
As shown in Figure 2.2, a 203-amino-acid peptide precursor translated from RNA, 
called preproendothelin, is cleaved by endopeptidase to a 39-am ino-acid 
intermediate, called "big endothelin". Big endothelin is hydrolysed at Trp21-Val22 
by some "endothelin-converting-enzym e" to the 21-am ino-acid peptide, 
"endothelin". Some research groups have speculated that the physiologically 
relevant "endothelin-converting-enzyme" could be a metal-dependent protease, 
sensitive to phosphoramidon inhibition (Sawamura et al, 1991; McMahon et al,
1991). Taken together, the presence of mRNA encoding the preproendothelin in the 
endothelial cells indicates that endothelin is produced by de novo synthesis and is 
processed in a manner similar to that of many peptide hormones and neuropeptides.
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NLys-Acg Arg-Arg
T
1 20 53 74 92 203
dibasic-pair * specific 
endopeptidase(s)
Trp-Val
1
N C ‘big endothelin'
putative 'endothelin- 
converting enzyme'
Ser
Met
Asp
Lys
GlulCysY Val
Figure 2.2: Possible pathway of endothelin-1 biosynthesis.
The putative secretory signal sequence and the endothelin sequence are shown 
by the hatched and the filled boxes, respectively. The rest of proendothelin 
sequence is indicated by an open box. A 39-amino-acid residue intermediate, so- 
called "big endothelin", is considered to be generated from proendothelin by the 
proteolytic cleavages at paired basic residues. Mature endothelin is then produced 
possibly through by a putative "endothelin converting enzyme".
(Source of figure: Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi 
M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular 
endothelial cells. Nature 1988; 332:411-415.)
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2.1.3. Cardiovascular effects of endothelin-1
The best defined characteristic of endothelin is its "highly-potent" (EC^q ranging 
between 2 X 1 0 '^  and 5 X 10"^ M) and long-lasting (longer than 30 minutes) 
vasoconstrictor effect. Endothelin-1 is the most potent vasoconstrictor known so far 
(Yanagisawa et al, 1988; Yanagisawa & Masaki, 1989b). The vasoconstrictor 
activity is resistant to antagonists of a-adrenergic, histaminergic, serotonergic, and 
muscarinic receptors, as well as inhibitors of cyclooxygenase and lipooxygenase, but 
can be reversed by the addition of isoproterenol, forskolin, or glyceryl trinitrate 
(Yanagisaswa et al, 1988). Some groups have observed that endothelin-1 was more 
potent in producing contractile activity on veins than on arteries (Cocks et al, 1989; 
M iller et al, 1989). The presence of the endothelium  can m odulate the 
vasoconstrictor effect of endothelin-1, and removal of the endothelium caused a 
reduction in EC^q values or an increase in Emax (Toupouzis et al, 1991; Eglen et al, 
1989; Kauser et al, 1990). In isolated rat aorta (Sakata et al, 1989), perfused 
mesenteries (de Nucci et al, 1988; Kitazumi et al, 1990), guinea pig aortic rings and 
perfused coronary resistance vessels (Folta et al, 1989), endothelin-1 has been 
reported to cause vascular relaxation in the pre-contracted vessels, which could be 
abolished by endothelium removal, methylene blue or oxyhaemoglobin treatment, 
suggesting that endothelin probably caused this relaxation via the release of 
endothelium-derived relaxing factor. On the other hand, the release of prostacyclin 
stimulated by endothelin-1 in the rat perfused mesentery arteries (Rakugi et al, 1989) 
and lungs (de Nucci et al, 1988), and the enhanced pressor response to endothelin-1 
by indomethacin pre-treatment (de Nucci et al, 1988) suggested that prostacyclin 
was also a potential modulator of endothelin-induced vasoconstriction.
Intravenous injection of endothelin-1 (0.1 to 3.0 nmol/kg) into rats or other 
animals generally caused two phases of blood pressure changes: an initial, short­
lived depressor response (lasting 0.5 to 2 minutes), followed by a potent, long-
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lasting pressor response (lasting more than 30 minutes) (Yanagisawa & Masaki, 
1989b). The pressor response was dose-related, and was mainly due to an increase in 
systemic resistance, with decreased cardiac output (Miller et al, 1989; Goetz et al, 
1988; Yang et al, 1991; King et al, 1990). The depressor response was associated 
vasodilation and a decrease in systemic resistance, while cardiac output was 
increased or unchanged (Yang et al, 1991; King et al, 1990; Rohmeiss et al, 1990; 
Hoffman et al, 1989). Of note here is that differences exist with regard to the 
vascular responses to endothelin-1 among different vascular beds, as well as among 
different species. The percentage increase in vascular resistance was greater in renal 
or mesenteric arteries than in hindquarter vessels (Gardiner et al, 1990; Pemow et al, 
1988; Hoffman et al, 1989), while Tippins et al (1989) observed that within the 
coronary circulation, resistance vessels were more sensitive to endothelin-1 than 
conductive arteries. An example of species differences is the effect of calcium 
antagonists on endothelin-1-induced vasoconstriction in porcine coronary arteries 
compared to canine coronary arteries (Masaki et al, 1990).
Recently, it has been reported that administration of low-dose endothelin-1 could 
induce a blood pressure reduction, with a reduction of total peripheral resistance and 
no secondary increase in blood pressure, in contrast to the better known depressor- 
pressor biphase response after higher doses of endothelin (Nakamoto et al, 1991; 
Minkes et al, 1989; Lippton et al, 1991). Indeed, renal vasodilation without 
subsequent constriction, induced after low doses of endothelin-1, has also been 
observed (Harris et al, 1991).
2.1.4. Mechanisms of action of endothelin-1 on the vasculature (Figure 2.3)
It was initially suggested that endothelin-1 acted as an endogeneous agonist of 
the dihydropyridine-sensitive Ca2+ channels, as its vasoconstrictor action depended 
on the presence of extracellular Ca2+ and could be inhibited by low doses of 
nicardipine (Yanagisawa et al, 1988). However, in cultured vascular smooth muscle
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cells, binding studies showed that endothelin-1 was bound to a specific, single­
population binding site and could not be displaced by calcium antagonists such as 
nicardipine or diltiazem (Clozel et al, 1989). Studies on cardiac membranes also 
showed that the endothelin-1 receptor is different from dihydropyridine-sensitive 
channels, and the latter are not the primary sites of action for endothelin-1 (Miyazaki 
et al, 1990; Gu et al, 1989). Furthermore, there are many reports indicating that 
endothelin-1 stimulates the production of inositol 1,4,5-trisphosphate and 1,2- 
diacylglycerol by way of phosphatidylinositol 4,5-bisphosphate hydrolysis. Inositol
9 -4-1,4,5-trisphosphate causes intracellular Ca release from endoplasmic reticulum,
which initiates vascular smooth muscle cell contraction (Pang et al, 1989; Ohlstein et
al, 1989; Wallnofer et al, 1989). After endothelin administration, both the elevation 
9 +of intracellular Ca concentration and the increase of inositol phosphates levels are
sustained for more than 15 minutes, which may in part explain the sustained nature
of its vasoconstrictor effects (Pang et al, 1989; Ohlstein et al, 1989).
The other product of phosphatidylinositol 4,5-bisphosphate hydrolysis, 1,2-
diacylglycerol, may also contribute to the effects of endothelin-1 on vascular smooth
2 -4-muscle cells, such as tonic contraction, and increased influx of extracellular Ca ,by 
activating membrane protein kinase C (Haller et al, 1990; Takuwa et al, 1990; 
Griendling et al, 1989). Recently, researchers have suggested that endothelin-1,
9-i
though not binding to dihydropyridine-sensitive Ca channels, may indirectly
2+activate membrane calcium channels and facilitate the influx of extracellular Ca ,
which may play some role in the tonic contraction (Van Renterghem et al, 1988;
Inoue et al, 1990; Takuwa et al, 1990; Marsault et al, 1990). This indirect activation
of membrane cationic channels may also explain the observation that the tonic
vascular contraction induced by endothelin-1 is partly dependent on the presence of
extracellular calcium (Yang et al, 1990; Takuwa et al, 1990; Marsault et al, 1990).
However, the extent to which dihydropyridine-sensitive calcium channel antagonists
may attenuate the vasoconstrictor effects of endothelin is open to controversy, and
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may vary according to species, vascular beds, or experimental conditions (Masaki et 
al, 1990).
Recently, there is some evidence to suggest that a guanine nucleotide-binding 
regulatory protein (G-protein) is involved in the signal transduction of endothelin- 
stimulated phosphoinositide hydrolysis, with formation of a membrane complex of 
receptor--G-protein—phospholipase-C, reminiscent of a-adrenergic and other 
receptor-mediated transmembrane signalling pathways (Takuwa et al, 1990; Kelly et 
al, 1990; Galron et al, 1990; Arai et al, 1990). In addition, it has been shown that, 
apart from activating the phospholipase C-mediated phosphoinositide pathway, 
endothelin also stimulates phospholipase A2  (Resink et al, 1989a; Reynolds et al,
1989) and phospholipase D (MacNulty et al, 1990), with the consequent release of 
arachidonic acid and choline, respectively, thus enlarging still further the list of 
potential secondary messengers involved in endothelin cellular action.
2.1.5. Other effects of endothelin-1
(A) Cardiac effects
In vitro studies showed that endothelin-1 at low doses was both an inotropic and 
chronotropic agent, and more distinctively, a potent coronary vasoconstrictor. At 
high doses, severe coronary vasoconstriction superseded by myocardial ischemia 
and a marked decline in cardiac performance was observed (Firth et al, 1990; 
Ishikawa et al, 1988; Ezra et al, 1989).
(B) Renal effects
At low doses of endothelin infusion, endothelin-1 was reported to cause renal 
vasodilation with concomitant diuresis and natriuresis, and no change in glomerular 
filtration rate (Harris et al, 1991). At high doses, endothelin-1 caused potent 
vasoconstriction in afferent as well as efferent arterioles, with decreases in 
glomerular filtration rate, renal plasma flow, urinary sodium excretion, and urine
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volume (Firth et al, 1988; Miller et al, 1989; Tsuchiya et al, 1990).
(C) Pulmonary effects
Endothelin-1 has been shown to be a potent constrictor for both pulmonary 
vessels and tracheal-bronchial smooth muscle (Cardell et al, 1990; Touvay et al,
1990). Endothelin-1 also stimulates the angiotensin converting enzyme activity in 
pulmonary artery endothelial cells, which might have some physiological 
implications (Kawaguchi et al, 1991).
(D) Endocrine interactions
Endothelin-1 has been shown to stimulate the release of atrial natriuretic peptides 
in vitro and in vivo (Stasch et al, 1989; Garcia et al, 1990). In vitro studies indicate 
that endothelin-1 inhibits renin release (Rakugi et al, 1988), stimulates aldosterone 
biosynthesis (Cozza et al, 1989), and stimulates the release of noradrenaline and 
adrenaline release from adrenal chromaffin cells (Boarder et al, 1989).
(E) Neural effects
It has been suggested that endothelin-1 exerts effects at neuroeffector junctions in 
arteries, as it can potentiate the nerve-stimulated or noradrenaline-stimulated pressor 
responses (Tabuchi et al, 1990; Wong-Dusting et al, 1990). Nishimura et al (1991) 
also reported that endothelin-1 caused depolarization, activated an inward current, 
and facilitated a long-lasting voltage-dependent calcium current in ganglion neurons. 
Intra-cistemal injection of endothelin-1 has been shown to cause severe, long-lasting 
cerebral vasospasm (Asano et al, 1989) and affect central neural control of the 
circulation and respiration in animals (Kuwaki et al, 1991).
(F) Mitogenic effects
Endothelin-1 has been reported to stimulate mitogenesis, with proto-oncogene 
expression, DNA synthesis, and cell proliferation, in vascular smooth muscle cells 
(Komuro et al, 1988), fibroblasts (Takuwa et al, 1989), mesangial cells (Simonson et 
al, 1989), and neural glial cells (MacCumber et al, 1990).
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2.1.6. Endothelin-1 in disease states
In view of its long-lasting vasoconstrictor effects on the vasculature, such as 
cerebral, coronary, and renal arteries, as well as the existence of mRNA and 
autoradiographic binding sites in many tissues throughout the body (MacCumber et 
al, 1989), people have speculated on the potential roles of endothelin-1 in 
pathophysiological states such as hypertension, cerebral vasospasm, Raynaud’s 
phenomenon, and uremia (Lerman et al, 1990; Cooke & Dzau, 1989). These ideas 
were further strengthened by the detection of raised levels of endothelin-1 in the 
circulation of patients with cardiovascular diseases (Lerman et al, 1990) and reports 
of hypertensive patients with "endothelin-secreting" tumours (Yokokawa et al,
1991). In addition, the mitogenic effect of endothelin-1 (see Section 1.5. for review) 
on vascular smooth muscle cells could indicate a possible role in hypertension and 
atherosclerosis. In the following, reports on endothelin-1 with respect to various 
disease states are reviewed and discussed.
(A) Endothelin-1 and hypertension
An increase in plasma endothelin-1 levels in essential hypertensive patients as 
compared to normotensive controls has been observed by some groups (Kohno et al, 
1990; Shichiri et al, 1990), while others could not confirm this finding. (Davenport 
et al, 1990; Schrader et al, 1990) Suzuki et al (1990) reported that plasma 
endothelin-1 levels in genetically hypertensive rats were lower than those in Wistar- 
Kyoto rats. However, no change was observed in plasma endothelin-1 levels in 
humans and rats with secondary hypertension, as compared to their normotensive 
controls (Schrader et al, 1990; Suzuki et al, 1990).
Binding studies in cultured vascular smooth muscle cells showed that the binding 
affinity for endothelin-1 was similar between spontaneously hypertensive and 
Wistar-Kyoto rats, while a decreased or unchanged maximal binding capacity 
(Bmax)in spontaneously hypertensive rats was observed (Clozel, 1989; Resink et al,
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1990). In contrast, an increased binding affinity of endothelin-1 in kidneys from 
spontaneously hypertensive rats has been reported (Jeng et al, 1991).
Reports on the vasoconstrictor activity of endothelin-1 in hypertensive animals 
are inconsistent, partly depending on the model or stage of hypertension, 
experimental conditions (in vivo or in vitro; conscious or anaethetised) as well as the 
specific vascular beds examined.
In 12-16 week spontaneously hypertensive rats, the blood pressure response to 
intravenous endothelin-1 has been reported to be increased (Martel et al, 1991), 
similar (Eglen et al, 1989; Hirata et al, 1989), or decreased (Winquist et al, 1989; 
Watanabe et al, 1989), as compared to Wistar-Kyoto rats.
An enhanced pressor response in the perfused mesenteric arteries from 
spontaneously hypertensive rats has been reported by some groups (Criscione et al, 
1990; MacLean & McGrath, 1990), while others (Tabuchi et al, 1990) observed no 
difference in responses. Similar pressor responses in the perfused tail arteries of 
spontaneously hypertensive and Wistar-Kyoto rats have also been reported 
(MacLean & McGrath, 1990).
An increased vasoconstrictor activity of endothelin-1, in terms of sensitivity or 
maximal tension development, has been observed in isolated aorta (Martel et al, 
1991; Clozel, 1989), renal artery (Tomobe et al, 1988), and mesenteric artery 
(Miyauchi et al, 1989), from 10-16-week spontaneously hypertensive rats as 
compared to their proper controls.
In animals with secondary hypertension, Yokokawa et al (1990) observed a 
significantly greater pressor response in both systemic and renal vascular beds in 
deoxycorticosterone-acetate-salt hypertensive rats as compared to normotensive 
control rats, de Carvalho et al (1990) reported that an enhanced vasoconstrictor 
response to endothelin-1 occurred in microvessels but not in macrovessels, from 
both Goldblatt renal hypertensive and deoxycorticosterone-acetate-salt hypertensive 
rats, as compared to normotensive controls.
(B) Endothelin-1 and atherosclerosis
An enhanced vasoconstrictor response to endothelin-1 in cerebral arteries from 
atherosclerotic animals has been observed (Lopez et al, 1990; Rossitch et al, 1991).
(C) Endothelin-1 and other disease states
Increased plasma endothelin concentrations have been observed in various disease 
states such as chronic renal failure (Schrader et al, 1990), acute myocardial 
infarction (Schrader et al, 1990; Miyauchi et al, 1989), acute renal failure (Shibouta 
et al, 1990), subarachnoid haemorrhage (Masaoka et al, 1989), cardiogenic shock 
(Cernacek & Stewart, 1989), pulmonary hypertension (Stewart et al, 1991), pre­
eclampsia (Greer et al, 1991), Raynaud’s phenomenon (Zamora et al, 1990), and 
sepsis (Pittet et al, 1991). Increased endothelin concentrations in cerebral spinal 
fluids in patients with subarachnoid haemorrhage (Suzuki et al, 1990), or in urine in 
patients with renal diseases (Ohta et al, 1991) have also been reported. Nevertheless, 
whether or how these increased endothelin concentrations are related to the 
vasospastic or hypertensive states remains to be elucidated.
Although some of the reports are controversial, taken together there is substantive 
evidence that alterations in the production of or responses to endothelin may 
contribute to the development of cardiovascular diseases or help to maintain and 
amplify disease once established. We therefore decided to include studies with 
endothelin in our protocol. However, most work with endothelin had been 
undertaken in the rat and even here much controversy existed as to its mechanism of 
action. It was therefore necessary to establish baseline parameters in normal rabbits 
before embarking on the main study with hypertensive and hypercholesterolemic 
animals. At the time the studies on phosphoinositide metabolism were undertaken, 
little had been published on endothelin’s effects on inositol phosphates production in 
vascular tissues. We therefore undertook some pilot studies in the rat, both for 
financial reasons, and also because at that time the rat was the only species in which
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the effects of endothelin had been studied in any detail.
2.2. Materials and methods
2.2.1. In vivo studies in the rabbit
(A) Blood pressure changes after endothelin injection in normal rabbits (n=6)
An arterial line was inserted for measurement of mean arterial pressure and heart 
rate in one ear under local anaesthesia (2% lignocaine), and a venous line for drug 
administration in the other. After catheter insertion, the rabbit was allowed to rest in 
an individual cage for 60 minutes before any measurement was made. Mean arterial 
pressure and heart rate were measured with a Statham P23 ID transducer and 
displayed using a Grass model 7B polygraph. Four doses of endothelin-1 (0.03, 
0.05, 0.10, & 0.20 nmol/kg) were given to each rabbit on two consecutive days, with 
a maximum of three dosages given in one day. The next dosage was not given until 
mean arterial pressure returned to baseline level, generally at least 30 minutes after 
the previous dosage. Mean arterial pressure and heart rate were followed 
continuously for the first 10 minutes after endothelin injection, and every 5 minutes 
thereafter.
(B) The effects of nifedipine on the endothelin-1-induced blood pressure changes in 
normal rabbits (n=7)
Another set of rabbits received first one dose of endothelin (0.10 nmol/kg), 
followed by a bolus injection of nifedipine (0.10 mg/kg) or vehicle followed 10 
minutes later by a bolus injection of endothelin (0.10 mg/kg). Nifedipine (0.10 
mg/kg) was used because it has been shown in our Department to cause marked falls 
in blood pressure in hypertensive rabbits and its interaction with other pressor agents 
has previously been studied. (Hamilton et al, 1987)
2.2.2. Studies of endothelin-l’s effects on phosphoinositide hydrolysis in rat aortic
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segments and rabbit aortic rings
(A) Studies in rat aortic segments
Sprague-Dawley rats were killed by cervical dislocation. Descending aorta were 
isolated and cleared of adherent tissue and then washed in Krebs Ringer bicarbonate 
buffer (KRB) solution for 10 minutes X 3 times, at 37°C with continuous bubbling 
of 95% 0 2 /5 % CC>2 . (KRB composition: NaCl 118.3 mM, KC14.7 mM, CaC^ 0.5 
mM, MgSC>4 1.2 mM, KH2PO4  1.2 mM, NaHCOg 25.0 mM, glucose 11.1 mM, 
bovine serum albumin 1.5%; pH 7.4.) The tissue was incubated for a further 10 
minutes in another KRB solution containing 10 mM LiCl and 2 pM imipramine. 
Afterwards the rat aorta was cut into 5 mm segments. One thoracic and one 
abdominal segment were put into each tube (except blank tubes) for incubation. The 
incubation medium was 0.5 ml KRB solution containing 10 mM LiCl (inhibiting the 
breakdown of inositol-1-monophosphate) and 2 pM imipramine (blocking the 
neuronal uptake of noradrenaline) and 0.5 pCi [^HJ-myoinositol. The tubes were 
incubated at 37°C under an atmosphere of 95% O2 /5 % CO2  for 4 hours unless 
otherwise stated. Different sets of experiments were conducted to investigate: (A) 
the dose-response relationships for phosphoinositide hydrolysis by endothelin (10“^  
to 10"^ M), (B) the time course of phosphoinositide hydrolysis stimulated by 
endothelin-1 (10“^ & 10"^ M) and noradrenaline (10"^ M), (C) the effect of 
endothelium removal on the endothelin (10"^ M)- and noradrenaline (10 '^  M)- 
stimulated phosphoinositide hydrolysis, (D) the effect of extracellular calcium in the 
KRB on the endothelin (10"^ M)- and noradrenaline (10 '^  M )-stim ulated 
phosphoinositide hydrolysis.
For dose response studies, endothelin-1 (10“^  to 10"  ^M) was added 30 minutes 
before the end of incubation. For time course studies, endothelin-1 or noradrenaline 
was added 5, 15, 30, and 60 minutes before the end of incubation. For endothelium 
removal, a cotton swab was gently applied on the aortic surface. For calcium
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dependence studies, KRB containing no Ca^+, as well as 0.5 mM Ca^+, were 
employed to compare the agonist-stimulated phosphoinositide hydrolysis in each 
medium. In addition, in some studies, EGTA (0.5 mM, final) was added 5 minutes 
before the addition of agonists to ensure complete removal of Ca^+ from the 
medium.
At the end of incubation, the radioactive [^H]-inositol mono-, bis-, and tris- 
phosphates were collected and counted after a series of separation procedures (see 
the "Materials and Methods" Section in "Chapter 6. Phosphoinositide Hydrolysis in 
Aorta from Hypertensive and Hypercholesterolemic Rabbits" for a detailed 
description). Background radioactivity in the blank tubes was deducted from both 
the basal, non-stimulated and agonist-stimulated radioactivity. Agonist-stimulated 
[■^H]-inositol phosphates formation was calculated as a percentage of basal values.
(B) Studies in rabbit aortic rings
Dose-response relationships for endothelin-stimulated phosphoinositide 
hydrolysis in New Zealand white rabbits were studied as in the rat aorta.
Aortic tissues were obtained from male Sprague-Dawley rats (Charles River 
Laboratory, Cheshire, UK.), weighing 150 to 250 g, and from male New Zealand 
white rabbits (Cheshire Rabbit Farms, Cheshire, UK.), aged 3-4 months, weighing 
2.0-2.5 kg.
Endothelin-1 was purchased from Scientific Marketing (Barnet, UK), and 
prepared as a 10'^ M stock solution, in 50 p.1 aliquots, and stored at -20°C. Dilutions 
were prepared from the stock aliquot immediately before use. Nifedipine was 
obtained from Sigma Chemical Co. (St Louis, USA) and dissolved in ethanol/arachis 
oil (v/v, 1:1) and protected from light at all times. [^-m yoinositol was purchased 
from Amersham International (Amersham, UK). Noradrenaline was prepared in
0.1% ascorbic acid. All other laboratory reagents unless specified were from Sigma 
Chemical Co. (Poole, UK)
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All results were expressed as mean ± S.D. Repeated measures analysis of 
variance was used to compare the various measurements, p < 0.05 was considered 
statistically significant.
2.3. Results
2.3.1. Blood pressure changes after endothelin-1 injection in rabbits
Baseline mean arterial pressure and heart rate were 68.0 ±3.1 mmHg and 227 ± 4 
bpm, respectively. Endothelin-1 (0.03, 0.05, 0.10, 0.20 nmol/kg) caused an initial 
depressor response (lasting less than 1 minute) followed by a long-lasting pressor 
response (generally at least 20 minutes). The pressor responses reached their peak 
levels between the 1st and 3rd minute after the injection of endothelin. There was a 
significant dose-dependent increase in the pressor response, while the depressor 
response tended to be dose-related, but did not reached significance overall possibly 
due to an insufficient number of data points. The maximal increases in blood 
pressure were 8.0 ± 2.8 mmHg, 10.0 ± 4.7 mmHg, 15.0 ± 2.1 mmHg, and 18.7 ± 6.5 
mmHg for the doses 0.03, 0.05, 0.10, and 0.20 nmol/kg endothelin,respectively. 
(Figure 2.4)
2.3.2. Effects of nifedipine on the endothelin-induced blood pressure changes 
Baseline mean arterial pressure decreased from 81.6 ± 2.6 mmHg to 77.1 ±1.4
mmHg, 10 minutes after the injection of nifedipine, but this failed to reach statistical 
significance. Nifedipine (0.1 mg/kg) significantly attenuated the pressor response to 
endothelin in the first minute (p < 0.05). From 2 to 5 minutes after endothelin, the 
nifedipine-induced attenuation was smaller and not statistically significant. From 5 
to 30 minutes, the endothelin-induced pressor response tended to return to baseline 
more slowly in the nifedipine-pretreated animals, but the difference was not 
significant (Figure 2.5). The depressor response was not affected by nifedipine pre-
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Figure 2.4: Changes in mean arterial pressure (a MAP) after endothelin-1 injection 
(0.03-0.20 nmol/kg, i.v.) in the rabbit.
Note the biphasic (depressor followed by pressor) responses. There was a 
significant dose-related pressor reponse to endothelin-1, and the maximum increases 
in blood pressure after 0.10 & 0.20 nmol/kg endothelin-1 were significantly greater 
than that after 0.03 nmol/kg (* & # : p < 0.05, respectively). (Mean ± S.D., n=6)
B-----B 0.03 nmol/kg endothelin-1.
A----- A 0.05 nmol/kg endothelin-1.
0 ----- 0  0.10 nmol/kg endothelin-1.
0.20 nmol/kg endothelin-1.
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Figure 2.5: Attenuation of the pressor response (a MAP) to endothelin-1 by 
nifedipine in the rabbit
Nifedipine bolus (0.1 mg/kg, i.v.) was given 10 minutes before the bolus 
injection of endothelin-1 (0.1 nmol/kg, i.v.; "time 0”).(* p < 0.05 versus endothelin 
alone. Mean ± S.D., n=7)
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treatment. Injection of vehicle had no effect on responses to endothelin, similar 
responses being observed after the first and second injection of endothelin under 
these conditions.
2.3.3. Endothelin-1-induced phosphoinositide hydrolysis in rat aortic segments
(A) Endothelin-stimulated phosphoinositide hydrolysis
Endothelin-1 (10"^ - 10"^ M) induced dose-dependent increases in 
phosphoinositide hydrolysis (i.e., [^H]-inositol phosphates formation). The increase 
was significant from 10'^ M onwards. N oradrenaline also increased 
phosphoinositide hydrolysis; however, the maximum increase with endothelin (1040 
± 438)% at 10"^ M was significantly greater than that induced by 10"^ M 
noradrenaline (306 ± 110)%. (Figure 2.6)
(B) Time course of endothelin- and noradrenaline-induced phosphoinositide 
hydrolysis
After the addition of endothelin (10"^ or 10"^ M), there was an initial rapid
o
increase in phosphoinositide hydrolysis. However, the rate of [JH]-inositol 
phosphates formation declined with time and there was little increase after 30 
minutes incubation with endothelin. On the other hand, noradrenaline (10"^ M)
'i
caused a continuous increase in pH]-inositol phosphates formation throughout 60 
minutes incubation. (Figure 2.7)
(C) Effect of endothelium removal on agonist-stimulated phosphoinositide 
hydrolysis
Endothelium removal significantly attenuated, but did not completely inhibit, 
endothelin-induced phosphoinositide hydrolysis. [^H]-inositol phosphates formation 
by 10"^ M endothelin decreased from (990 ± 201)% to (430 ± 229)% after the 
endothelium removal. In contrast, endothelium removal did not affect noradrenaline- 
induced [^H]-inositol phosphates formation ((188 ± 56)% and (231 ± 68)% of basal 
levels, in the presence, or Absence of endothelium, respectively). (Figure 2.8)
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Figure 2.6: Endothelin-1-stimulated [ ^H]-inositol phosphates formation in rat aorta.
( * p < 0.05 versus controls without endothelin-1. Mean ± S.D., n= 6 -10.)
The Mstograph shows noradrenaline-stimulated [ ^H]-inositol phosphates formation 
at 10 M for comparison.
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Figure 2.7: Time course of [^H]-inositol phosphates formation stimulated by 
endothelin-1 or noradrenaline.
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(D) Effect of extracellular calcium on the agonist-stimulated phosphoinositide 
hydrolysis
[^H]-inositol phosphates formation by 10“^  M endothelin was (435 ± 166)% 
when the aortic segments were incubated in 0 mM Ca2+ KRB, as compared to (669 
± 211)% at 0.5 mM Ca2+ KRB (p > 0.05), and was further decreased to (231 ± 
49)% when 0.5 mM EGTA was added into the 0 mM Ca2+ KRB (p < 0.05) 5 
minutes before the introduction of endothelin. [^H]-inositol phosphates formation by 
10"^ noradrenaline was (225 ± 79)% when incubated in 0 mM Ca2+ KRB, as 
compared to 259 ± 49% at 0.5 mM Ca2+ KRB (p > 0.05), while [^Hj-inositol 
phosphates formation by noradrenaline was (180± 35)% when incubated in 0.5 mM 
EGTA and 0 mM Ca2+ KRB (p > 0.05). (Table 2.1)
2.3.4. Endothelin-1-induced phosphoinositide hydrolysis in rabbit aortic rings 
Endothelin (10‘  ^ - 10"^ M) also caused a dose-dependent increase in
phosphoinositide hydrolysis in rabbit aortic rings, and the increase was significant 
from 10-7 M (204 ± 51)% to 10"  ^M (270 ± 92)%. However, the magnitude and the 
slope of endothelin-stimulated phosphoinositide hydrolysis was lower than that in rat 
aortic segments. (Figure 2.9)
2.4. Discussion
1. Endothelin-induced blood pressure changes in rabbits
Our study showed that intravenous injection of endothelin-1 caused two phases 
of blood pressure changes: an initial, short-lived depressor response (lasting less 
than 1 minute), followed by a long-lasting pressor response (generally lasting for 
more than 20 minutes). A depressor/pressor profile has also been reported by others 
in anaesthetized or conscious rabbits (Cocks et al, 1989; Lippton et al, 1991), dogs 
(Tsuchiya et al, 1990), cats (Minkes et al, 1989) and rats (King et al, 1990; Miyauchi
Table 2.1. Effect of calcium depletion on phosphoinositide hydrolysis by endothelin-1 and 
noradrenaline in rat aorta, (data expressed as % Basal [ 3H]-inositol phosphates)
KRB Conditions Endothelin-1 (10"** M) Noradrenaline (10"^ M)
0.5 mM [Ca2+]0 669 ±211% 259149%
OmM [Ca2+]0 4351166% 225 1 79%
OmM [Ca2+]„ +
0.5 mM EGTA
231 ± 49% 180135%
( Mean ± SX)., n = 5, * p < 0.05 vs 0.5 mM [Ca^4^ )
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Figure 2.9: Endothelin-1-stimulated [ ^H]-inositol phosphates formation in rabbit 
aorta.
(#  p< 0.05 versus controls without endothelin-1. Mean ± S.D., n= 7)
Also included in the figure is the endothelin-1-stimulated response in rat aorta for 
comparison.
A  in rabbit aorta.
@ in rat aorta.
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et al, 1989). The dose ranges for the pressor response were similar in this study to 
those reported by others in rabbits (Cocks et al, 1989; Lippton et al, 1991), dogs 
(Nakamoto et al, 1989), and rats (Miyauchi et al, 1989).
We also found that the dihydropyridine-sensitive calcium channel blocker, 
nifedipine, at the dosage of 0.1 mg/kg, could significantly attenuate, but not 
completely block, the pressor response to endothelin-1 (0.1 nmol/kg). The ability of 
a dihydropyridine-sensitive calcium channel blocker to reduce the in vivo pressor 
response was also demonstrated by others in rats (Knuepfer et al, 1989; Miyauchi et 
al, 1989), cats (Minkes et al, 1989), rabbits (Seino et al, 1990), and dogs (Otsuka et 
al, 1990). These findings are in line with the proposal that endothelin-1, though its 
binding sites are different from the dihydropyridine-sensitive calcium channels 
(Clozel et al, 1989; Gu et al, 1989; Miyazaki et al, 1990), may indirectly activate 
membrane calcium channels, and facilitate the influx of extracellular Ca^+ ions 
(Van Renterghem et al, 1988; Inoue et al, 1990; Marsault et al, 1990; Takuwa et al, 
1990).
We also found that endothelin-1 dose-dependently stimulated phosphoinositide 
hydrolysis in rabbit aortic rings. The ability of endothelin-1 to induce both 
vasoconstriction and phosphoinositide hydrolysis in arterial tissues has also been 
observed by others (Ohlstein et al, 1989; Pang et al, 1989; Rapoport et al, 1990). Of 
note here is that in our studies, the dose-response curves for in vivo pressor 
responses were to the left of the dose-response curves for phosphoinositide 
hydrolysis. Several explanations for this can be put forward;
(1) The phosphoinositide hydrolysis pathway is a major, but not exclusive, pathway, 
for endothelin-induced pressor or vasoconstrictor effects. Indeed, the susceptibility 
of the pressor response to calcium antagonists’ attenuation, as discussed above, 
argues for a complex regulating mechanism to bring about the end results-pressor or 
vasoconstrictor effects. Moreover, endothelin can stimulate phospholipase C as well
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as phospholipase A2  in vascular smooth muscle cells (Resink et al, 1989a; Reynolds 
et al, 1989). The arachidonic acid produced via the phospholipase A2  pathway may 
engender potential second messengers by way of cyclooxygenase or lipooxygenase 
pathways, which may contribute to the vasoconstrictor effects.
(2) A significant shift in the concentration-response curve for phosphoinositide 
hydrolysis to the right of that obtained for vascular contraction stimulated by other 
vasoconstrictors such as a  ^ -adrenoceptor agonists has been reported (Rapoport et al, 
1987; Langlands & Diamond, 1990). The presence of spare receptors for 
phosphoinositide hydrolysis which are not necessarily involved in the contractile 
response may account for such a shift (Langlands & Diamond, 1990). Alternatively,
as stressed by Karaki (1989), contractility of vascular smooth muscle may be
9 +  9 +regulated not only by [Ca^ but also by the Ca^ sensitivity of the contractile
9-i 2+
elements; i.e., the increase in [Ca ]^ , as well as the increase in the Ca sensitivity, 
contributes to the contractile processes.
(3) Different vascular beds were examined, i.e., aorta for phosphoinositide studies vs 
resistance arterioles for the in vivo experiments, as the latter were the main 
determinant for systemic resistance and therefore blood pressure changes.
The depressor response, which was short-lived, tended to be dose-related as well. 
Recent studies have suggested that potential dilator mechanisms, such as the 
secretion of endothelium-derived relaxing factor, the secretion of prostacyclin, or the 
secretion of atrial natriuretic peptide, may all contribute to this depressor/dilator 
response, depending on the animal species, the presence of hypertension, or the 
vascular beds examined, and on the doses applied (de Nucci et al, 1988; Kitazumi et 
al, 1990; Garcia et al, 1990; Lippton et al, 1991; Harris et al, 1991). Further studies 
by us also suggested that the cyclooxygenase inhibitor-indomethacin, or the nitric 
oxide synthase inhibitor-Nw-Nitro-L-arginine-methyl ester, as well as the presence 
of perinephritis hypertension, all modulated the depressor response to endothelin-1
in the rabbit (Hamilton et al, personal communication).
2. Endothelin-stimulated phosphoinositide hydrolysis in rat and rabbit aorta
Our results demonstrate that in the dose range 10“^  to 10'^ M, endothelin-1 
stimulated phosphoinositide hydrolysis in both rat and rabbit aorta, and the increase 
in rH]-inositol phosphates formation was greater in rat aorta than in rabbit aorta at 
all concentrations. Thus in terms of phosphoinositide hydrolysis stimulation, 
endothelin-1 is more efficacious in the rat aorta than in the rabbit aorta. So far no 
other comparative studies in the rat and rabbit aorta on endothelin-stimulated 
phosphoinositide hydrolysis are available in the literature. It remains to be elucidated 
whether the difference in these two species in our studies is due to differences in the 
receptor density, or the signal-transducing apparatus such as G-proteins or 
phospholipase C.
In the rat aorta, the effect of endothelin-1 on the stimulation of phosphoinositide 
hydrolysis was more potent as well as more efficacious than that of noradrenaline. 
This finding echoed the findings in the vessel strip studies showing endothelin-1 as 
the most potent among the common vasoconstrictors (Yanagisawa et al, 1988).
Our data also suggested that extracellular Ca depletion by incubation m 0 mM 
Ca^+ KRB, and more distinctly, incubation in 0 mM Ca^+ KRB and 0.5 mM 
EGTA, could attenuate, but not completely abolish the endothelin-stimulated 
phosphoinositide hydrolysis in the rat aorta. The attenuation of stimulated 
phosphoinositide hydrolysis by Ca^+ depletion was more pronounced in the case of 
endothelin-1 than that of noradrenaline. The absence of statistical significance for 
some comparisons could be due to our small sample size (n= 5). (In the case of
9 1
endothelin-stimulated phosphoinositide hydrolysis in 0 vs 0.5 mM Car KRB, a 
reduction was seen in 4 out of 5 experiments.) Rapoport (1987) also found that
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noradrenaline-stimulated phosphoinositide hydrolysis in rat aorta was significantly
9 I
attenuated in the Ca free and EGTA incubation media as compared to the normal-
9  i
Ca KRB media. In contrast, Ohlstein et al (1989) reported that endothelin- 
stimulated phosphoinositide hydrolysis was not affected by Ca^+-free plus EGTA 
incubation in the rabbit aorta. EGTA is a very strong chelator, and may modify 
levels of free intracellular as well as extracellular Ca^+. Results with EGTA must 
therefore be treated with caution; different results may depend upon the exact assay
9 ,
conditions and chelation of intracellular Ca could also contribute to the effects on 
agonist-induced phosphoinositide hydrolysis. In cultured rat aortic smooth muscle 
cells, Muldoon et al (1989) observed that endothelin-stimulated phosphoinositide 
hydrolysis was partially diminished by extracellular calcium depletion. Similarly, a
9  i
partial inhibition in endothelin-stimulated [Ca^ elevation was reported in cultured
rat aortic smooth muscle cells (Danthuluri & Brock, 1990). Thus, in our and others’
studies on rat vascular smooth muscle cells, endothelin-stimulated phosphoinositide
94 -hydrolysis was affected by extracellular Ca depletion.
In the time course study of endothelin-stimulated phosphoinositide hydrolysis in 
the rat aorta, there was an attenuation of [JH]-inositol phosphates formation with 
time after 30 minutes of stimulation. Various explanations for this are possible:
(1) Could it be due to substrate ([^HJ-phosphoinositides) exhaustion ?
Comparison of the radioactivities in the lipid phase, which comprised membrane
[^Hj-phosphoinositides, in the non-stimulated tubes with the endothelin-stimulated 
tubes, showed that there was little reduction in the [^Hj-phosphoinositides even after 
60 minutes of stimulation (Huang et al, 1989). Moreover, the time course studies 
were conducted using 10"^ and 10“^  M endothelin. In other experiments we showed 
that the [^H]-inositol phosphates formation stimulated by 10"^ M endothelin was 
consistently greater than that by 10"^ or 10"  ^M endothelin. Thus the possibility of 
substrate exhaustion is not substantiated.
(2) Could it be due to desensitization by protein kinase C which could be activated
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via the phosphoinositide pathway ?
To test this hypothesis, we added the protein kinase C inhibitor, H7 (50 p.mol/1) 
into the incubation medium 10 minutes prior to the administration of endothelin, and 
found that it had no effect on the [^H]-inositol phosphates formation in our study 
(Huang et al, 1989), although this concentration of H7 has previously been shown to 
abolish the inhibitory action of one phorbol ester, 12-o-tetradecanoyl-phorbol 13- 
acetate, on the phosphoinositide hydrolysis (Berta et al, 1988).
(3) Could it be due to receptor down-regulation ?
Hirata et al (1988b) showed that in primary cultures of rat aorta, exposure to 
endothelin for 24 hours led to a substantial decrease in [ ^ 1 ] -endothelin binding 
capacity, but not binding affinity, and to attenuated responses. Autoradiographic 
studies also revealed the internalisation of endothelin receptors within the cell and 
subsequent sequestration by the lysosomes. In our in vivo studies, no alteration of 
responses was observed in the rabbit on repeated dosing with endothelin, suggesting 
that in vivo prologed exposure may be required before down-regulation or 
desensitization is observed. However, repeated dosing may not have the same 
consequences as continued exposure to the agonist. Thus the attenuation of [ H]- 
inositol phosphates formation after 30 minutes of endothelin stimulation might be 
due to receptor down-regulation, but this remains to be confirmed.
Phosphoinositide hydrolysis by endothelin in the rat aorta did not depend on the 
presence of the endothelium, although it was attenuated with endothelium removal. 
The possibility of damage or loss of smooth muscle by the procedure is not favoured 
since, in concurrent experiments, phosphoinositide hydrolysis by noradrenaline was 
not affected by endothelium removal. So far we have no satisfactory explanation for 
this interesting finding. On the other hand, studies in the vessel strips showed that 
the tension development, i.e., vasoconstriction induced by endothelin, could be 
enhanced by endothelium removal (Eglen et al, 1989; Kauser et al, 1990).
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In summary, we have shown that endothelin-1 can induce a short-lived depressor 
response followed by a long-lasting pressor response in conscious rabbits. The 
pressor response was dose-related, and reached a maximum between 1 and 3 minutes 
after injection of endothelin. Moreover, this pressor response was attenuated by 
nifedipine.
Endothelin-1 also stimulated phosphoinositide hydrolysis in both rat and rabbit
aorta; the effect was greater in the rat.
Endothelin-stimulated phosphoinositide hydrolysis was attenuated after 30
9 +minutes stimulation, and also by extracellular Ca depletion, and by endothelium 
removal. Endothelin-stimulated phosphoinositide hydrolysis was greater than that by 
noradrenaline.
The effects on phosphoinositide hydrolysis were only examined in aorta, but this
94 -work is consistent with the hypothesis that increased [Ca^ ]^ , via stimulation of 
phosphatidylinositol 4,5-bisphosphate hydrolysis, and an influx of extracellular 
calcium may both contribute to the vasoconstrictor response to endothelin.
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CHAPTER 3 
OVERALL DESIGN FOR STUDIES ON 
HYPERTENSIVE AND HYPERCHOLESTEROLEMIC RABBITS
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Chapter 3. Overall Study Design
In this chapter, the study design is discussed, including selection of animals and 
measurements made. Overall effects of treatment on parameters such as body 
weight, blood pressure, and survival are presented.
3.1. Preparation of hypertensive and hypercholesterolemic rabbits
3.1.1. Animal groups
Male New Zealand white rabbits aged 3-4 months were obtained from Cheshire 
Rabbit Farms (Cheshire, UK) and allocated to one of four different groups:
(1) Control Group—sham operated, normal diet.
(2) Hypercholesterolemic Group—sham operated, 0.3% cholesterol diet.
(3) Hypertensive Group—renal wrapping operation, normal diet.
(4) Hypertensive-Hypercholesterolemic Group—renal wrapping operation, 0.3% 
cholesterol diet.
3.1.2. Renal wrapping operation
Perinephritis hypertension was induced by unilateral renal wrapping in 
cellophane and contralateral nephrectomy. Sham operated animals had one kidney 
removed and the other kidney manipulated but not wrapped. The operation was 
performed under barbiturate anaesthesia (sodium pentobarbitone, 30-40 mg/kg).
Perinephritis hypertension was first established by Page (1939) when he applied 
cellophane around the kidney in the dog, rabbit, or cat, and found that it induced an 
intensive inflammatory reaction around the kidney; as a result, sustained 
hypertension appeared in 3 to 4 weeks in the animals (Page, 1939; Graef & Page, 
1940). Brace et al (1974) reported that in dogs the inflammatory reaction (scar 
tissue) around the wrapped kidney generated an increase of pressure (25-30 mmHg)
62
in the kidney, while the mean arterial pressure rose by an average of 66 mmHg. 
Several groups have put forward possible mechanisms for the generation of 
hypertension in this model. Page (1939) suggested that the pathophysiological 
mechanism for the rise in blood pressure in this model was similar to that of the 
Goldblatt renal hypertension model induced by constricting the renal arteries. Later, 
some divergent results emerged with regard to the importance of the renin- 
angiotensin system in the etiology of this model of hypertension. In dogs and 
rabbits, one-kidney wrapping and contralateral nephrectomy induced hypertension 
apparently independent of the renin-angiotensin system. Plasma renin activity was 
not elevated and chronic hypertension was not reduced by blockade of the renin- 
angiotensin system with angiotensin antagonists (Bumpus et al, 1973; Johnson et al, 
1976; Ichikawa et al, 1977). In contrast, two-kidney cellophane wrapping induced 
hypertension with increased plasma renin activity. The chronic hypertension could be 
reduced by inhibitors of angiotensin converting enzyme (Denton & Anderson, 1985; 
DeForrest et al, 1989). Thus although renal wrapping is a reliable model for 
inducing secondary hypertension in animals, the mechanisms causing hypertension 
may differ with respect to operation procedures and remain to be clarified.
Hamilton & Reid (1983) reported that unilateral renal wrapping and contralateral 
nephrectomy in rabbits induced a rise of 35-50 mmHg in mean arterial pressure in 
the established phase of hypertension (3 to 6 weeks after operation and later on), but 
no significant changes in heart rate, plasma noradrenaline, adrenaline, sodium, 
potassium, or bicarbonate levels. Plasma renin activity and renal excretory function 
were not altered either. No change in body weight profile was observed due to renal 
operation.
3.1.3.0.3% Cholesterol diet
A 0.3% cholesterol diet was prepared by mixing rabbit chow and appropriate
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amounts of cholesterol dissolved in ether. Ether was then evaporated off. Cholesterol 
diet was started in the hypercholesterolem ic and the hypertensive- 
hypercholesterolemic groups on the day after the renal operation.
The control and the hypertensive groups received normal rabbit chow (suppliers).
The rabbit, being herbivorous, is susceptible to hypercholesterolemia and 
atherosclerosis when challenged with a cholesterol diet, because it has great 
difficulty in metabolizing and excreting cholesterol. Thus the rabbit is widely used 
as an animal model of hypercholesterolemia and atherosclerosis induced by 
cholesterol diet (Stehbens, 1986). Nevertheless, researchers have found some 
important differences between experimentally-induced and human clinical 
hypercholesterolemia and atherosclerosis. Firstly, the correlation between the serum 
cholesterol level and the extent of lipid deposition is often poor in experimental 
animals, whereas human autopsy findings show a significant correlation between 
serum cholesterol and the severity of atherosclerotic lesions (Stehbens, 1986; 
Solberg & Strong, 1983). Secondly, in the cholesterol-fed rabbit aorta, the lipid- 
containing lesions are generally more extensive proximally than distally, in contrast 
to the enhanced severity in the abdominal aorta and iliac arteries in man (Stehbens, 
1986). Despite these differences, cholesterol-diet feeding in the rabbit is an easily 
reproducible model of experimental hypercholesterolemia and atherosclerosis. 
Cholesterol feeding in rabbits can induce hypercholesterolemia and fatty streaks, 
fibrous plaques, and eventually, complicated atherosclerotic lesions, in aorta and 
other major conduit arteries. Early atherosclerotic lesions in the cholesterol-fed 
rabbit occur in predilection sites such as ascending aorta, aortic arch, and branch 
orifices in the descending thoracic and abdominal aorta. Monocyte adherence to the 
endothelial surface, lipid-laden macrophages in the intima, smooth muscle cell 
accumulation in the intima, lipid accumulation in the endothelial cells, intimal 
smooth muscle cells, as well as in the extracellular space, bulging of the intimal fatty 
lesions into the lumen, accumulation of extracellular collagen and fibrous matrix,
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smooth muscle cell proliferation, and necrotic lipid lesions, have all been observed 
either in sequence or concurrently (Stehbens, 1986; Rosenfeld et al, 1987). 
Moreover, the severity of atherosclerotic lesions can be aggravated by the imposition 
of experimental hypertension upon the cholesterol-fed rabbits (Stehbens, 1986). In 
primates, cholesterol-feeding and experimental hypertension have additive effects 
on the extent of atherosclerotic lesions (Hollander et al, 1976; McGill et al, 1985).
3.2. Study protocols:
3.2.1. Overall scheme of study
Four groups of animals were studied as shown in Table 3.1 in order to examine 
effects of hypertension, hypercholesterolem ia, and hypertension- 
hypercholesterolemia on a number of cardiovascular parameters with a view towards 
identifying possible sites of interaction of the disease states.
Blood pressure, heart rate, body weight, plasma cholesterol levels and general 
health were monitored throughout the study. Responses to a range of vasoconstrictor 
and vasodilator drugs were studied at 2-3, 6-7, and 13-16 weeks. P latelet 
intracellular Ca^+ levels and aortic phosphoinositide metabolism were examined at 
the 17th and 18th weeks after surgery, respectively, as shown in Table 3.1.
3.2.2. Measurement of mean arterial pressure, heart rate, plasma cholesterol, and 
body weight
After 2-hours fasting, a polypropylene catheter was inserted into the central ear 
artery of the rabbit under local anaesthesia (2% lignocaine). 1 ml of blood was 
collected into a lithium heparin tube and centrifuged at 2500 rpm for 10 minutes. 
Plasma was collected and assayed for cholesterol levels using an enzymatic 
colorimetric method (Boehringer Mannheim Reagent).
Mean arterial pressure and heart rate were measured from the arterial line after
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Table 3.1. Overall scheme of study in the rabbits
Time Procedures Types of measurement
Pre-Op. week Recruitment & Allocation A B
Day 0 Renal wrapping or sham operation
Day 1 0.3% cholesterol or normal diet
Week 1 B
Week 2 B
Week 3 A B C
Week 4 B
Week 5 A B
Week 6 B
Week 7 A B C
Week 8 B
Week 9 A B
Week 10 B
Week 11 A B
Week 12 B
Weeks 13-16 A B C
Week 17 A B D
Week 18 Rabbits killed and aorta prepared E
* Time in reference to renal operation date.
A: Measurement of mean arterial pressure, heart rate, & plasma cholesterol.
B: Measurement of body weight
C: Measurement of vascular reactivity to pressor & depressor drugs.
D: Measurement of platelet [C a ^ j.
E: Measurement of aortic phosphoinositide responses to endothelin-1 & noradrenaline.
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the rabbit was allowed to rest for 60 minutes in an individual cage in a quiet warm 
laboratory. The arterial line was connected to a Statham P23 ID transducer and 
arterial pressure was displayed using a Grass Model 7B polygraph. Heart rate was 
determined from the pressure trace.
Mean arterial pressure, heart rate, and plasma cholesterol were measured before 
the renal operation (initial readings) and thereafter fortnightly.
Rabbit body weight was measured each week and the general wellbeing of the 
animal assessed.
3.2.3. Sudan Red staining of the atherosclerotic lesions
To demonstrate the extent of fatty deposition on the intimal surface of aorta and 
femoral artery in groups on normal and cholesterol diets, Sudan Red staining was 
carried out on the opened segments when the rabbits were killed for the 
phosphoinositide study at the 18th week. The staining method was adopted from 
published papers (Holman et al, 1958). In short, the opened aorta and femoral artery 
were pinned on a silicone bed and rinsed briefly in 70% alcohol, then immersed in 
the Sudan Red staining solution (5 g Sudan IV in 500 ml of 70% ethyl alcohol and 
500 ml of acetone). After 15 minutes of staining with intermittent agitation, the 
specimens were differentiated in 80% alcohol for 20 minutes, then washed in 
running tap water for 1 hour.
3.3. Data analysis
1. All measurements of mean arterial pressure, heart rate, plasma cholesterol, and 
body weight at each time point were expressed as mean ± S.D. (n = 15-20 in each 
group) Repeated measures analysis of variance was used to compare each 
experimental group with the control group, p < 0.05 was considered significant.
2. Survival and causes of death analysis—All the rabbits that died prematurely
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before the completion of the scheduled studies were recorded. Only the deaths which 
occurred 2 weeks or more after surgery were analyzed for probable causes of death, 
as early deaths were attributed to anaesthesia overdose, surgical stress, or related 
causes. Deaths were ascribed to cardiovascular causes when signs of hypertensive 
encephalopathy such as unstable gait, convulsion, oral or nasal bleeding, or autopsy 
findings of haemorrhagic spots in the brain or myocardial infarct lesions in the heart 
were observed. Deaths were ascribed to non-cardiovascular causes when specific 
reasons such as death due to lignocaine anaesthesia or drug injection, diarrhea, 
sacrifice due to severe ear infection or loss of appetite and weight, were identified.
"Life Tables and Survival Functions" (BMDP1L--BMDP Statistical Software, 
Inc., Los Angeles, U.S.A.) were employed to compare the patterns of total as well as 
cardiovascular deaths in each experimental group with those in the control group. 
Breslow analysis was used and p < 0.05 was considered significant
3.4. Results
3.4.1. Mean arterial pressure profiles
As shown in Figure 3.1, there were no differences in mean arterial pressure at the 
initial, pre-operation time point between any of the groups. From 2-3 weeks on, 
mean arterial pressure was significantly higher in both the hypertensive and 
hypertensive-hypercholesterolemic groups as compared to the control group. There 
was no difference in mean arterial pressure between the hypercholesterolemic and 
the control groups or between the hypertensive and the hypertensive- 
hypercholesterolemic groups throughout the whole study. Mean arterial pressure in 
the hypertensive and the hypertensive-hypercholesterolemic groups tended to 
stabilize after 6-7 weeks. The mean arterial pressure in the hypertensive and the 
hypertensive-hypercholesterolmic groups rose from between 60-70 mmHg at the 
initial, pre-operation time point to 110-140 mmHg at the established phase of 
hypertension.
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Figure 3.1: Mean arterial pressure profiles in each group of rabbits.
( * & # — p < 0.05 for the hypertensive and the hypertensive-hypercholesterolemic 
groups versus the control group, respectively. Mean ± S.D., n = 16 - 20.)
□  Control group.
A Hypercholesterolemic group.
A  Hypertensive group.
#  Hypertensive-Hypercholesterolemic group.
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3.4.2. Heart rate profiles
As shown in Figure 3.2, there was no difference in heart rate between the 
experimental groups and the control group at either the initial or later time points up 
to 14-15 weeks. At 16-17 weeks, the heart rates in the hypercholesterolemic and the 
hypertensive-hypercholesterolemic groups were significantly less than that in the 
control group.
3.4.3. Plasma cholesterol profiles
As shown in Figure 3.3, initial plasma cholesterol levels were between 1.0 and 
1.3 mmol/L, and there was no difference between groups. Later on, plasma 
cholesterol levels in the control and the hypertensive groups stabilized between 0.7 
and 1.1 mmol/L; there was no difference between them at any time points. In the 
hypercholesterolemic and the hypertensive-hypercholesterolemic groups, plasma 
cholesterol levels rose sharply and continually with cholesterol feeding, and all the 
plasma cholesterol levels in both groups (except for the 2-3 week point in the 
hypertensive-hypercholesterolemic group) were significantly greater than those in 
the control group. They rose from 7.2-10.6 mmol/L at 2-3 weeks to 29.5-33.1 
mmol/L at 16-17 weeks. Of note is that there was noticeable variation in individual 
susceptib ility  to cholesterol feeding among the rabbits in both the 
hypercholesterolemic and the hypertensive-hypercholesterolemic groups, hence the 
standard deviation was quite large at some points in both groups.
3.4.4. Body weight profiles
As shown in Figure 3.4, there was no difference in body weight between any of 
the experimental groups and the control group initially or at any time point up to 10- 
11 weeks. At 12-13,14-15, and 16-17 weeks, the body weight in the control group
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Figure 3.2: Heart rate profiles in each group of rabbits.
( * & # — p < 0.05 versus the control group, respectively. Mean ± S.D., n = 15 - 
20.)
□  Control group.
A Hypercholesterolemic group.
♦  Hypertensive group.
0  Hypertensive-Hypercholesterolemic group.
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Figure 3.3: Plasma cholesterol profiles in each group of rabbits.
( * & # - - -  p < 0.05 for the hypercholesterolem ic and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively. Mean ± S.D., n 
= 16-19.)
□  Control group.
A Hypercholesterolemic group.
♦  Hypertensive group.
#  Hypertensive-Hypercholesterolemic group.
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Figure 3.4: Body weight profiles in each group of rabbits.
( * & # & a — p < 0.05 for the hypercholesterolemic, the hypertensive, and the 
hypertensive-hypercholester olemic groups versus the control group, respectively. 
Mean ± S.D., n = 15 -17.)
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was significantly greater than that in any experimental group.
3.4.5. Fatty deposition in the aorta and femoral arteries
Representative pictures of the aorta (at the thoracic and abdominal juncture) and 
the femoral artery (middle part) from each group are shown in Colour Plates 1 to 8.
Of note here is that there was little or no Sudan Red staining in the aorta or the 
femoral artery from the control and the hypertensive groups, suggesting little fatty 
deposition in either group. However, the aortic intimal surface was grossly deposited 
with Sudan Red in both the hypercholesterolem ic and the hypertensive- 
hypercholesterolemic groups, suggesting a high degree of fatty deposition in these 
two cholesterol-fed groups. To a lesser degree than the aortic surface, the femoral 
arterial surface was also stained with Sudan Red in both cholesterol-fed groups, 
suggesting that the fatty deposition was less diffuse or extensive in the femoral 
artery.
3.4.6. Survival and causes of death
In the control group, there was one death related to lignocaine injection, one 
death to drug injection, one death as a result of sacrifice due to severe ear infection, 
and one death as a result of diarrhea, making up a total of four "non-cardiovascular 
deaths". One "cardiovascular death" was assigned because the rabbit exhibited 
cyanotic outlook, and on the previous day, blood pressure was only 50 mmHg at 16- 
17 weeks after operation.
In the hypercholesterolemic group, one death was related to drug injection, one 
death as a result of sacrifice due to severe ear infection, and one to severe weight 
loss, making up a total of three "non-cardiovascular deaths". There was no 
cardiovascular death in this group.
In the hypertensive group, there were three deaths related to drug injection, and
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Colour Plate 1: Representative specimen of the aortic intima in the rabbit from the 
Control group, using Sudan Red staining technique.
Colour Plate 2: Representative specimen of the femoral intima in the rabbit from the 
Control group, using Sudan Red staining technique.
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Colour Plate 3: Representative specimen of the aortic intima in the rabbit from the 
Hypercholesterolemic group, using Sudan Red staining technique.
Colour Plate 4: Representative specimen of the femoral intima in the rabbit from the 
Hypercholesterolemic group, using Sudan Red staining technique.
* Note: The fatty depositions were stained with Sudan Red.
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Colour Plate 5: Representative specimen of the aortic intima in the rabbit from the 
Hypertensive group, using Sudan Red staining technique.
Colour Plate 6: Representative specimen of the femoral intima in the rabbit from the 
Hypertensive group, using Sudan Red staining technique.
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Colour Plate 7: Representative specimen of the aortic intima in the rabbit from the 
Hypertensive-Hypercholesterolemic group, using Sudan Red staining technique.
Colour Plate 8: Representative specimen of the femoral intima in the rabbit from the 
Hypertensive-Hypercholesterolemic group, using Sudan Red staining technique.
* Note: The fatty depositions were stained with Sudan Red.
one to severe weight loss, making up a total of four "non-cardiovascular deaths". Six 
"cardiovascular deaths" were ascribed with signs of hypertensive encephalopathy 
such as unstable gait, oral or nasal bleeding, convulsion, or autopsy findings of left 
ventricular hypertrophy, or haemorrhagic spots in the brain. One occurred at 2-3 
weeks, one at 3-4 weeks, one at 4-5 weeks, one at 8-9 weeks, and two at 15-16 
weeks.
In the hypertensive-hypercholesterolemic group, one death was related to 
lignocaine injection, and two deaths to drug injection, making up a total of three 
"non-cardiovascular deaths". There were eleven deaths ascribed as "cardiovascular", 
two at 3-4 weeks, three at 4-5 weeks, two at 6-7 weeks, two at 7-8 weeks, and two at 
9-10 weeks, with physical signs of unstable gait, oral or nasal bleeding, convulsion, 
or autopsy findings of left ventricular hypertrophy or cerebral haemorrhage.
In the "Life Tables and Survival Functions" analysis, there was no significant 
difference in the profile of "total deaths" between the control group and any 
experimental group. (Figure 3.5) There was no significant difference in the profile of 
"cardiovascular deaths" between the control group and the hypercholesterolemic 
group. (Figure 3.6 & Table 3.2) In contrast, both the hypertensive and the 
hypertensive-hypercholesterolemic groups suffered more cardiovascular deaths than 
the control group, the difference being significant. (p= 0.038 and 0.009, 
respectively) (Figure 3.6) However, there was no significant difference between the 
hypertensive and the hypertensive-hypercholesterolemic groups, although at later 
time points, the hypertensive-hypercholesterolemic group tended to have more 
cardiovascular deaths than the hypertensive group. (Figure 3.7)
3.5. Summary and discussion
1. Hypertension and hypercholesterolemia were induced in the renal cellophane 
wrapping and 0.3% cholesterol diet models, respectively. Blood pressure rose and 
stabilized at about 6-7 weeks after operation in the two groups which had undergone
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Figure 3.5: Profiles showing cumulative proportion of animals surviving in each 
group of rabbits when both cardiovascular and non-cardiovascular deaths were 
counted.
The abscissa axis is the number of study days in referece to the renal operation 
date as Day 0, and the ordinate axis is the ratio of survivors in reference to the 
starting point as 1.0. Note that although there were more total deaths in the 
hypertensive and the hypertensive-hypercholesterolemic groups as compared to the 
control group, the difference did not reach significance.
A----- Control group.
B----- Hypercholesterolemic group.
C----- Hypertensive group.
D----- Hypertensive-hypercholesterolemic group.
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Figure 3.6: Profiles showing cumulative proportion of animals surviving in each 
group of rabbits when only cardiovascular deaths were counted.
ftThe abscissa axis is the number of study days in referece to the renal operation 
date as Day 0, and the ordinate axis is the ratio of survivors in reference to the 
starting point as 1.0. There were significantly more cardiovascular deaths in the 
hypertensive ( *— p = 0.038.) and the hypertensive-hypercholesterolemic groups ( 
# — p = 0.009.)as compared to the control group, while there was no difference in 
cardiovascular deaths between the hypercholesterolemic and the control groups.
A------Control group.
B------Hypercholesterolemic group.
C------Hypertensive group.
D------Hypertensive-hypercholesterolcmic group.
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Figure 3.7: Profiles showing cumulative proportion of animals surviving in the 
hypertensive and the hypertensive-hypercholesterolemic groups when only 
cardiovascular deaths were counted.
The abscissa axis is the number of study days in referejpe to the renal operation 
date as Day 0, and the ordinate axis is the ratio of survivors in reference to the 
starting point as 1.0. Note that although there were more cardiovascular deaths in the 
hypertensive-hypercholesterolemic group as compared to the hypertensive group 
(32.4% vs 25.0%, respectively), the difference did not reach significance.
H------Hypertensive group.
C----- Hypertensive-hypercholesterolemic group.
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Table 3.2. Data of survivals and causes of death in each group of rabbits
Category Control Gr. Choi. Gr. Ht. Gr. Ht-Chol. Gr.
Total No. of rabbits 21 23 24 34
No. of CV deaths 1 0 6 11
% of CV deaths 4.8% 0% 25.0%* 32.4% *
No. of non-CV deaths 4 3 4 3
No. of survivals 16 20 14 20
* p <  0.05 vs Control group.
( Abbreviations: CV, cardiovascular, Choi, hypercholesterolemic; Ht, hypertensive.)
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cellophane wrapping, while plasma cholesterol continued to rise from the time of 
introduction of the cholesterol diet, even up to the last sampling time (16-17 weeks).
2. Perinephritis hypertension did not change the plasma cholesterol profile, and vice 
versa, cholesterol feeding did not change the blood pressure profile, in the rabbit.
3. Cholesterol feeding or perinephritis hypertension generally did not change the 
profiles of body weight or heart rate.
4. Cholesterol feeding induced a marked degree of fatty deposition in the intimal 
surface of aorta and to a lesser degree, in the femoral artery. In contrast, there was 
little or no fatty deposition in the aorta or femoral artery in the "normal-diet" 
normotensive or hypertensive rabbits.
5. There was no difference in the likelihood of cardiovascular deaths between the 
control group and the hypercholesterolemic group. Both the hypertensive and the 
hypertensive-hypercholesterolemic groups had significantly more cardiovascular 
deaths than the control group. The hypertensive-hypercholesterolemic group tended 
to have more cardiovascular deaths than the hypertensive group, suggesting that 
hypercholesterolemia could augment cardiovascular mortality in the hypertensive 
animals. However, the difference between the hypertensive and the hypertensive- 
hypercholesterolemic groups was not significant in our study. The absence of 
significance could be due to small sample size. Much larger groups would be 
required to detect small differences between these groups.
Thus hypertension in this study was an important risk factor for cardiovascular 
deaths and hypercholesterolemia tended to augment this risk, although no synergism 
or interaction was detected in these two groups in terms of plasma cholesterol, blood 
pressure, heart rate, or body weight.
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CHAPTER 4
PRESSOR AND DEPRESSOR RESPONSES IN 
HYPERTENSIVE AND HYPERCHOLESTEROLEMIC RABBITS
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C hapter 4. Pressor and D epressor Responses in H ypertensive and
Hypercholesterolemic Rabbits
4.1. Introduction
For several decades haemodynamic studies have played a crucially important part 
in hypertension research. Studies carried out on the offspring of hypertensive parents 
and in the early stages of hypertension in animal models have identified  
"predisposing characteristics" in terms of haemodynamic parameters which would 
subsequently lead to the established phase of hypertension, with increased peripheral 
resistance as its hallmark. Hence "neurogenic" and "volume" variants have been 
proposed as two main patterns of early haemodynamic events in primary 
hypertension (Folkow, 1982). On the other hand, studies on haemodynamic changes 
in established hypertension (either primary or secondary in etiology) are also 
essential in understanding the pathophysiology of hypertensive states. Investigations 
of the pressor or depressor responses to agonists such as noradrenaline, adrenaline, 
angiotensin II, or other neurotransmitters, hormones, or drugs have played a major 
part in these haemodynamic studies.
4.1.1 In vivo haemodynamic changes in response to various agonists in hypertension
a. a-Adrenoceptor agonists
In patients with essential hypertension, increased pressor responses to 
noradrenaline have been reported (Mendlowitz & Naftchi, 1958; Vlachakis, 1979). 
Similar observations have been made in several animal models of experimental 
hypertension, including spontaneously hypertensive rats (Hicks et al,1983), 
deoxycorticosterone-salt hypertensive and Goldblatt renal hypertensive rats (Finch 
& Haeusler, 1974), and perinephritis hypertensive rabbits (Hamilton & Reid, 1983).
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Enhanced pressor responses to phenylephrine and other selective (Xj-adrenoceptor 
agonists have also been shown in essential hypertensive patients (Jie et al, 1986), 
spontaneously hypertensive rats (Hicks et al, 1983), and perinephritis hypertensive 
rabbits (Hamilton & Reid, 1983). Thus there is an increased response to a j -  
adrenoceptor agonists reported in various forms of hypertension. An enhanced otj- 
adrenoceptor-mediated pressor response has also been observed in essential 
hypertensive patients (Jie et al, 1986), and perinephritis hypertensive rabbits 
(Hamilton et al, 1986).
b. p-Adrenoceptor agonists
Most published papers have reported a decreased responsiveness to bolus 
injections of isoproterenol in essential hypertensive patients in terms of heart rate 
changes (chronotropism) (Feldman, 1987); however, an increased or similar 
response to isoproterenol has been observed in borderline hypertensive patients 
(Messerli et al, 1976; London et al, 1976; Henquet et al, 1982). In spontaneously 
hypertensive rats, a decreased in vivo response to isoproterenol was seen in the 
"established phase", but not in the "developing phase" of hypertension (Toal & 
Leenen, 1984; Pfeffer et al, 1974). A reduced in vivo response to isoproterenol, 
measured as tail skin temperature changes, has also been observed in renal 
hypertensive rats (Katovich et al, 1978). Thus the picture with respect to p- 
adrenoceptor-mediated responses in vivo may vary with the stage of hypertension.
c. Angiotensin II
Enhanced pressor responses to angiotensin II have also been reported in essential 
hypertensive patients (Doyle & Black, 1955), spontaneously hypertensive rats 
(Hicks et al, 1983), and deoxycorticosterone-salt hypertensive rats (Finch, 1971). In 
contrast, Hamilton & Reid (1983) found similar pressor responses to angiotensin II
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in perinephritis hypertensive and control normotensive rabbits, in the presence of 
increased pressor responses to noradrenaline and phenylephrine. Toal & Leenen 
(1985) observed a significantly decreased pressor response to angiotensin II in 
spontaneously hypertensive rats compared to Wistar-Kyoto rats. Thus the picture 
with regard to angiotensin II-mediated responses in vivo is confused.
d. Acetylcholine
Wright & Angus (1986) reported a significant reduction in "maximal dilatation" 
(but not sensitivity) to acetylcholine in the in vivo study of the iliac vascular beds in 
perinephritis hypertensive rabbits, whereas neither the sensitivity nor the reactivity 
to adenosine or serotonin was changed.
Recently, a loss of "endothelium-dependent" vascular relaxation to acetylcholine 
in essential hypertensive patients has been demonstrated in vivo, using forearm 
blood flow measurement, while the "endothelium-independent" vascular relaxation 
to sodium nitroprusside was not impaired (Panza et al, 1990; Linder et al, 1990). An 
impairment of endothelium-dependent vascular relaxation to acetylcholine was also 
reported in vivo in cerebral arterioles from stroke-prone spontaneously hypertensive 
rats (Mayhan et al, 1987).
e. Endothelin-1
Endothelin-1, a 21-sequence peptide isolated from cultured porcine endothelial 
cells, has been shown to be a highly potent and long-lasting vasoconstrictor in 
various vascular beds in a wide range of species (Yanagisawa & Masaki, 1989b). 
Conflicting results have been published with regard to in vivo pressor responses to 
endothelin in spontaneously hypertensive rats. Martel et al (1991) reported an 
increased pressor response, whereas Watanabe et al (1989) and Winquist et al (1989) 
observed a decreased response, while a similar response was found by others (Hirata 
et al, 1989; Eglen et al, 1989). In perinephritis hypertensive rabbits, we found a
greater maximum pressor response to endothelin-1 (Huang et al, 1990). Yokokawa 
et al (1990) also observed a greater pressor response to endothelin-1 in 
deoxycorticosterone-acetate-salt hypertensive rats.
f. Antagonists
There are also reports in which the in vivo dilator response to the calcium 
channel blocker verapamil (Robinson et al, 1982; Hulthen et al, 1982), or a- 
adrenoceptor antagonist prazosin (Amann et al, 1981) in the forearm resistance 
vessels was "enhanced" in essential hypertensive patients, whereas the response to 
sodium nitroprusside was similar in hypertensive patients and normotensive 
controls, suggesting a selective functional change in the arteries of essential 
hypertensive patients.
In summary, altered contraction or relaxation to a range of agonists and 
antagonists has been reported in established hypertension. However, although 
increased in vivo responsiveness is the most common finding, differences were 
observed depending both on the stimuli and the model of hypertension studied.
4.1.2. In vitro vascular responses to various agonists in hypertension
a. a-Adrenoceptor agonists
There are few in vitro vessel strip studies on human hypertension. Available data 
show a lack of evidence for "enhanced" a-adrenoceptor excitation-coupling in 
resistance arterioles or temporal arteries (Aalkjaer et al, 1987; Horwitz et al, 1974), 
with no change in sensitivity to noradrenaline or phenylephrine being observed.
Reports on the "reactivity" or "sensitivity" to a-adrenergic stimulation in arterial 
strips of spontaneously hypertensive rats have been inconsistent and contradictory 
(For review, see Bhalla et al, 1989). "Increased", "decreased" or "similar" maximal
89
tension development to noradrenaline has been reported by different groups. 
Similarly, reports on the sensitivity to noradrenaline are contradictory. Moreover, 
results from in vitro vessel strip studies are not always in line with in vivo studies or 
studies in perfused vascular beds (Triggle & Laher, 1985; Bhalla et al, 1989). It has 
been claimed that a specific a-adrenergic hypersensitivity in spontaneously 
hypertensive rats can be unmasked only after neuronal blockade (Mulvany et al, 
1980; Bhalla et al, 1989).
In secondary, experimental hypertension, an "enhanced" a-adrenergic 
vasoconstrictor response in isolated strips or perfused vascular beds has been 
reported in various models of hypertension, including deoxycorticosterone/NaCl 
hypertension (Katovich et al, 1984; Finch, 1971), Goldblatt renal hypertension 
(Finch, 1971; Collis & Alps, 1975), and aldosterone-salt hypertension (Jones et al, 
1988).
Thus the picture of in vitro vascular a-adrenergic responsiveness in primary 
hypertension is confused, whereas most studies on secondary hypertension show 
enhanced responsiveness.
b. p-Adrenoceptor agonists
A "decreased" vasodilator response to isoproterenol has been reported by most 
groups (For review, see Feldman, 1987). In contrast, Spector et al (1969) found an 
increased aortic relaxant response to isoproterenol in 7-to-10-week spontaneously 
hypertensive rats.
c. Angiotension II
Most studies on in vitro angiotensin II responsiveness in hypertension have been 
conducted in "isolated perfused vascular beds". A greater vasoconstrictor response to 
angiotensin II has been observed in mesenteric and renal arteries from spontaneously 
hypertensive rats (McGregor & Smirk, 1968; Collis & Vanhoutte, 1977), renal
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arteries from stroke-prone spontaneously hypertensive rats (Berecek et al, 1980a), 
mesenteric arteries from Goldblatt renal hypertensive rats (McGregor & Smirk, 
1968; Collis & Alps, 1975), and renal arteries from deoxycorticosterone 
hypertensive rats (Berecek et al, 1980b).
d. Serotonin
In animal studies, an increased in vitro vasoconstrictor response to serotonin was 
reported in aorta, mesenteric (Huzoor-Akbar et al, 1989) and hindquarter arteries 
(Cheng & Shibata, 1980) from spontaneously hypertensive rats, and aorta from 
stroke-prone spontaneously hypertensive rats (Turla & Webb, 1990), and femoral 
arteries from deoxycorticosterone-salt hypertensive rats (Mecca & Webb, 1984). In 
contrast, Spector et al (1969) found a decreased contractile response in aorta from 
spontaneously hypertensive rats.
e. Endothelin-1
Reports on vascular responses to endothelin-1 have also been controversial. Both 
Clozel (1989) and Martel et al (1991) found "an increase in sensitivity but a decrease 
in maximal tension" to endothelin-1 in aorta from 13-to-16-week spontaneously 
hypertensive rats, whereas Criscione et al (1990) showed "a similar sensitivity but 
decreased maximal tension" in aorta from spontaneously hypertensive rats of similar 
age. "An increase in sensitivity but similar maximal tension development" has been 
observed in mesenteric (Miyauchi et al, 1989) and renal (Tomobe et al, 1988) 
arteries from 12-week spontaneously hypertensive rats. In contrast, MacLean & 
McGrath (1990) reported " a similar sensitivity and maximal tension development" 
to endothelin-1 in isolated perfused tail artery from spontaneously hypertensive 
rats. In secondary hypertension, de Carvalho et al (1990) found" a similar sensitivity 
and maximal tension development" to endothelin-1 in aorta from Goldblatt renal
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hypertensive, deoxycorticosterone-acetate-salt hypertensive, and control Wistar rats.
f. Acetylcholine
The impairment of "endothelium-dependent" vascular relaxation to acetylcholine 
has been shown in such vessel strips as (1) aorta from spontaneously hypertensive 
rats (Sunano et al, 1989; Konishi & Su, 1983), stroke-prone spontaneously 
hypertensive rats (Sunano et al, 1989), Dahl hypertensive rats (Luscher et al, 1987), 
and New Zealand genetic hypertensive rats (Winquist et al, 1984), (2) carotid 
arteries from spontaneously hypertensive rats (Hongo et al, 1988), and (3) resistance 
arteries from spontaneously hypertensive rats (Dohi et al, 1990) as well as stroke- 
prone spontaneously hypertensive rats (Tesfamariam & Halpern, 1988). The 
endothelium-independent vascular relaxation to sodium nitroprusside was not 
impaired in these studies.
In secondary hypertension, the impairment of endothelium-dependent vascular 
relaxation to acetylcholine has also been observed in aorta from coarctation 
hypertensive, renal hypertensive, and deoxycorticosterone-salt hypertensive rats. 
(Lockette et al, 1986; Van de Voorde et al, 1988), while the maximal relaxation to 
sodium nitroprusside was preserved.
4.1.3. Vascular reactivity and the duration of hypertension
Recently, more and more papers have been published on the effect of the duration 
of hypertension on vascular reactivity, in an attempt to understand the sequence of 
events in the evolution and development of haemodynamics from borderline 
hypertension to established hypertension in patients. Most longitudinal studies 
strengthen the observation that a primary increase in cardiac output is followed after 
a time by a secondary increase in total peripheral resistance, while cardiac output 
decreases (Weiss & Safar, 1989; Lund-Johansen & Omvik, 1990).
Weidmann et al (1980) observed that both the threshold dose and the mean
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pressor dose (for increasing blood pressure by 20 mmHg) in noradrenaline dose- 
response curves were decreased slightly in borderline hypertensives and markedly in 
established essential hypertensives, as compared to normotensive subjects.
In spontaneously hypertensive rats, Toal & Leenen (1985) found that the the 
pressor responses to noradrenaline and angiotensin II changed in the direction of 
"increased" responsiveness at 4 to 6 weeks of age, "similar" responsiveness at 8 
weeks, to "decreased" responsiveness at 14 to 16 weeks, as compared to age- 
matched Wistar-Kyoto rats. On the other hand, Smeda et al (1988) reported that 
there was a "decreased" sensitivity but enhanced contractile response to 
noradrenaline in the perfused kidneys of pre-hypertensive (4 to 5 weeks of age) 
spontaneously hypertensive rats, while at the established stage (21 weeks of age) of 
hypertension, there was a similar sensitivity but enhanced contractile response to 
noradrenaline in spontaneously hypertensive rats, as compared to their age-matched 
Wistar-Kyoto controls. Berecek et al (1980a) observed that there was a significant 
shift to the left of the dose-response curves to noradrenaline, angiotensin II, 
serotonin, and vasopressin in perfused kidneys of stroke-prone spontaneously 
hypertensive rats at 4 weeks, 2 months, and 4 months of age, as compared to their 
age-matched controls from Wistar-Kyoto rats, and the slopes and maximum 
responses of the dose-response curves became greater with age in the hypertensive 
rats.
Vanhoutte et al (1980) found an "increased" pressor response to exogenous 
noradrenaline in perfused kidneys of adult spontaneously hypertensive rats (4 to 6 
months old), and a similar response to sympathetic nerve stimulation, as compared 
to Wistar-Kyoto rats; however, a similar response to exogenous noradrenaline but a 
greater pressor response to sympathetic nerve stimulation was observed in young 
spontaneously hypertensive rats (7 weeks old).
In secondary hypertension, Berecek et al (1980b) reported that enhanced renal
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vascular reactivity to noradrenaline, angiotensin II, and vasopressin occurred at the 
pre-hypertensive stage (4 days after deoxycorticosterone-salt administration), and 
the enhanced vascular reactivity was further augmented at the established stage (61 
days after). Collis & Alps (1975) also found an enhanced contractile response to 
noradrenaline and angiotensin II in perfused mesenteric arteries from the pre­
hypertensive stage of Goldblatt renal hypertensive animals, while an increased 
contractile response to KC1 occurred only at the established stage of hypertension.
On the other hand, it has been reported that there is a progressive decrease in the 
p-adrenoceptor (isoproterenol) sensitivity both with increasing blood pressure and 
increasing age in essential hypertensive patients (Bertel et al, 1980; London et al, 
1976). A progressive impairment of relaxation response to isoproterenol from the 
pre-hypertensive stage, through the developing stage, to the established stage of 
hypertension has also been observed in aorta from both spontaneously hypertensive 
rats (Cheng & Shibata, 1981), and deoxycorticosterone-salt hypertensive rats 
(Katovich et al, 1984).
In comparing the endothelium-dependent vascular relaxation in spontaneously 
hypertensive rats versus Wistar-Kyoto rats, both hypertension and age were reported 
to be the determining factors of the degree of impaired relaxation (Hongo et al, 
1988; Dohi et al, 1990; Sunano et al, 1989). Sunano et al (1989) also found that the 
age-related impairment of relaxation was greater in hypertensive rats.
In summary, there are many reports suggesting that the duration of hypertension 
is an important factor in aggravating the impairment of endothelium-dependent 
vascular relaxation and p-adrenoceptor-mediated responses. The effect of the 
duration of hypertension on vasoconstrictive responses to noradrenaline or 
angiotensin II reported so far is not a consistent picture.
4.1.4. In vivo haemodynamic changes in response to various agonists in 
hypercholesterolemia or atherosclerosis
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There are numerous reports of altered vascular reactivity to agonists in 
hypercholesterolemic or atherosclerotic humans and animals, and it has been 
suggested that such changes could contribute to vasospasm and sudden death (Lopez 
et al, 1989a; Shimokawa et al, 1988; Shimokawa & Vanhoutte, 1989).
a. a-adrenoceptor agonists
An enhanced in vivo pressor response to a-adrenoceptor agonists such as 
noradrenaline and phenylephrine has been reported in atherosclerotic rabbits (Hof & 
Hof, 1988). However, when specific vascular beds are examined, different results 
are observed. In hypercholesterolemic but not yet atherosclerotic animals, a greater 
in vivo vasoconstrictor response to noradrenaline was observed in the coronary 
artery from the dog (Rosendorff et al, 1981) and the hindlimb small arteries from 
cynomolgus monkeys (Heistad et al, 1984). Whereas, in atherosclerotic cynomolgus 
and rhesus monkeys, the vasoconstrictor response to noradrenaline and 
phenylephrine in hindlimb arteries was similar in atherosclerotic and control animals 
(Heistad et al, 1984; Armstrong et al, 1985). Lopez et al (1989b) observed a greater 
in vivo vasoconstrictor response to phenylephrine in colon vascular beds from 
atherosclerotic cynomolgus monkeys. Thus the picture with aj-adrenergic 
vasoconstrictor response may differ with regard to the duration of cholesterol 
feeding and extent of atherosclerosis (Heistad et al, 1984) as well as the vascular 
beds examined (Heistad et al, 1984; Lopez et al, 1989a).
b. Angiotensin II
Hof & Hof (1988) reported an increased in vivo pressor response to angiotensin 
II in atherosclerotic rabbits, whereas Armstrong et al (1985) found a similar 
response to angiotensin II in perfused hindlimb arteries from atherosclerotic and 
control monkeys.
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c. Serotonin
In hindlimb arteries from normal cynomolgus monkeys, serotonin caused 
vasodilation, but this may be impaired and converted to vasoconstriction in 
atherosclerotic animals (Heistad et al, 1984; Lopez et al, 1989a). Potentiation of the 
vasoconstrictor response to serotonin was also observed in cerebral, ocular, and 
mesenteric arteries (Faraci et al, 1989; Lopez et al, 1989b). Duration of the 
atherogenic diet was a factor in altering the serotonin response in 
hypercholesterolemic monkeys (Heistad et al, 1984; Lopez et al, 1989a). Wright & 
Angus (1986) reported an almost twofold increase in sensitivity for vasodilation to 
serotonin in hindlimb arteries from rabbits fed on 1% cholesterol diet for 4 weeks, 
but the maximal dilation was unchanged.
d. Thromboxane A2
Potentiation of the vasoconstrictor responses to thromboxane A2  has also been 
shown in hindlimb, cerebral, and ocular arteries from atherosclerotic monkeys 
(Lopez et al, 1989a; Faraci et al, 1989). Lopez et al (1990) also observed the 
potentiation of vasoconstrictor response to endothelin-1 in hindlimb arteries from 
atherosclerotic monkeys.
e. Acetylcholine
Impairment of endothelium-dependent vascular dilatation to acetylcholine 
(Ludmer et al, 1986) and increased blood flow (Cox et al, 1989) was observed in 
vivo in human atherosclerotic coronary arteries, while endothelium-independent 
vascular dilation to nitroglycerin was preserved. Similarly, impaired vasodilation to 
acetylcholine but not nitroprusside was demonstrated in vivo in hindlimb arteries 
and resistance arteries from atherosclerotic rabbits fed on 1% or 2% cholesterol diet 
for 8-12 weeks (Girerd et al, 1990; Bossaller et al, 1987a; Yamamoto et al, 1988). 
Lopez et al (1989a) also found that endothelium-dependent vascular dilation to
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adenosine 5 ’-diphosphate was im paired in hindlim b arteries from 
hypercholesterolemic as well as atherosclerotic monkeys. Creager et al (1990) 
reported that in forearm resistance vessels from hypercholesterolemic men, both 
endothelium-dependent and endothelium-independent vasodilation (to metacholine 
and nitroprusside, respectively) were impaired, while the vasoconstrictor response to 
phenylephrine was not different from that in normocholesterolemic controls.
4.1.5. In vitro vascular responses to various agonists in hypercholesterolemia and
atherosclerosis
a. a-Adrenoceptor agonists
Kalsner & Richards (1984) reported an enhanced contractile response to 
noradrenaline in coronary arteries from patients who died of coronary artery disease 
as compared to those who died of non-cardiovascular disease. In cholesterol-fed 
hypercholesterolemic rabbits, contractile responses to noradrenaline in aorta have 
been reported to exhibit "increased" (Heric & Tackett, 1985), "similar" (Simonsen et 
al, 1991; Kishi & Numano, 1984), or "decreased" responsiveness (Ibengwe & 
Suzuki, 1986; Verbeuren et al, 1986). Wines et al (1989) found a decreased 
contractile response to noradrenaline in aorta from both Watanabe heritable 
hyperlipidemic rabbits and cholesterol-fed New Zealand white rabbits as compared 
to normal-diet rabbits. In other vascular strips, the picture is also inconsistent. In 
cholesterol-fed rabbits, an increased contractile response to noradrenaline in carotid 
arteries (Tesfamariam et al, 1989), or an increased sensitivity but similar maximal 
response to noradrenaline in basilar arteries (McCalden & Nath, 1989), or a 
decreased sensitivity but similar maximal response to noradrenaline in femoral 
arteries (Simonsen et al, 1991), have been reported by different groups. As for the 
other a-adrenergic agonist, phenylephrine, a similar contractile response in aorta 
from cholesterol-fed atherosclerotic rabbits (Henry & Yokoyama, 1980) or a
97
decreased response in aorta from Watanabe heritable hyperlipidemic rabbits 
(Kolodgie et al, 1990) has been reported.
b. Serotonin
Vascular responses to serotonin or ergonovine in hypercholesterolemic or 
atherosclerotic coronary arteries have aroused particular interest because of their 
potential pathophysiological implications in coronary vasospasm and sudden death 
(Schroeder et al, 1977). Kalsner & Richards (1984) found a distinctively enhanced 
contractile response to serotonin and histamine in coronary arteries from patients 
who died of coronary heart disease. In animal studies, an enhanced contractile 
response to serotonin has been observed in (A) aorta from diet-induced 
hypercholesterolemic or atherosclerotic rabbits (Merkel et al, 1990; Kishi & 
Numano, 1984; Heric & Tackett, 1985), (B) aorta from Watanabe heritable 
hyperlipidemic rabbits (Yokoyama et al, 1983; Wines et al, 1989), (C) coronary 
arteries from diet-induced hypercholesterolemic-atherosclerotic pigs (Shimokawa & 
Vanhoutte, 1989).
In contrast, similar contractile responses to serotonin were reported in aorta, or 
small cerebral, mesenteric, and femoral arteries from cholesterol-fed atherosclerotic 
rabbits as compared to their controls from normal-diet rabbits (Verbeuren et al, 
1986; Simonsen et al, 1991).
c. Ergonovine
An enhanced contractile response to ergonovine has been observed in aorta from 
cholesterol-fed New Zealand white rabbits (Henry & Yokoyama, 1980) as well as 
from Watanabe heritable hyperlipidemic rabbits (Yokoyama et al, 1983).
d. Histamine
An enhanced contractile response to histamine in aorta from cholesterol-fed New
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Zealand white rabbits (Heric & Tackett, 1985) and W atanabe heritable 
hyperlipidemic rabbits (Kolodgie et al, 1990) was observed by some groups, 
whereas Wines et al (1989) found a decreased contractile response in aorta from 
Watanabe heritable hyperlipidemic rabbits.
e. Angiotensin II
Either "increased" or "similar" maximum contraction to angiotensin II has been 
reported in aorta from hypercholesterolemic or atherosclerotic rabbits (Merkel et al, 
1990; Kishi & Numano, 1984).
f. (3-Adrenoceptor agonists
Vaso-relaxation responses to the p-adrenoceptor agonist, isoproterenol, were 
shown to be similar in coronary arteries from atherosclerotic patients and non- 
atherosclerotic patients by one group (Forstermann et al, 1988), but another group 
(Berkenboom  et al, 1987) reported a significantly  reduced response in 
atherosclerotic coronary arteries. Merkel et al (1990) also found that in modestly 
hypercholesterolemic rabbits (plasma cholesterol level 223 mg/dl), vaso-relaxation 
to isoproterenol was impaired in pre-constricted aorta.
g. Acetylcholine
The impairment of endothelium-dependent vaso-relaxation to acetylcholine or 
other agonists in isolated arteries from hypercholesterolemic or atherosclerotic 
humans and animals has been reported by many researchers. The impairment has 
been shown in (A) human atherosclerotic coronary arteries (Berkenboom et al, 1987; 
Bossaller et al, 1987b; Forstermann et al, 1988), (B) hypercholesterolemic or 
atherosclerotic rabbit aorta (Bossaller et al, 1987b; Guerra et al, 1989; Jayakody et 
al, 1987; Ibengwe & Suzuki, 1986; Verbeuren et al, 1986; Simonsen et al, 1991),
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coronary arteries (Osborne et al, 1989; Vrints et al, 1990), and intracranial arteries 
(Kanamaru et al, 1989), (C) aorta from Watanabe heritable hyperlipidemic rabbits 
(Kolodgie et al, 1990), (D) hypercholesterolemic or atherosclerotic pig coronary 
arteries (Cohen et al, 1988; Shimokawa & Vanhoutte, 1989), and cerebral arteries 
(Shimokawa et al, 1988), (E) coronary arteries (Sellke et al, 1990) and iliac arteries 
(Friedman et al, 1986) from cholesterol-fed atherosclerotic monkeys. Most of these 
reports showed that the endothelium -independent vascular relaxation to 
nitroprusside or isoproterenol or nitroglycerin was preserved. As stressed by the 
Vanhoutte group, the impairment of endothelium-dependent vascular relaxation to 
aggregating platelets and related vasoactive substances in coronary and cerebral 
arteries may predispose these hypercholesterolemic or atherosclerotic animals to 
coronary or cerebral vasospasm, thus having significant pathophysiological 
implications associated with hypercholesterolemia or atherosclerosis (Shimokawa et 
al, 1988; Shimokawa & Vanhoutte, 1989).
In summary, there are many reports suggesting that hypercholesterolemia or 
atherosclerosis may alter the in vitro vascular responses of isolated arteries. The 
picture of change differs with regard to duration or severity of hypercholesterolemia, 
species of animal, vascular tissues examined, as well as agonists employed for study. 
To further complicate the issue, in vitro results are not always consistent with in vivo 
results.
4.1.6. Vascular reactivity and the duration of hypercholesterolem ia and 
atherosclerosis
As mentioned briefly in the previous section, duration of hypercholesterolemia 
plays an important part in the vascular reactivity to agonists. Heric & Tackett (1985) 
reported that in rabbits fed on 0.6% cholesterol diet, the augmented contractile 
responses to noradrenaline, histamine, and serotonin were most prominent at 4
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weeks of cholesterol feeding; the augmented contractile responses were attenuated 
with longer duration of cholesterol feeding (6 and 8 weeks), as compared to age- 
matched normal-diet rabbits. Lopez et al (1989a) compared the in vivo vascular 
responses of monkeys after 4,9, and 19 months of atherogenic diet with age-matched 
control animals, and found that with a longer duration of atherogenic diet, the 
vasoconstrictor response to serotonin was progressively potentiated, while the 
vasodilator response to adenosine 5’-diphosphate was progressively attenuated. Thus 
vascular responses to serotonin, adenosine 5’-diphosphate, and thromboxane ^  
analogue, all of which are products released after platelet aggregation, were altered 
in a direction that would favour greater vasoconstriction with longer duration of 
atherogenesis.
A progressive impairment of endothelium-dependent relaxation with longer 
duration of atherogenic diet has also been observed in rabbits (Verbeuren et al, 1986; 
Kanamaru et al, 1989) and monkeys (Lopez et al, 1989a), while the endothelium- 
independent relaxation was largely preserved. Kolodgie et al (1990) also found that 
the endothelium -dependent relaxation in aorta from W atanabe heritable 
hyperlipidemic rabbits was progressively impaired as the severity of intimal lesions 
increased with age.
Thus with the exception of the study of Heric & Tackett (1985), responses were 
more severely modified the longer the duration of atherogenesis.
In summary, both hypertension and hypercholesterolemia result in alterations in 
response to a range of agonists. The degree and direction of changes appear to 
depend on the agonist, the model studied, and the duration of disease. Impaired 
responses to acetylcholine and serotonin have received prom inence in 
atherosclerosis, while in hypertension, increased responses to a wide range of 
contractile agonists including the endogeneous vasoconstrictors noradrenaline and
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angiotensin II have been extensively reported.
In man, the two disease states are frequently found in conjunction with one 
another and could interact resulting in increased contraction and decreased 
relaxation and an enhanced risk of coronary vasospasm. Against this background, 
responses to a range of agonists have been examined during the development of 
hypertension and hypercholesterolemia, alone or in combination, in the rabbit.
4.2 Materials and methods
For a detailed description of the four groups of rabbits, see the "Overall Study 
Design" Chapter.
Groups of rabbits were studied at 14-21 days, 42-49 days, and 91-112 days 
postoperatively. An arterial line was inserted under local anaesthesia in one ear, for 
blood pressure and heart rate m easurem ent, and a venous line for drug 
administration in the other. Basal mean arterial pressure and heart rate were obtained 
when the rabbit had been left for 60 minutes to recover after the insertion of the 
catheters. Each animal was conscious and was kept in an individual cage in a quiet 
warm laboratory throughout the study. Pressor and depressor responses to a range 
of agonists were measured in each rabbit. At most two drugs were given in one day 
to the same animal, with a 60 minute interval in between. The protocol for drug 
administration was as detailed below:
14-21 Days (2-3 Weeks) Study:
(A) Noradrenaline: 0.05,0.10,0.50, 3.00, & 10.0 |xg/kg.
(B) Angiotensin II: 0.0005,0.0010,0.0050,0.0200,0.100, & 0.300 |ag/kg.
(C) Acetylcholine: 0.05,0.10,0.30,1.00, 3.00, & 10.0 jxg/kg.
(D) Nitroprusside: 2.5, 5.0, 10.0, & 20.0 |xg/kg/min, each dosage given for 10 
minutes via a Braun infusion pump and the rate increased stepwise.
(E) Isoproterenol: 0.05,0.10, & 0.30 (ig/kg.
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42-49 Days (6-7 Weeks) Study:
(A) Noradrenaline: 0.05, 0.10, 0.50, 1.00, 3.00, & 5.00 pg/kg.
(B) Angiotensin II: 0.0005,0.0010, 0.0050, 0.0200, 0.100, & 0.300 pg/kg.
(C) Endothelin-1: 0.03, 0.05,0.10, & 0.20 nmol/kg.
(D) Acetylcholine: 0.05,0.10,0.30, 1.00, 3.00, & 10.0 pg/kg.
(E) Nitroprusside: 2.5, 5.0, 10.0, & 20.0 pg/kg/min, each dosage given for 10 
minutes via a Braun infusion pump and the rate increased stepwise.
(F) Isproterenol: 0.05, 0.10, & 0.30 pg/kg.
91-112 Days (13-16 Weeks) Study:
(A) Noradrenaline: 0.05,0.10, 0.30,1.00, 3.00, & 10.0 pg/kg.
(B) Angiotensin II: 0.0005, 0.0010, 0.0050, 0.0200, 0.100, & 0.300 pg/kg.
(C) Endothelin-1: 0.10 nmol/kg.
(D) Acetylcholine: 0.05, 0.10, 0.30, 1.00, 3.00, & 10.0 pg/kg.
The drugs given each day to rabbits were random ized and, except for 
nitroprusside, the doses of each agonist were given in random order. After the 
injection of endothelin-1, blood pressure was monitored continuously for the first 10 
minutes and thereafter every 5 minutes for at least 30 minutes.
Most animals were studied at 2 out of the 3 time points. The animals could only 
be used a limited number of times, and it was not humanely possible to study all 
drugs in all rabbits at all times. In addition, some animals died during the course of 
the 16-week experimental period. It had been hoped to study all drugs at all time 
points; however, this was not possible within the time constraints of this thesis.
Noradrenaline, isoproterenol, acetylcholine, and angiotensin II were purchased 
from Sigma Chemical Co. (Poole, U.K.). Sodium nitroprusside was from Roche
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Products (Welwyn Garden City, U.K.). Endothelin-1 was from Scientific Marketing 
(Barnet, U.K.). Noradrenaline and isoproterenol were prepared in 0.1% ascorbic 
acid. Acetylcholine and angiotensin II were dissolved in 0.9% saline. Sodium 
nitroprusside was prepared in 5% dextrose and protected from light. Endothelin-1 
was prepared as a 10"^ M stock solution and 50 pi aliquots stored at -20 °C. All drug 
solutions were prepared fresh on the study day.
Pressor or depressor responses were examined in terms of changes in mean 
arterial pressure (a MAP). Each experimental group was compared to the control 
group using repeated measures analysis of variance for each agonist. When the 
hypertensive and the hypertensive-hypercholesterolemic groups were compared to 
the control group, repeated measures analysis of covariance with basal mean arterial 
pressure as covariate were also carried out to examine whether the starting blood 
pressure could account for any differences. In the case of isoproterenol, changes in 
heart rate ( a HR) were also compared. All results were expressed as Mean ± S.D. p 
< 0.05 was considered statistically significant.
4.3. Results
4.3.1. 2-3 Weeks Study:
(A) Noradrenaline
There was a greater pressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in blood pressure changes ( a MAP) reached significance at all doses 
except the highest for the hypertensive group, and at all doses for the hypertensive- 
hypercholesterolemic group versus the control group, but when examined in relation 
to the starting mean arterial pressure (analysis of covariance), this difference did not 
remain significant. (Tables 4.1 & 4.2)
There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.1)
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(B) Angiotensin II
There was a greater pressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in aMAP reached significance at 0.0005, 0.001, 0.005, 0.020, & 0.100 
(ig/kg for the hypertensive group, and at 0.0005, 0.001, 0.005, & 0.020 |Xg/kg for the 
hypertensive-hypercholesterolemic group versus the control group. When examined 
in relation to the starting mean arterial pressure, this difference did not remain 
significant. (Tables 4.1 & 4.2)
There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.2)
(C) Acetylcholine
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in aMAP reached significance at all dose points for the hypertensive 
group and at all dose points except the highest (10.0 Jig/kg) for the hypertensive- 
hypercholesterolemic group versus the control group. Moreover, when examined in 
relation to the starting mean arterial pressure, these significant differences persisted. 
(Tables 4.3 & 4.4)
There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.3)
(D) Nitroprusside
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at all infusion doses for both groups
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versus the control group. When examined in relation to the starting mean arterial 
pressure, this difference remained significant only at the lowest dose (2.5 pg/kg/min 
for 10 minutes). (Tables 4.3 & 4.4)
There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.4)
(E) Isoproterenol
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in aMAP reached significance at all three dose points versus the control 
group. Moreover, when examined in relation to the starting mean arterial pressure, 
these significant differences persisted. (Tables 4.3 & 4.4)
There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.5)
The chronotropic response ( a HR) was also analyzed. There was no difference in 
chronotropic response in the hypertensive, hypercholesterolemic, or hypertensive- 
hypercholesterolemic groups as compared to the control group (Figure 4.6).
4.3.2. 6-7 Weeks Study:
(A) Noradrenaline
There was a greater pressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at 0.05, 0.10, 0.50, & 1.00 pg/kg for the 
hypertensive group, and at 0.10 & 0.50 pg/kg  for the hypertensive- 
hypercholesterolemic group versus the control group. When examined in relation to 
the starting mean arterial pressure, the significant difference persisted for the 
hypertensive-hypercholesterolemic group, but not for the hypertensive group. 
(Tables 4.1 & 4.2)
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Figure 4.1: Changes in blood pressure (a MAP) in response to noradrenaline in 
groups of rabbits 2-3 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 6 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.2: Changes in blood pressure (a MAP) in response to angiotensin II in 
groups of rabbits 2-3 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 8 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.3: Changes in blood pressure (a MAP) in response to acetylcholine in 
groups of rabbits 2-3 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 7 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; # & A , p < 0.05 
for the hypertensive and the hypertensive-hypercholesterolemic groups versus the 
control group, respectively, when analysis of covariance was camied out with basal 
mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.4: Changes in blood pressure (a MAP) in response to nitroprusside infusion 
in groups of rabbits 2-3 weeks after surgery and dietary manipulation.
(M ean ± S.D ., n = 6 - 10. * & **, p < 0.05 for the hypertensive and the 
hypertensive-hypercholesterolemic groups versus the control group, respectively; # 
& ##, p < 0.05 for the hypertensive and the hypertensive-hypercholesterolemic 
groups versus the control group, respectively, when analysis of covariance was 
camied out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.5: Changes in blood pressure (a MAP) in response to isoproterenol in 
groups of rabbits 2-3 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 6 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; # & ##, p < 0.05 
for the hypertensive and the hypertensive-hypercholesterolemic groups versus the 
control group, respectively, when analysis of covariance was carrried out with basal 
mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.6: Changes in heart rate (a HR) in response to isoproterenol in groups of 
rabbits 2-3 weeks after surgery and dietaiy manipulation.
There is no difference in the chronotropic responsiveness (aHR) to isoproterenol 
between the control group and any of the experimental groups. (Mean ± S.D., n = 6 - 
9.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.7)
(B) Angiotensin II
There was a greater p ressor resopnse in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at all dose points for both groups versus 
the control group. Moreover, when examined in relation to the starting mean arterial 
pressure, these significant differences still persisted for both groups. (Tables 4.1 &
4.2)
There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.8)
(C) Endothelin-1
Each group of rabbits responded to endothelin-1 injection in two phases: an 
initial depressor response (within the first 30 seconds) followed by a pressor 
response which reached a maximum at 1-4 minutes and lasted for more than 20 
minutes. There was a dose-related increase in the pressor response and the depressor 
response also tended to be dose-related.
The depressor response was greater in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. This 
depressor response was significantly greater at the 0.03 & 0.05 nmol/kg dose points 
for the hypertensive group, and at the 0.03 dose point for the hypertensive- 
hypercholesterolemic group versus the control group. When examined in relation to 
the starting mean arterial pressure, these significant differences still persisted for 
both groups at the 0.03 nmol/kg dose point.
The pressor response during the first 5 minutes after endothelin-1 injection was
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greater in both the hypertensive and the hypertensive-hypercholesterolemic groups 
as compared to the control group. The maximum pressor response was significantly 
greater in both groups at the 0.03 nmol/kg dose point versus the control group. 
When examined in relation to the starting mean arterial pressure, these differences 
no longer reached significance.
Neither the depressor nor the pressor response was different between the 
hypercholesterolemic and control groups at any dose of endothelin-1. (Figure 4.9, 
4.10,4.11, & 4.12)
(D) Acetylcholine
There was a greater depressor response in the hypertensive group as compared to 
the control group, and the difference in a MAP was significant at 0.05, 0.10, & 1.00 
(ig/kg dose points. When examined in relation to the starting mean arterial pressure, 
the significant difference persisted only for the 0.05 Jig/kg dose point (Tables 4.3 & 
4.4). The depressor response tended to be g reater in the hypertensive- 
hypercholesterolemic group than in the control group, but the difference did not 
reach significance.
There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.13)
(E) Nitroprusside
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at the 5.0, 10.0, & 20.0 ng/kg/min 
infusion doses for the hypertensive versus the control group. When examined in 
relation to the starting mean arterial pressure, this difference did not remain 
significant. (Tables 4.3 & 4.4)
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There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups (Figure 4.14)
(F) Isoproterenol
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups compared to the control group. The 
difference in a MAP reached significance at all three dose points for both the 
hypertensive and the hypertensive-hypercholesterolemic groups versus the control 
group. When examined in relation to the starting mean arterial pressure, these 
differences did not remain significant. (Tables 4.3 & 4.4)
There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.15)
The chronotropic response ( a HR) was also analyzed. There was no difference in 
the chronotropic response in the hypertensive, the hypercholesterolemic, or the 
hypertensive-hypercholesterolemic groups as compared to the control group. (Figure 
4.16)
4.3.3.13-16 Weeks Study:
(A) Noradrenaline
There was a greater pressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in AMAP was significantly greater at all dose points for both groups 
versus the control group. Moreover, when examined in relation to the starting mean 
arterial pressure, these significant differences still persisted for both groups. (Tables 
4.1 & 4.2)
There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.17)
119
80 -|
70 -  
60 -
CD
X  50 H
E
E
0_
<
40  
30 -  
20 -  
10 -  
0  -
##
*♦
0.05 0.10 0 .50  1.00 3.00 5.00
Noradrenaline Dose ( n g /k g )
Figure 4.7: Changes in blood pressure (a MAP) in response to noradrenaline in 
groups of rabbits 6-7 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 6 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; ##, p < 0.05 for 
the hypertensive-hypercholesterolemic group versus the control group when analysis 
of covariance was carrried out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.8: Changes in blood pressure (a MAP) in response to angiotensin II in 
groups of rabbits 6-7 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 7 - 8. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; # & ##, p < 0.05 
for the hypertensive and the hypertensive-hypercholesterolemic groups versus the 
control group, respectively, when analysis of covariance was carrried out with basal 
mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.9: Changes in blood pressure (A MAP) in response to 0.03 nmol/kg 
endothelin-1 bolus in groups of rabbits 6-7 weeks after surgery and dietary 
manipulation.
Note the biphasic profiles. (Mean ± S.D., n = 7 - 8. * & **, p < 0.05 for the 
hypertensive and the hypertensive-hypercholesterolemic groups versus the control 
group, respectively; # & ##, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively, when analysis 
of covariance was carrried out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.10: Changes in blood pressure ( a MAP) in response to 0.05 nmol/kg 
endothelin-1 bolus in groups of rabbits 6-7 weeks after surgery and dietary 
manipulation.
Note the biphasic profiles. (Mean ± S.D., n = 7 - 8. * & **, p < 0.05 for the 
hypertensive and the hypertensive-hypercholesterolemic groups versus the control 
group, respectively.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.11: Changes in blood pressure (a MAP) in response to 0.10 nmol/kg 
endothelin-1 bolus in groups of rabbits 6-7 weeks after surgery and dietary 
manipulation.
Note the biphasic profiles. (Mean ± S.D., n = 9 -10.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.12: Changes in blood pressure (a MAP) in response to 0.20 nmol/kg 
endothelin-1 bolus in groups of rabbits 6-7 weeks after surgery and dietary 
manipulation.
Note the biphasic profiles. (Mean ± S.D., n = 8 - 9.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O  Hypertensive-hypercholesterolemic group.
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Figure 4.13: Changes in blood pressure (a MAP) in response to acetylcholine 
groups of rabbits 6-7 weeks after surgery and dietary manipulation.
(Mean ±S.D .,n  = 9 -  11. * ,p <  0.05 for the hypertensive group versus the control 
group; #, p < 0.05 for the hypertensive group versus the control group when analysis 
of covariance was carrried out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.14: Changes in blood pressure ( a MAP) in response to nitroprusside 
infusion in groups of rabbits 6-7 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 9 - 10. *, p < 0.05 for the hypertensive group versus the control 
group.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O  Hypertensive-hypercholesterolemic group.
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Figure 4.15: Changes in blood pressure (a MAP) in response to isoproterenol in 
groups of rabbits 6-7 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 6 - 8. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.16: Changes in heart rate (a HR) in response to isoproterenol in groups of 
rabbits 6-7 weeks after surgery and dietary manipulation.
There is no difference in the chronotropic responsiveness (aHR) to isoproterenol 
between the control group and any of the experimental groups. (Mean ± S.D., n = 6 - 
8.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
129
(B) Angiotensin II
There was a greater pressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at all dose points for both groups versus 
the control group. When examined in relation to the starting mean arterial pressure, 
the differences remained significant at the 0.0005, 0.0010, 0.005, & 0.020 Jig /k g  for 
the hypertensive group, and at the 0.0005, 0.0010, & 0.005 Jig /kg  dose points for the 
hypertensive-hypercholesterolemic group versus the control group. (Tables 4.1 &
4.2)
There was no d ifference in the p ressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.18)
(C) Endothelin-1
Only one dose (0.10 nmol/kg) of endothelin-1 was given to each group. The 
depressor as well as the pressor responses were greater in both the hypertensive and 
the hypertensive-hypercholesterolemic groups as compared to the control group. The 
maximum pressor response was significantly greater for both groups versus the 
control group. When examined in relation to the starting mean arterial pressure, 
these significant differences still persisted for both groups.
Neither the depressor nor the pressor response was different between the 
hypercholesterolemic and control groups. (Figure 4.19)
(D) Acetylcholine
There was a greater depressor response in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. The 
difference in a MAP reached significance at all dose points for both groups versus 
the control group. When examined in relation to the starting mean arterial pressure, 
these significant differences still persisted for both groups. (Tables 4.3 & 4.4)
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There was no d ifference in the depressor response betw een the 
hypercholesterolemic and control groups. (Figure 4.20)
4.4. Discussion
(1) At 2-3 weeks after renal wrapping operation, when the rabbits were at the 
developing stage of hypertension, there were greater pressor responses to 
noradrenaline and angiotensin II, as well as greater depressor responses to 
acetylcholine, isoproterenol, and nitroprusside in both the hypertensive and the 
hypertensive-hypercholesterolemic groups as compared to the control group. When 
the starting mean arterial pressure was taken into account in analysis of covariance, 
only the depressor responses to isoproterenol and acetylcholine rem ained 
significantly greater in both groups versus the control group. Using the same model 
of hypertensive rabbits, Nixon et al (1990) reported that phospholipase C activity in 
response to noradrenaline, but not endothelin-1, was increased in the aorta and 
femoral artery of rabbits at 2 weeks during the development of hypertension. It is 
unclear how that finding relates to this study as there is no indication of changes in 
phospholipase C activity related to the development of hypertension in this study. 
However, Nixon et al did not examine inositol phosphates formation in the small 
arterioles, which are the major contributors to blood pressure changes in the 
conscious rabbits. It is possible that the changes observed in the aorta and femoral 
artery were not reflected in smaller vessels, or that changes occurred later or earlier 
in arterioles. Using the same model of hypertensive rabbits, Hamilton & Reid 
(1983) also found that the greater pressor response to noradrenaline was not 
apparent when the results were expressed as a percentage change. Berecek & Bohr 
(1978) also reported greater pressor responses to noradrenaline and angiotensin II at 
the developing stage of hypertension in deoxycorticosterone-acetate-salt 
hypertensive pigs, but no account was taken of baseline arterial pressure. An
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Figure 4.17: Changes in blood pressure (a MAP) in response to noradrenaline in 
groups of rabbits 13-16 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 7 - 9. * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; # & ##, p < 0.05 
for the hypertensive and the hypertensive-hypercholesterolemic groups versus the 
control group, respectively, when analysis of covariance was carrried out with basal 
mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.18: Changes in blood pressure (A  MAP) in response to angiotensin II in 
groups of rabbits 13-16 weeks after surgery and dietary manipulation.
(Mean ± S.D., n = 7 - 8 . * & **, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively; # & ##, p < 0.05 
for the hypertensive and the hypertensive-hypercholesterolemic groups versus the 
control group, respectively, when analysis of covariance was carrried out with basal 
mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.19: Changes in blood pressure (aM A P) in response to 0.10 nmol/kg 
endothelin-1 bolus in groups of rabbits 13-16 weeks after surgery and dietary 
manipulation.
Note the biphasic profiles. (Mean ± S.D., n = 7 - 9. * & **, p < 0.05 for the 
hypertensive and the hypertensive-hypercholesterolemic groups versus the control 
group, respectively; # & ##, p < 0.05 for the hypertensive and the hypertensive- 
hypercholesterolemic groups versus the control group, respectively, when analysis 
of covariance was carrried out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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Figure 4.20: Changes in blood pressure (a MAP) in response to acetylcholine in 
groups of rabbits 13-16 weeks after surgery and dietary manipulation.
(M ean ± S.D ., n = 7 - 10. * & **, p < 0.05 for the hypertensive and the 
hypertensive-hypercholesterolemic groups versus the control group, respectively; # 
& ##, p < 0.05 for the hypertensive and the hypertensive-hypercholesterolemic 
groups versus the control group, respectively, when analysis of covariance was 
carrried out with basal mean arterial pressure as covariate.)
□  Control group.
A Hypercholesterolemic group.
O Hypertensive group.
O Hypertensive-hypercholesterolemic group.
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increased constrictor dose-response curve to noradrenaline and angiotensin II at the 
early, developing stage of hypertension was also observed in perfused renal vascular 
beds from spontaneously hypertensive rats (Berecek et al, 1980a) and in perfused 
mesenteric vasculature from Goldblatt renal hypertensive rats (Collis & Alps, 1975).
Our results also showed that there were greater depressor responses to 
acetylcholine, isoproterenol, and nitroprusside in both the hypertensive and the 
hypertensive-hypercholesterolemic groups at 2-3 weeks after operation, but only the 
receptor-mediated responses, i.e., acetylcholine and isoproterenol vasodilation, 
remained significantly greater after analysis of covariance with starting mean 
arterial pressure as covariate. Depressor responses to isoproterenol are mediated via 
activation of cAMP, and those to acetylcholine via cGMP activation. Unfortunately 
within the constraints of this thesis it was not possible to examine the activity of 
these second messenger systems. However, as nitroprusside acts directly on the 
cGMP system and the chronotropic response to isoproterenol involves cAMP, our 
results suggest that there is no generalized change in the activity of cAMP or cGMP 
during the development of perinephritis hypertension. However, changes in the 
cAMP system in relation to the development of genetic hypertension in rats have 
been reported (Hamet & Tremblay, 1990). Messerli et al (1976) reported that there 
was a greater depressor response to isoproterenol infusion in borderline hypertensive 
patients compared to normotensive controls. When the results were analyzed in 
terms of chronotropic responsiveness ( a  HR), there was no difference between 
either the hypertensive or the hypertensive-hypercholesterolemic group and the 
control group. Thus there were discordant patterns of vasodilator ^-adrenoceptor- 
mediated) and chronotropic (P^-adrenoceptor-mediated) responsiveness in our 
hypertensive rabbits. No change in the chronotropic response has also been reported 
in borderline hypertensive patients (London et al, 1976; Henquet et al, 1982) and in 
early-stage aorta-coarctation hypertensive rats (Cervoni et al, 1981)
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Taken as a whole, there were greater pressor and depressor responses to the 
agonists exam ined in both the hypertensive and the hypertensive- 
hypercholesterolemic rabbits at 2-3 weeks after renal operation; moreover a selective 
increase in responsiveness to receptor-m ediated agonists was shown when 
comparing depressor responses to acetylcholine and isoproterenol with those to 
nitroprusside using analysis of covariance with starting mean arterial pressure as 
covariate.
On the other hand, 2-3 weeks of cholesterol feeding, which caused the plasma 
cho leste ro l level to rise  from 1.3 ± 0.5 to 10.6 ± 5.9 m m ol/L in the 
hypercholesterolemic group, had no effect on either the pressor or the depressor 
responses in the cholesterol-fed rabbits as compared to the control rabbits. Merkel et 
al (1990) reported that in moderately hypercholesterolemic rabbits, the in vitro aortic 
relaxation responses to isoproterenol and carbamylcholine chloride were decreased, 
while aortic constrictor responses to noradrenaline and angiotensin II were 
unchanged. One poin t of note is that the aorta is very suscep tib le  to 
hypercholesterolemia, whereas resistance arterioles (the main determinant of 
peripheral resistance and therefore blood pressure) are little affected (Simonsen et al, 
1991). Differences in experimental conditions (in vivo and in vitro) as well as 
vascular beds (systemic resistance arterioles and aorta) may also contribute to the 
different conclusions derived from our and Merkel et al’s studies. Creager et al 
(1990) showed that in modestly hypercholesterolemic humans, the forearm 
resistance arterioles displayed impaired vasodilative responses to methacholine and 
nitroprusside, but similar vasoconstrictor responses to phenylephrine. Differences in 
species (human and rabbits) and investigation methods (local and systemic 
resistance arterioles) exist between ours and Creager et al’s study.
The picture of generally similar pressor as well as depressor responses between 
the hypertensive and the hypertensive-hypercholesterolemic groups also suggested
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that hypercholesterolemia had little effect on the vascular reactivity in these rabbits.
Thus at 2-3 weeks only the imposition of perinephritis hypertension altered the 
vascular responses of the rabbits, while hypercholesterolemia had little effect on 
responses.
(2) At 6-7 weeks after renal wrapping operation, when the rabbits were at the 
established stage of hypertension, there were greater pressor responses to 
noradrenaline and angiotensin II, as well as greater depressor responses to 
acetylcholine, isoproterenol, endothelin-1 and nitroprusside in the hypertensive 
group as compared to the control group. When starting mean arterial pressure was 
taken into account in the analysis of covariance, only the pressor response to 
angiotensin II and the initial depressor response to 0.03 nmol/kg endothelin-1 
remained significantly greater in the hypertensive group. Hamilton & Reid (1983) 
also found that there was a greater pressor response to noradrenaline in 6-to-8-week 
perinephritis hypertensive rabbits; when expressed as a percentage change, the 
difference in the pressor response was not significant. In contrast, no difference in 
the pressor response to angiotensin II between hypertensive and control rabbits was 
reported in their study. The dose range of angiotensin II in their study (0.5—5.0 
|Xg/kg) was higher than that of this study (0.0005-0.300 (Xg/kg), which was similar 
to that used in Hof & Hof (1988)’s study. Enhanced in vivo pressor responses to 
noradrenaline and angiotensin II, and the depressor response to acetylcholine, were 
also observed in the hindlimb vessels from 5-week bilateral-renal-wrapped 
hypertensive rabbits (Wright et al, 1987; Wright & Angus, 1986). Angell-James et al 
(1980) also found there were greater in vivo pressor responses to angiotensin II and 
phenylephrine in perinephritis hypertensive rabbits, although only one or two doses 
were given in that study. Enhanced in vivo pressor responses to noradrenaline and 
angiotensin II at the established phase of hypertension were also reported in other 
animal models of secondary hypertension, such as deoxycorticosterone-salt
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hypertensive rats (Finch, 1971), and pigs (Berecek & Bohr, 1978), and Goldblatt 
renal hypertensive rats (Collis & Alps, 1975).
In line with our previous findings (Huang et al, 1990), endothelin-1 (0.03-0.20 
nmol/kg) caused a dose-related increase in the pressor responses in the hypertensive 
as well as normotensive rabbits. The depressor as well as pressor responses tended to 
be higher in the hypertensive group compared to the control group. Miyauchi et al 
(1989) reported that in 12-week spontaneously hypertensive and Wistar-Kyoto rats, 
the pressor response was only significantly increased at the highest dose (2  
nmol/kg). Yokokawa et al (1990) also observed a greater pressor response to 
endothelin-1 in 6-week deoxycorticosterone-acetate-salt hypertensive rats.
In contrast to the earlier study at 2-3 weeks, the depressor responses to 
acetylcholine and isoproterenol were no longer significantly increased when analysis 
of covariance was used. It is possible that the early increase in depressor responses 
was related to changes occurring during the development of hypertension which 
were not apparent in the established phase of the disease.
Our studies showed that although there was a greater depressor response to 
isoproterenol in the hypertensive group compared to the control group, there was no 
difference in terms of chronotropic responsiveness between these two groups, again 
suggesting a discordant picture of vasodilative and chronotropic responsiveness in 
the hypertensive rabbits. No difference in chronotropic responsiveness was observed 
in the aorta-coarctation hypertensive rats (Cervoni et al, 1981), and Goldblatt renal 
hypertensive rats (Ayobe & Tarazi, 1984) as compared to their normotensive 
controls. There are few data on the in vivo depressor responsiveness to 
isoproterenol in secondary hypertension to compare with our findings of increased 
responsiveness in perinephritis hypertensive rabbits, although some in vitro strip or 
perfused vessel studies also showed an enhanced vasorelaxing response to 
isoproterenol in the developing and established phase of animal hypertension
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(Spector et al, 1969; Deragon et al, 1978; Dadkar et al, 1980).
In contrast, 6-7 weeks of cholesterol feeding, which caused plasma cholesterol 
levels to rise from 1.3 ± 0.5 to 17.6 ±8.1 mmol/L in the hypercholesterolemic group, 
had no effect on either the pressor or depressor responses in the cholesterol-fed 
rabbits as compared to the controls. W right & Angus (1986) found that the 
sensitivity ( E D ^ o f  the hindlimb vascular beds from l%-cholesterol-diet-for-4- 
week rabbits to acetylcholine was not changed. Verbeuren et al (1986) observed that 
in vitro aortic contractile responsiveness to serotonin was not changed in 0.3%- 
cholesterol-for-8-week rabbits. (We also used 0.3% cholesterol diet.) In their study, 
the relaxant response to acetylcholine was attenuated in aorta from cholesterol-fed 
rabbits, but the response in pulmonary artery was not affected. No results were 
available in Verbeuren et al’s study with regard to vascular resistance vessels, which 
may be more relevant to in vivo studies, as there is good evidence that vascular 
reactivity may be altered in large arteries from cholesterol-fed rabbits, but not in 
small arteries (Simonsen et al, 1991)
In the hypertensive-hypercholesterolemic group, there was a greater pressor 
response to angiotensin II and a greater depressor response to isoproterenol, as 
compared to the control group. The pressor responses to noradrenaline and 
endothelin-1 and the depressor responses to acetylcholine and nitroprusside, tended 
to be higher in the hypertensive-hypercholesterolemic group than those in the 
control group. The generally similar picture of the pressor as well as the depressor 
responses in the hypertensive-hypercholesterolemic group in comparison with the 
hypertensive group also strengthens our claim that only the im position of 
perinephritis hypertension altered the vascular reactivity of the rabbits, while 
cholesterol-feeding did not have any effect.
(3) At 13-16 weeks after renal wrapping operation, when the rabbits had well 
established hypertension, there were greater pressor responses to noradrenaline,
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angiotensin II, and endothelin-1 (0.1 nmol/kg), as well as a depressor response to 
acetylcholine in both the hypertensive and the hypertensive-hypercholesterolemic 
groups as compared to the control group. In addition, when starting mean arterial 
pressure was taken into account using analysis of covariance, these differences 
remained significant for both groups versus the control group. Thus as the rabbits 
progressed from the developing stage (2-3 weeks), through the established stage (6-7 
weeks), and into the long established stage (13-16 weeks), the pressor responses to 
noradrenaline, angiotensin II, and endothelin-1 in the hypertensive rabbits 
progressively diverged from those in the normotensive rabbits. As shown in Tables 
4.1 & 4.2, the degree of difference in the pressor responses increased with the 
duration of hypertension. This may, at least in part, be due to altered geometry of the 
arterial wall. It was hoped that analysis of covariance would allow for this. 
However, in Poiseuille’s law, the pressure (P) and flow (Q) are related to fourth 
power of the radius (r^), while analysis of covariance assumes a linear relationship 
between the covariate (basal mean arterial pressure) and response. It is possible that 
a linear relationship between basal mean arterial pressure and the responsiveness to 
agonists is not the most appropriate; the relationship may be more complex, although 
this was not apparent from inspection of plots of blood pressure versus response.
A progressive increase in the pressor response to noradrenaline and angiotensin II 
with increased duration of hypertension has also been observed in spontaneously 
hypertensive rats (Berecek et al, 1980a), Goldblatt renal hypertensive rats (Collis & 
Alps, 1975), and deoxycorticosterone-salt hypertensive rats (Berecek et al, 1980b). 
The presence of increased pressor responsiveness to agonists in the developing stage 
of hypertension, together with further increases as the disease progresses, may 
indicate that both "functional" and "structural" factors are im portant in the 
pathophysiological changes of hypertension.
In contrast, 13-16 weeks of cholesterol feeding, which caused the plasma
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cho leste ro l level to rise  from 1.3 ± 0.5 to 33.1 ± 10 m m ol/L in the 
hypercholesterolemic group, had no effect on either the pressor or the depressor 
responses in the cholesterol-fed rabbits as compared to the controls. This was also 
echoed in the sim ilar picture of the pressor and depressor responses in the 
hypertensive and the hypertensive-hypercholesterolemic groups. Hof & Hof (1988) 
reported that pressor responses to noradrenaline and angiotensin II were greater in 
the cholesterol-fed atherosclerotic rabbits, while the depressor response to 
acetylcholine was similar between atherosclerotic and control rabbits. On the other 
hand, Armstrong et al (1985) observed that the in vivo pressor responses to 
noradrenaline and angiotensin II in diet-induced atherosclerotic monkeys were not 
changed as compared to control animals. Chilian et al (1990) also showed that the in 
vivo pressor response to phenylephrine in the coronary resistance arteries was not 
altered in atherosclerotic monkeys. Simonsen et al (1991) reported that the vascular 
reactivity to noradrenaline, serotonin, acetylcholine, or nitroprusside was not 
changed in the resistance arteries from 12-week-1%-cholesterol-diet rabbits. Thus 
there are several reports supporting our observations that cholesterol feeding does 
not alter the vascular reactivity of the systemic or resistance vessels, despite 
induction of impressive hypercholesterolemia in the animals.
(4) The parallel increase in the pressor responsiveness (to noradrenaline, angiotensin 
II, and endothelin-1) in the hypertensive rabbits suggested that this is a generalised 
response. This finding  agrees with B erecek et al (19 8 0 b )’s resu lts  in 
deoxycorticosterone-salt hypertensive rats, and Collis & Alps (1975)s* in Goldblatt 
renal hypertensive rats. One possible common denominator for this could be the 
enhanced responsiveness of the receptor-mediated phosphoinositide pathway, but 
our results (see "Chapter 6 . Phosphoinositide Hydrolysis in Aorta from Hypertensive 
and Hypercholesterolemic Rabbits") and those of Nixon et al (1990), using the aorta 
in the same model of perinephritis hypertension, do not support this hypothesis.
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However these studies were carried out in aorta, and it remains to be investigated 
whether the resistance vessels from the hypertensive animals have generalised 
perturbations of phosphoinositide metabolism which could explain the results of the 
pressor responses. One other possible explanation for the increased pressor 
responses is that there is altered sensitivity of actin-myosin fibrils to Ca^+ occurring 
with developing hypertension, resulting in a generalised increase in the pressor 
responses.
In contrast to the pressor responses, the depressor responses did not show any 
increase with the duration of hypertension. When examining the depressor responses 
to acetylcholine the greatest increases were observed early (at 2-3 weeks) and late (at 
13-16 weeks) and it is possible that different mechanisms are involved at the 
different stages of hypertension. The discordant patterns of changes in the pressor 
responses as compared to the depressor responses with the duration of hypertension 
suggest that the structural factor is not the only mechanism for the altered vascular 
reactiv ity  in the hypertensive rabbits, and the im position of perinephritis 
hypertension could have different impacts on the contractile (phosphoinositide- 
related) processes and the relaxant (cAMP- or cGMP-related) processes.
In summary, our results showed that during the developing as well as the 
established stages of perinephritis hypertension, there were greater pressor responses 
to noradrenaline, angiotensin n, and endothelin-1, and greater depressor responses to 
acety lcho line , isopro terenol and n itroprusside . On the o ther hand, 
hypercholesterolemia and atherosclerosis induced by 0.3% cholesterol diet had no 
effect on either the pressor or the depressor responses in the rabbits throughout the 
study. Both functional and structural changes contributed to the altered vascular 
reactivity in the hypertensive rabbits.
143
CHAPTER 5
PLATELET INTRACELLULAR CALCIUM LEVELS IN 
HYPERTENSIVE AND HYPERCHOLESTEROLEMIC RABBITS
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C hapter 5. P la te le t In trace llu la r  Calcium  Levels in H ypertensive and
Hypercholesterolemic Rabbits
5.1. Introdution
5.1.1. Platelets as a model for studying intracellular calcium levels ([Ca^+]p  in 
hypertension
Changes in intra-cellular calcium concentrations ([Ca^^p are important signals 
for contraction and tension developm ent in vascular smooth muscle cells 
(Karaki,1989). Blaustein (1984) has proposed that the elevation of peripheral 
vascular resistance, which is the hallmark of primary hypertension, may be due to an
9 4 -elevation of [Csr this enhances the contractile state of the smooth muscle cells.
9 +This hypothesis has engendered efforts to measure [Ca of vascular smooth 
muscle cells in hypertension (Sada et al, 1990). However, work on vascular smooth 
muscle cells is technically more demanding and in human essential hypertension, 
almost impracticable for ethical reasons. Hence, there has been an endeavour to find 
a substitute which is easily accessible, available for multiple sampling, and reliable 
as an assay specimen. Platelets are a potential candidate because: (1) they can be 
isolated as a homogeneous specimen. (2 ) they are readily accessible and acceptable 
for multiple sampling. (3) they have some intracellular apparatus in common with 
vascular smooth muscle cells, e.g., an alpha-2 -adrenoceptor adenyl cyclase system 
and a calcium-dependent contraction-coupling mechanism (Erne et al, 1984). 
Nevertheless, some major differences exist between platelets and vascular smooth 
muscle cells. For example, voltage-dependent calcium channels, which play an 
important role in the regulation of calcium content of vascular smooth muscle cells, 
have been reported to be absent in platelets (Doyle & Ruegg, 1985). Secondly,
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platelets do not have the capacity to synthesise receptor proteins, thus may not be a 
suitable model for studying receptor regulation in response to drug challenges in 
vascular tissues (Hamilton & Reid, 1986).
5.1.2. Signalling systems for platelet activation or inhibition
There are three main second messenger systems that are involved in the activation 
or inhibition of platelets: (1) the inositol trisphosphate & diacylglycerol pathway, (2 ) 
the cAMP pathway, and (3) the cGMP pathway (Rink & Sage, 1990).
(1) Agonists that increase the production of inositol trisphosphate & diacylglycerol
9 +by way of phosphatidylinositol 4,5-bisphosphate hydrolysis, increase [Ca and 
activate platelets. Exogenous diacylglycerol, and the tumour promoter, phorbol ester, 
activate protein kinase C and stimulate a slow secretion and aggregation without 
elevating [Ca^+]j (Rink, 1983).
(2) Agonists that elevate cAMP levels suppress platelet function in response to 
stimuli (Rink & Sage, 1990), whereas alpha-2-adrenoceptor agonists that inhibit 
adenyl cyclase and decrease cAMP levels, can activate platelets (Grant & Scrutton, 
1979).
(3) Agonists such as nitroprusside that elevate cGMP cause inhibition of platelet 
responses to stimuli (Rink & Sage, 1990). Endothelium-dependent relaxing factor 
and nitric oxide have been shown to inhibit platelet aggregation and adhesion, with 
stimulation of guanylate cyclase and elevation of cGMP levels (Radomski et al,
1987).
5.1.3. Platelet [Ca^+]^  in hypertension and atherosclerotic diseases
9  +Erne et al in 1984 reported that platelet [Ca ]j was significantly higher in 
patients with essential hypertension than in normotensive controls, was significantly 
correlated with blood pressure levels, and was reduced from the elevated levels in 
hypertensive patients after treatment with anti-hypertensive drugs, correlating with 
the fall in blood pressure (Erne et al, 1984). Ever since there have been reports on 
this subject with conflicting findings. Although several groups also showed a
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9 +significantly higher platelet [Ca in hypertensive patients than in controls (Astarie 
et al, 1989; Bruschi et al, 1985; Haller et al, 1987; Pritchard et al, 1989), no
9 4 -significant difference in platelet [Ca^ between hypertensives and controls has also 
been reported (Barr & Reid, 1989; Taylor et al, 1989). Moreover, in contrast to the
9 i
strong correlation between platelet [Ca^ and blood pressure as reported by Erne 
et al (1984), recent studies have suggested either a weak correlation (Haller et al, 
1987; Lechi et al, 1988; Pritchard et al, 1989), or no correlation (Le Quan-Sang et al, 
1987; Cooper et al, 1987; Hvarfner et al, 1988) between [Ca^+]^  and blood pressure.
Studies in animal models of hypertension also gave inconsistent findings. 
Increased basal platelet [Ca^+]i in spontaneously hypertensive rats as compared to 
Wistar-Kyoto rats has been reported by some groups (Bruschi et al, 1985; Vasdev et 
al, 1988; Baba et al, 1987; Oshima et al, 1990). In contrast, Murakawa et al (1986)
9  ,
and Zimlichman et al (1986) found no differences in platelet [Ca^‘r]j between 
spontaneously  hypertensive rats and W istar-K yoto  rats. In secondary, 
experimentally-induced hypertension, such as deoxycorticosterone-acetate-salt 
hypertensive rats (Murakawa et al, 1986; Baba et al, 1987), two-kidney-one-clip 
hypertensive rats (Baba et al, 1987), and perinephritis hypertensive rabbits (Barr et 
al, 1989), no increase in platelet [Ca^+]^  has been reported.
9  ,
So far there are little data on platelet [Ca^ in hypercholesterolemic or 
atherosclerotic conditions. Nevertheless, platelet activity has been reported to be 
elevated in patients with hypercholesterolemia, hyperlipidemia, and atherosclerosis 
(For review, see Aviram & Brook, 1987).
9.
We therefore undertook to investigate basal platelet [Ca^ in hypertensive or 
hypercholesterolemic rabbits, in conjunction with studies on phosphoinositide 
hydrolysis and in vivo vascular dose response curves in these animals.
5.2. Materials and methods
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For a detailed description of the four groups of rabbits, see the "Overall Study 
Design" Chapter. At the 17th week after renal operation, an arterial line was inserted
9 4 -in the rabbit ear to collect blood for platelet [Ca^ measurement.
9 ml of blood from each rabbit was collected into 1 ml 3.8% sodium citrate.
Platelet rich plasma was prepared from the blood by centrifugation at 800 rpm, at 22
°C for 15 minutes. The platelet rich plasma was removed, and prostacyclin (PG^,
5x10'^ M) was added and incubated for 5 minutes at 37 °C to prevent activation of
platelets during centrifugation. A platelet pellet was obtained by centrifugation at
2000 rpm, at 22 °C for 15 minutes. The supernatant was discarded and the platelet
pellet resuspended in a Ca^+ free buffer (136.9 mM NaCl, 2.7 mM KCL, 2mM
M gC^, 11.9 mM NaHCO^, 5.5 mM glucose, 0.32 mM NaF^PC^, 0.35% bovine
serum albumin; pH 6.5). Quin 2-AM (20 fiM) was added and the platelet suspension
was incubated for 30 minutes at 37 °C. Five minutes before the completion of
incubation, PGI2  (5x10'^ M) was added. The platelet suspension was then separated
from any extraneous dye by centrifugation at 2000 rpm, at 22 °C for 15 minutes. The
9 4 -platelet pellet was resuspended in a Ca^ containing buffer (136.9 mM NaCl, 2.7
mM KC1, 1.3 mM CaC^, 0.5 mM M gC^, 11.9 mM NaHCC^, 5.5 mM glucose,
0.32 mM N a^P C ^ , 0.35% bovine serum albumin; pH 7.4) and incubated at 37 °C
before use. Fluorescence was measured on a Perkin-Elmer LS-3 luminescence
spectrometer with standard monochromator settings of 339 nm excitation and 492
2 4 -nm emission. Three separate aliquots of each sample was used for platelet [Ca ]j 
measurement and the mean of these was calculated.
Basal platelet [Ca^+]j was calculated from the fluorescence levels using the 
equation:
[Ca2+]i = 115 X [(F-Fmin) + (Fmax-F)],
9-i
where 115 is the dissociation constant for Quin 2-Ca complex,
F is the reading ffom the resting platelets,
FmQY is obtained by lysing the platelets with digitonin (50 fiM),
I I l d A
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Fmin is obtained (after Fmax) by chelating all the free Ca^+ with EGTA (40
mM).
Quin-2-AM ester was purchased from Lancaster Synthesis (Morecambe, UK), 
and prepared by dissolving 50mg in 7.43 ml dimethylsulphoxide (DMSO) and 
making up to 10 ml solution. Aliquots were stored at -20°C. All other laboratory 
reagents were from Sigma Chemical Co. (Poole, UK).
Analysis of variance was used to compare the platelet [Ca^+]j in the four 
groups of rabbits. All results were expressed as mean ± S.D. P < 0.05 was 
considered statistically significant
5.3. Results
As shown in Figure 5.1, there were no significant differences in basal platelet
9 +  9 +[Ca. \  between the four groups. Mean values of platelet [Ca^ in the control,
hypercholesterolemic, hypertensive, and hypertensive-hypercholesterolemic groups
were 205.0 ± 37.7, 215.3 ± 50.5, 212.2 ± 42.9, and 211.9 ± 53.1 nM respectively.
(n= 7-11)
The basal mean arterial pressure, heart rate, body weight, and plasma cholesterol 
levels at this time for each group of rabbits are shown in Table 5.1.
5.4. Discussion
Our results show that neither high blood pressure (30-40 mmHg above normal) 
nor hypercholesterolemia (> 25 mmol/L) was reflected as changes in the basal 
platelet [Ca^+]^  in rabbits four months after the cellophane wrapping or 0.3% 
cholesterol diet. Taking together our results (16-17 weeks after operation) and earlier 
results from our department (6 -8  weeks after operation) (Barr et al, 1989), we 
conclude that in the established phase of perinephritis hypertension in the rabbits, 
there is no change in basal platelet [Ca^+] j. Other forms of secondary hypertension
149
300 -i
250 -
200  -
A co
O 150 -
_(D
CD
Q_
100 -
50
0 Control Hypercholesterolemic Hypertensive
group group group
Hypcrtensive-
Hypercholesterolemic
group
Figure 5.1: Basal platelet [Ca2+]j in each group of rabbits 17 weeks after surgery 
a n d  dietary manipulation. (Mean ± S.D., n= 7-11)
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Table 5.1. Mean arterial pressure, heart rate, plasma cholesterol, and body weight at the 17th 
week when platelet [Ca was measured in each group of rabbits. (Mean ± S.D., n=13-17)
Category Control Gr. Choi. Gr. Ht. Gr. Ht-Chol. Gr.
Mean arterial pressure (mmHg) 78±5 78±5 116113* 10817*
Heart rate (bpm) 211±21 179125* 199128 180125*
Plasma cholesterol (mmol/L) 0.7±0.3 33.119.6* 0.710.3 29.5111.9*
Body weight (kg) 4.1±0.5 3.510.4* 3.510.5* 3.510.3*
* p < 0.05 vs Control group.
Abbreviations for groups: Choi. Hypercholesterolemic; H t — Hypertensive;
Ht-Chol. — Hypertensive-Hypercholesterolemic
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in animals (deoxycorticosterone-acetate-salt hypertension, and 2-kidney-1-clip
hypertension in rats) (Baba et al, 1987; Murakawa et al, 1986) also did not cause an
increase in platelet [Ca^+]^ . However, it would be interesting to see whether platelet 
2+[Ca is increased in the developing stage of secondary hypertension, for example,
during the 2nd and 3rd week after cellophane operation in our model. Or whether
9 +increased platelet [Ca ]j is only to be found in primary hypertension— in
spontaneously hypertensive rats or essentially hypertensive patients, as suggested in
some reports (Bruschi et al, 1985; Baba et al, 1987; Vasdev et al, 1988; Erne et al,
1984; Haller et al, 1987; Pritchard et al, 1989). It is also possible that platelet 
9 +[Ca does not in fact reflect hypertensive states, either primary or secondary 
(Murakawa et al, 1986; Zimlichman et al, 1986; Barr & Reid, 1989; Barr et al, 
1989).
9 +Our results also indicate that basal platelet [Ca ] j was not increased in severe 
hypercholesterolemia (> 25 mmol/L) with concurrent atherosclerotic lesions.
Although platelet activity in terms of secretion or aggregation has been reported to 
be different in hypercholesterolemic animals, there was no mention of basal platelet 
[Ca^+]j levels or relevant Ca^+ kinetics in platelets (Aviram & Brook, 1987). 
However, Strickberger et al (1988) reported that there is an increased influx of 
C a^+, namely plasm a membrane calcium perm eability, in aortic tissue in 
cholesterol-fed rabbits.
Two questions arise from these reports:
9  .
Firstly, if there is any perturbation in the Ca dynamics as well as kinetics in the 
vascular smooth cells in hypertensive and/or hypercholesterolemic states, is it 
always mirrored in platelets ?
Secondly, Ca^+ perturbation—dynamics or kinetics—may not be confined to one 
single parameter, i.e., other counter or compensatory mechanisms may also come 
into play so that the overall picture is not different under various hypertensive and/or
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hypercholesterolemic conditions. In other words, the gross normality can conceal a 
host of abnorm alities offsetting each other. Thus, whether platelet [Ca* 
measurement is a good approach or not to unravel any changes or abnormalities in 
cellular Ca^+ dynamics or kinetics in hypertension or hypercholesterolemia is open 
to question.
153
CHAPTER 6
PHOSPHOINOSITIDE HYDROLYSIS IN AORTA FROM 
HYPERTENSIVE AND HYPERCHOLESTEROLEMIC RABBITS
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Chapter 6 . Phosphoinositide H ydrolysis in Aorta from Hypertensive and
Hypercholesterolemic Rabbits
6.1. Introduction
9 4 -6.1.1. Intracellular Cer concentrations and vascular smooth muscle contraction
Contraction-relaxation cycles in vascular smooth muscle cells are largely
9 +  9 4 -dependent on changes in the intracellular Ca^ concentrations ([Ca^ ]p (Karaki,
1989). Activation of receptors by agonists may lead to release of intracellular second
9 +messengers, which in turn modulate intracellular [Ca^ levels and vascular smooth 
muscle contraction. There are three main "second messenger systems" involved in
9  i
the regulation of [Ca and thereby the contraction-relaxation of vascular smooth 
muscle cells. They are:
(1) The phosphoinositide hydrolysis system (i.e., inositol 1,4,5-trisphosphate and
1,2 -diacylglycerol system).
(2) The cAMP system.
(3) The cGMP system. (Figure 6.1) (Karaki, 1989)
Agonists such as noradrenaline can stim ulate the production of inositol
trisphosphate and diacylglycerol by way of phosphatidylinositol 4,5-bisphosphate
9 - i -hydrolysis, increase [Ca^ and cause the contraction of vascular smooth muscle 
cells.
Agonists such as isoproterenol can elevate cAMP levels in vascular smooth
9 4 -  9 - i -muscle cells, decrease [Ca as well as the Ca sensitivity of contractile
elements, and thus relax the smooth muscle (Karaki, 1989).
Agonists such as nitroprusside can elevate cGMP levels in vascular smooth
9-i_ o  I
muscle cells, decrease [Ca-6 ]j as well as Ca sensitivity of contractile elements,
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Figure 6.1: Second messenger systems involved in the contraction or relaxation of 
vascular smooth muscle cells.
(Abbreviations: AC, adenyl cyclase; ANF, atrial natriuretic factor, ER, endoplasmic 
reticulum; Gs& Gi, stimulatory and inhibitory G-proteins for adenyl cyclase, 
respectively; pGC & sGC, particulate and soluble guanylate cyclase, respectively; 
PK, protein kinase; SNP, sodium nitroprusside.) For more detailed description, see 
the text.
(Source of figure: Hamet P & Tremblay J. Cyclic nucleotides in the pathogenesis of 
hypertension. In Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, 
Diagnosis, and Management. New York: Raven Press, 1990: 617-635.)
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and cause relaxation of the smooth muscle (Karaki, 1989).
6.1.2. The phosphoinositide second messenger system in vascular smooth muscle 
contraction
Phosphoinositide hydrolysis is the most important pathway in receptor-activated 
vascular smooth muscle contraction.
In the following section, an outline of the general pattern of the phosphoinositide 
messenger system in vascular smooth cells is presented.
As shown in Figures 6.1 and 6.2, on the binding of agonists to receptors, an 
enzyme phospholipase C on the cell membrane is activated. It stimulates the 
hydrolysis of membrane phosphatidylinositol 4,5-bisphosphate into two products: 
inosito l 1 ,4 ,5 -trisphosphate  and 1 ,2 -d iacy lg lycero l. A gonists acting via 
phospholipase C include noradrenaline, angiotensin II, vasopressin, serotonin, 
endothelin, and platelet-derived growth factor (Hashimoto et al, 1986; Rapoport, 
1987; Nabika et al, 1985; Griendling et al, 1986; Roth et al, 1986; Resink et 
al, 1988; Block et al, 1990). Although G-proteins are believed to be involved as 
transducers of the external signals to the membrane phosphoinositide second 
messenger system, the identity of the G proteins remains speculative (LaBelle & 
Murray, 1990; Cheung et al, 1990; Takuwa et al, 1990; Reynolds et al, 1989). It is 
possible that more than one G protein is involved. Some research groups have 
reported  that in a -ad ren erg ic  m ediated phosphoinositide hydrolysis or 
vasoconstriction, pretreatment with pertussis toxin, which is a widely used Gj- 
protein ribosylating agent, only partially reduced the response (Berta et al, 1988; 
Liebau et al, 1989; Boonen & De May, 1990), while other groups have suggested a 
crucial role of one or more "non G^-proteins" in mediating the phosphoinositide 
hydrolysis response to noradrenaline or endothelin in vascular smooth muscle cells 
(Cheung et al, 1990; Takuwa et al, 1990; LaBelle & Murray, 1990).
The inositol trisphophate formed from phosphatidylinositol 4,5-bisphosphate
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hydrolysis then diffuses through the cytosol to bind to a receptor site on the
9 4 -endoplasmic reticulum, thereby releasing Ca stored intracellularly in the latter 
(Kowarski et al, 1985; Somlyo et al, 1985; Somlyo et al, 1988). Inositol trisphophateA
9 4 -induces a rapid, short-lived increase in [Ca and thereby a phasic contraction of 
vascular smooth muscle cells (Somlyo et al, 1985; Somlyo et al, 1988). Inositol
9 - i
trisphosphate is rapidly metabolized and the increase in [Ca is not maintained
(Hashimoto et al, 1986; Grieldling et al, 1986; Alexander et al, 1985; Takuwa et al,
s
1990; Sasaguri et al, 1985). The inosito l trisphophate binding site on the 
endoplasmic reticulum has been shown to exhibit enantiomer specificity as well as 
structural-activity relationships. D-l,4,5-trisphosphate is the most potent stimulant
9 .
for Ca release as compared to L-l,4,5-trisphosphate or other inositol trisphosphate 
analogues or inositol 1,3,4,5-tetrakisphosphate (Polokoff et al, 1988; Ehrlich &
9 4 -Watras, 1988). Some reports suggest that inositol trisphosphate-induced Ca^ 
release from the endoplasmic reticulum could be specifically inhibited by heparin 
(Ehrlich & Watras, 1988; Kobayashi et al, 1988a; Yamamoto et al, 1990) and might 
involve some guanine nucleotide-binding protein (G protein) on the endoplasmic 
reticulum for the Ca^+ release process (Kobayashi et al, 1988a; Kobayashi et al, 
1988b; Somlyo et al, 1988).
9 , o I
Thus the cytosolic Ca^ concentration ([Ca ]j) rises from approximately 0.1 
|j,M in the unstimulated state to 1-10 |iM in the agonist-stimulated state (Abdel-Latif, 
1986; Sato et al, 1988; Hirano et al, 1991). Ca^+ ions bind to calmodulin. The Ca^+- 
calmodulin complex then activates myosin light chain kinase, which in turn 
phosphorylates the myosin light chain, thus facilitating the "cross-bridging " with 
actin, and consequently initiating smooth muscle contraction (Kamm & Stull, 1989).
Inositol 1,3,4,5-tetrakisphosphate is one of the metabolic products of inositol 
1,4,5-trisphosphate (Downes & MacPhee, 1990). It has been detected in the arterial 
tissues after noradrenaline stimulation (Ollerenshaw, et al, 1988a; Pijuan & Litosch,
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1988). However, the exact role of inositol 1,3,4,5-tetrakisphosphate in the sequence
of events of vascular contraction remains to be defined, despite some speculations 
9 +about its role in [Ca^ dynamics and kinetics in other cell types (Berridge & 
Irvine, 1989).
1,2-Diacylglycerol, the other product of phosphatidylinositol 4,5-bisphosphate 
hydrolysis, remains within the cell membrane, and, in conjuction with the elevated 
[Ca2+]i; translocates the cytosolic protein kinase C to the cell membrane and thereby 
activates protein kinase C (Nishizuka, 1986; Haller et al, 1990).
It has been proposed that the activated protein kinase C performs a variety of 
functions:
(1) Activated protein kinase C has been shown to cause a slow, but sustained
contraction of vascular smooth muscle cells (Haller et al, 1990; Jiang & Morgan,
1987; Forder et al, 1985), in line with a sustained increase in diacylglycerol
production after agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis
(Griendling et al, 1986; Griendling et al,1989; Takuwa et al, 1990). It has been
suggested that protein kinase C causes tonic contraction by phosphorylating the late-
phase contractile apparatus called filamin-actin-desmin (Rassmussen et al, 1987;
Haller et al, 1990). Activated protein kinase C has also been reported to enhance the
Ca^+ sensitivity of vascular contractile proteins (Itoh et al, 1988), and vascular
1+contraction can be induced by activated protein kinase C without raising [Ca 
(Jiang & Morgan, 1987; Itoh & Lederis, 1987).
(2) Activated protein kinase C has been shown to exert an inhibitive effect on the 
subsequent phosphatidylinositol 4,5-bisphosphate hydrolysis (Roth et al, 1986; 
Brock et al, 1985; Araki et al, 1989) and vascular contraction (Danthuluri & Deth, 
1984; Khalil & Van Breemen, 1988).
9 +(3) Activated protein kinase C was found to induce an increase in Ca'6 influx from 
the extracellular space into vascular smooth muscle cells (Khalil & Van Breemen,
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Figure 6.2: Shematic picture of the phosphoinositide messenger system in vascular 
smooth muscle cells.
An agonist, e.g., noradrenaline, binds to the receptor (R) in the cell membrane 
and activates phospholipase C (PLC) via a transducer G-protein (G) and thereby 
stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP?)- The 
hydrolysis products, inositol 1,4,5-trisphosphate (IP3 ) and diacylglycerol (DAG), 
are keys to specific subsequent cellular processes. IP3 stimulates die release of Ca 
from sarcoplasmic (endoplasmic) reticulum (SR) via a specific H^-receptor protein, 
and eventually triggers muscle contraction. DAG translocates cytoplasmic protein 
kinase C (PKC) to the cell membrane and the activated PKC may phosphorylates a 
range of substrates including Na+/H+ exchange, and contractile proteins. Mitogens, 
e.g., platelet-derived growth factor (PDGF) possibly induce cell growth or 
proliferation in part via phosphoinositide second messenger pathway.
(Source of figure: Hathaway DR, March KL, Lash JA, Adam LP, & Wilensky RL. 
V ascular smooth muscle: A review of the m olecular basis of contractility. 
Circulation 1991; 83: 382-390).
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1988).
(4) Activated protein kinase C was reported to be involved in the activation of 
membrane Na+/H+ antiport and thereby cellular alkalisation (Berk et al, 1987; 
Hatori et al, 1987).
C
6.1.3. The role of the phosphinositide messenger system in mitogenecity and the
4
proliferative process of vascular smooth muscle cells
Proliferation of vascular smooth muscle is well recognized as central to the 
pathology of major vascular diseases such as hypertension and atherosclerosis 
(Schwartz et al, 1986; Mulvany & Simonsen, 1989). Studies on cellular and 
molecular responses to growth factors suggest an involvement of phosphoinositide 
hydrolysis in cell proliferation. At earlier stages of cell proliferation the following 
changes have been observed (For review , see Taylor, 1986; H eagerty & 
Ollerenshaw, 1990; Berridge, 1986):
(1) An increase in phosphoinositide turnover reflecting increased phospholipase C 
activity.
9 +(2) An increase in cytosolic Ca concentrations.
(3) Stimulation of a Na+/H+ antiport leading to an increase in cytosolic pH (namely, 
cellular alkalisation).
(4) An increase in tyrosine-specific protein kinase activity.
In cultured vascular smooth muscle cells, an enhanced cell proliferation or gene 
expression, associated with increased phosphoinositide metabolism (increase in 
[Ca^+]j, inositol trisphosphate, phospholipase C activity, or protein kinase C 
activity) could be induced with the addition of angiotensin II (Paquet et al, 1990), 
serotonin (Paquet et al, 1989), bradykinin (Paquet et al, 1989), endothelin (Muldoon 
et al, 1989), platelet-derived growth factor (Block et al, 1990), epidermal growth 
factor (Scott-Burden et al, 1989a) and low-density lipoprotein (Block et al, 1990; 
Scott-Burden et al, 1989b)
161
In cultured vascular smooth muscle cells, both phosphoinositide metabolism and 
cell proliferation rate were increased in spontaneously hypertensive rats as compared 
to Wistar-Kyoto rats, in non-stimulated (Resink et al, 1987) and more distinctively, 
in agonist-stimulated conditions (Paquet et al, 1989; Scott-Burden et al, 1989a; 
Paquet et al, 1990).
However, the phosphoinositide messenger system is not the only trigger for cell 
growth in the regulation of proliferation of vascular smooth muscle cells; the cAMP 
messenger system has also been implicated (Hamet & Tremblay, 1990).
6.1.4. Phosphoinositide metabolism in hypertension and atherosclerotic diseases
Since the phosphoinositide pathway is a common signalling system for both 
smooth muscle contraction and proliferation (See Sections 6.1.2. and 6.1.3.), much 
effort has been gone into investigating whether phosphoinositide metabolism is 
perturbed in hypertension and atherosclerotic diseases. In this regard, both vascular 
smooth muscle cells and other non-muscle cells have been employed in investigating 
the possible perturbations of phosphoinositide metabolism in hypertension or 
atherosclerotic diseases. The latter includes blood elements such as platelets, 
erythrocytes, and leukocytes, mainly because these are more easily accessible than 
vascular smooth muscle cells and they also have the phosphoinositide system present 
in the cell m em brane. In the fo llow ing section, the lite ra tu re  reports on 
phosphoinositide metabolism in hypertension and atherosclerotic diseases are 
reviewed and discussed.
6 .1.4.1. Phosphoinositide metabolism in hypertension
Studies on phosphoinositide metabolism can be broadly categorized into three 
types:
(1) On the content of the phosphoinositides in the cell membrane, namely the 
am ount of phospho tidy linosito l, p hosphatidy linosito l 4-phosphate, and
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phosphatidylinositol 4,5-bisphosphate, in the "non-stimulated" cells, measured after 
[^H] or [^ P ] radiolabelling.
(2) On the activity of membrane phospholipase C under basal, non-stimulated 
cond itions, m easured as rad io ac tiv ity  of various in o sito l phosphates or 
diacylglycerol after radiolabelling the phosphoinositides with [^H] or [^P ]; this is 
the basal rate of phosphoinositide hydrolysis.
(3) On the response of phosphoinositide hydrolysis to the challenge of agonists, 
namely the relative yield of inositol 1-monophosphate, inositol 1,4-bisphosphate, 
and inositol 1,4,5-trisphosphate or diacylglycerol after stimulation as compared to 
non-stimulated, basal states. This gives a measure of the activity of membrane 
phospholipase C in response to agonists.
(1) The content of the phosphoinositides in the membrane
A higher content of, or a h igher [ H] or [ P] inco rporation  into, 
phosphatidylinositol 4,5-bisphosphate, has been reported in (A) resistance arteries 
from 5-week spontaneously hypertensive rats (Durkin et al, 1990), (B) cultured 
vascular smooth muscle cells from 20-week spontaneously hypertensive rats (Resink 
et al, 1987), (C) erythrocytes from 12-week spontaneously hypertensive rats 
(Boriskina et al, 1978), as compared to their controls from age-matched Wistar- 
Kyoto rats. Similarly, a higher [^ P ]  incorporation into phosphatidylinositol 4,5- 
bisphosphate was found in platelets (Dimitrov et al, 1986) and erythrocytes (Marche 
et al, 1985) from patients with essential hypertension as compared to their controls 
from age-matched normotensive subjects.
In contrast, no difference in [^ P ]  incorporation into phosphatidylinositol 4,5- 
bisphosphate was observed in (A) aorta from 3-to-4-m onth spontaneously 
hypertensive rats (Ek et al, 1989), (B) platelets from 12-to- 15-week spontaneously 
hypertensive rats (Koutouzov et al, 1987), (C) platelets from patients with essential 
hypertension (Remmal et al, 1988), (D) erythrocytes from patients with essential 
hypertension (Riozzi et al, 1987), compared to their proper controls.
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To further com plicate the issue, a decreased [ ^ P ]  incorporation  into 
phosphatidylinositol 4,5-bisphosphate in primary hypertension was reported to be 
manifest at the pre-hypertensive stage, and tended to disappear at the established 
stage of hypertension (Durkin et al, 1990; Riozzi et al, 1987). Kiselev et al (1981) 
also observed that the higher incorporation of [ P] into phosphatidylinositol 4,5- 
bisphosphate in erythrocytes from 1-month spontaneously hypertensive rats was 
reversed to the opposite at 4-month of age.
In secondary, experimental hypertension, Boriskina et al (1978) found a 
significantly higher content of phosphatidylinositol 4,5-bisphosphate in erythrocytes 
from Goldblatt renal hypertensive rats, 8 weeks after operation, compared to their 
controls from Wistar-Kyoto rats.
(2) Basal, non-stimulated rate of phosphoinositide hydrolysis ( or phospholipase C 
activity)
A significantly higher rate of basal phosphoinositide hydrolysis has been reported 
in (A) aorta from 5-week spontaneously hypertensive rats (Heagerty et al, 1986), (B) 
aorta from 4-week as well as 14-week spontaneously hypertensive rats (Uehara et al,
1988), (C) renal cortex and medulla from 10-week and 40-week stroke-prone 
spontaneously hypertensive rats (Kawaguchi et al, 1987), (D) erythrocytes from 16- 
week spontaneously hypertensive rats (Tremblay et al, 1990), and (E) cultured aortic 
smooth muscle cells from 20-week spontaneously hypertensive rats (Resink et al,
1987), compared to their proper controls from Wistar-Kyoto rats.
In contrast, no difference in basal phosphoinositide hydrolysis was observed in
(A) aorta from 19-week (Heagerty et al,1986) and 3-to-4-month (Ek et al, 1989) 
spontaneously hypertensive rats, and from 4-to-8-month stroke-prone spontaneously 
hypertensive rats (Turla & Webb, 1990), (B) resistance arteries from 5-week and 12- 
week spontaneously hypertensive rats (Durkin et al, 1990), (C) cultured aortic 
smooth muscle cells from 11-week spontaneously hypertensive rats (Paquet et al,
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1989), (D) renal cortex from 13-week spontaneously hypertensive rats (Jeffries et al,
1988), (E) platelets from 12-to-15-week spontaneously hypertensive rats 
(K outouzov et al, 1988), (F) cu ltured  neurons from 1-day spontaneously 
hypertensive rats (Feldstein et al, 1986), (G) cultured fibroblasts from 10-week 
spontaneously hypertensive rats (Zhu et al, 1990), as compared to their proper 
controls from Wistar-Kyoto rats.
In secondary, experimental hypertension, the results were also divergent. A 
higher rate of basal phosphoinositide hydrolysis was observed in (A) aorta from 
aldosterone-salt hypertensive rats (3-to-4-week administration) (Jones et al, 1988),
(B) aorta of the "pressure-loaded" segment from coarctation hypertensive rats (9-to- 
20-day after operation) (Ollerenshaw et al, 1988b), (C) cardiac atria and ventricles 
(but not femoral arteries) from deoxycorticosterone-acetate-salt hypertensive rats (4- 
week administration) (Eid & de Champlain, 1988), compared to their proper controls 
from normotensive rats.
In contrast, no difference in basal phosphoinositide hydrolysis was reported in 
(A) aorta from perinephritis hypertensive rabbits (1-, 2-, & 6 -week after operation) 
(Nixon et al, 1990), (B) mesenteric (Takata et al, 1989) and femoral (Eid & de 
Champlain, 1988) arteries from deoxycorticosterone-acetate-salt hypertensive rats 
(4 -week administration), compared to their proper controls from normotensive 
animals.
(3) Response of phosphoinositide hydrolysis or phospholipase C activity to agonist 
stimulation
An increased response of phosphoinositide hydrolysis to agonist stimulation has 
been observed in (A) aorta challenged by serotonin from 20-week spontaneously 
hypertensive rats (Huzoor-Akbar et al, 1989) and 4-to-8-month stroke-prone 
spontaneously hypertensive rats (Turla & Webb, 1990), (B) resistance arteries 
stimulated by noradrenaline from 5-week and 12-week spontaneously hypertensive 
rats (Durkin et al, 1990), (C) platelets stimulated by thrombin from both 12-to-15-
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week spontaneously hypertensive rats (Koutouzov et al, 1987) and patients with 
essential hypertension (Marche et al, 1989), (D) cultured aortic smooth muscle cells 
from 11-week spontaneously hypertensive rats, stimulated by angiotensin II, 
serotonin, and bradykinin (Paquet et al, 1989; Paquet et al, 1990), and from 20-week 
spontaneously hypertensive rats, stimulated by angiotensin II, endothelin-1, and 
epidermal growth factor (Resink et al, 1989b; Resink et al, 1990; Scott-Burden et al, 
1989a), (E) cultured fibroblasts from 10-week spontaneously hypertensive rats, 
stimulated by thrombin and arginine-vasopressin (Zhu et al, 1990), compared to 
their proper controls.
In contrast, a reduced response of phosphoinositide hydrolysis (or phospholipase 
C activity) was shown in (A) aorta stimulated by noradrenaline from 5-week and 19- 
week (Heagerty et al, 1986), as well as 3-to-4-month (Ek et al, 1989), spontaneously 
hypertensive rats, (B) renal cortex stimulated by noradrenaline from 4-week and 13- 
week spontaneously hypertensive rats (Jeffries et al, 1988), (C) cultured neurons 
stimulated by noradrenaline from 1-day spontaneously hypertensive rats (Feldstein 
et al, 1986), compared to their proper controls.
In secondary, experim ental hypertension , an increased  response of 
phosphoinositide hydrolysis was reported in (A) aorta and femoral arteries 
stimulated by noradrenaline from perinephritis hypertensive rabbits (2 -week, but not 
1-week or 6 -week after operation) (Nixon et al, 1990), (B) aorta (Takata et al, 1989), 
or cardiac atria and ventricles, and femoral arteries (Eid & de Champlain, 1988), 
stimulated by noradrenaline from 4-week-treated deoxycorticosterone-acetate-salt 
hypertensive rats, or cardiac atria and mesenteric arteries stimulated by endothelin-1 
or noradrenaline (de Cham plain et al, 1989) from 3-w eek-treated  
deoxycorticosterone-acetate-salt hypertensive rats, (C) aorta stimulated by 
noradrenaline from 3-to-4-week-treated aldosterone-salt hypertensive rats (Jones et 
al, 1988), compared to their proper controls.
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In contrast, no change in the response of phosphoinositide hydrolysis was 
observed in (A) aorta stimulated by endothelin-1 from 2-week-after-operation 
perinephritis hypertensive rabbits (in contrast to the results from noradrenaline 
stimulation) (Nixon et al, 1990), (B) platelets stimulated by thrombin from 6-to-7- 
week-treated deoxycorticosterone-acetate-salt hypertensive rats (Limon et al, 1990), 
as compared to their proper controls.
From the results surveyed above, some points are worthy of note:
(1) Changes in phosphoinositide metabolism may differ with regard to the stage of 
hypertension (Durkin et al, 1990; Heagerty et al, 1986; Nixon et al, 1990).
(2) Changes in phosphoinositide metabolism may differ with regard to different 
tissues examined (Eid & de Champlain, 1988) and even differ between aorta and 
resistance arteries (Heagerty et al, 1986; Durkin et al, 1990).
(3) Changes in phosphoinositide metabolism may differ with regard to the agonists 
used for stimulation (Nixon et al, 1990; Zhu et al, 1990).
(4) Changes in phosphoinositide metabolism may differ with regard to different 
models of hypertension (Limon et al, 1990).
(5) Changes in phosphoinositide metabolism may differ with regard to the presence 
or absence of agonist stimulation (Durkin et al, 1990; Nixon et al, 1990; Turla & 
Webb, 1990; Paquet et al, 1989).
6 .1.4.2. Phosphoinositide metabolism in hypercholesterolemic or atherosclerotic 
states
In contrast to the published reports on phosphoinositide m etabolism  in 
hypertension , little  is known about phosphoinositide m etabolism  in 
hypercholesterolemic or atherosclerotic states.
W inocour et al (1990) reported  that there was a s ign ifican tly  higher 
phospho inositide  hydrolysis in th rom bin-stim ulated  p la te le ts  from 
hypercholesterolemic rats than normocholesterolemic rats. Moreover, a similar
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conclusion was drawn whether the hypecholesterolem ia was "genetically- 
determined" or "diet-induced".
In summary, there is a considerable body of evidence suggesting that alterations 
in phosphoinositide metabolism may occur in cardiovascular diseases. However, 
controversy exists with different results reported depending on the experimental 
models, the parameters examined, the agonists used, and the duration or severity of 
the disease state. We have therefore included an investigation into phosphoinositide 
metabolism in our studies on hypertension and hypercholesterolemia in the rabbits. 
Phosphatidylinositol 4,5-bisphosphate hydrolysis in response to two very different 
agonists, noradrenaline and endothelin-1, was examined.
6.2. Materials and methods
For a detailed description of the four groups of rabbits, see the "Overall Study 
Design" chapter. At the 18th week after renal operation, the rabbits were killed by 
intravenous injection of sodium pentobarbitone (60 mg/kg). The thoracic and 
abdominal aorta were isolated immediately and cleared of adherent connective tissue 
and then washed for 10 minutes X 3 times in Krebs Ringer bicarbonate buffer 
(KRB) solution, at 37 °C with continuous bubbling of 95% C>2/5 % CO^  (KRB 
composition: NaCl 118.3 mM, KC1 4.7 mM, CaCl2  0.5 mM, MgSO^ 1.2 mM, 
KH2 PO4  1.2 mM, NaHC0 3  25.0 mM, glucose 11.1 mM, myoinositol 0.1 mM, 
bovine serum albumin 1.5%; pH 7.4) The tissue was incubated for a further 10 
minutes in another KRB solution containing 10 mM LiCl and 2 jiM imipramine. 
Afterwards the aorta was put on a Mcllwan tissue chopper and cut into 1 mm rings. 
5 Thoracic and 4 abdominal rings were weighed and put into each tube (except blank 
tubes) for incubation. The incubation medium was 0.3 ml KRB solution containing 
10 mM LiCl (inhibiting the breakdown of inositol-1-monophosphate) and 2 pM
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imipramine (blocking the neuronal uptake of noradrenaline) and 0.5 p Ci [^H]- 
myoinositol (Amersham International, Amersham, U.K.). The tubes were incubated 
at 37 °C under an atmosphere of 95% 5% CC>2 for 3.5 hours. Then agonists
(noradrenaline 10“*\ 10“^, & 10"^ M; endothelin-1 10'^, 10"^, & 10"^ M) were 
added as appropriate. Noradrenaline was prepared in 0.1 % ascorbic acid solution.
0.1% Ascorbic acid solution was added into blank and control tubes, which gave a 
measure of radioactivity in blanks and basal inositol phosphates formation, 
respectively. Tubes were incubated for a further 30 minutes. At the end of 
incubation, 2 ml of methanol: chloroform: hydrochloric acid (40:20:1, v/v) was 
added into each tube. Tubes were sonicated for 45 minutes. More chloroform (0.63 
ml) and distilled water (1.26 ml) was added to form two layers. The tubes were 
centrifuged at 2500 rpm for 10 minutes. 2 ml of aqueous (upper) phase was removed 
and the pH adjusted to between 6.8  and 7.2. This aqueous phase, which contained 
inositol mono-, bis-, and tris- phosphates, was then passed through a 1 ml Dowex 
anion-exchange resin column (Dowex 1-X8 resin, 100-200 mesh, formate form, pH 
4.0-5.0). 15 ml of unlabelled myoinositol (5 mM) was run through the column to 
wash away extraneous [^H -myoinositol. Finally, 2 ml of 1 M ammonium formate in
'i
0.1 M formic acid was added to elute all the rH]-inositol phosphates. The elute was 
collected in scintillation vials and 15 ml scintillant added. [ H]-Inositol phosphates 
formation was counted by a liquid scintillation counter.
Basal [^H]-inositol phosphates formation is calculated as counts/min per mg of 
tissue weight. Stimulated [^H]-inositol phosphates formation was calculated as a 
percentage of basal values.
Endothelin-1 was purchased from Scientific Marketing (Barnet, U.K.). All other 
reagents unless specified were from Sigma Chemical Co. (Poole, U.K.).
Between-group comparisons were carried out using repeated measures analysis of 
variance for each agonist. All results were expressed as Mean ± S.D. p< 0.05 was 
considered statistically significant.
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6.3 Results
(1) Tissue weights
As shown in Table 6.1, tissue weights (5 thoracic and 4 abdominal aortic rings, 1 
mm width each) were significantly higher in the hypercholesterolemic as well as the 
hypertensive-hypercholesterolemic groups than in the control group. The mean 
tissue weights were also higher in the hypertensive group than in the control group, 
but the difference did not reach significance.
(2) Basal [^H]-inositol phosphates formation
a
There was no difference in basal [JH]-inositol phosphates formation per mg of 
tissue weight between the four groups. (Table 6.1)
(3) [^H]-Inositol phosphates formation by noradrenaline
'l
As shown in Figure 6.3, there was a dose-related increase in [JH]-inositol 
phosphates formation in response to noradrenaline (10"^ - 10"^ M) in each group.
The stimulation tended to be higher in each renal operated group than its 
normotensive counterpart, but the difference only reached significance for the 
hypertensive group vs the control group at 10“^  M noradrenaline.
The stimulation tende to be lower in each cholesterol-fed group than its normal- 
diet counterpart, and this difference reached significance for both the control group 
vs the hypercholesterolemic group, and the hypertensive group vs the hypertensive- 
hypercholesterolemic group at 10"^ M noradrenaline.
(4) [^H]-Inositol phosphates formation stimulated by endothelin-1
a
As shown in Figure 6.4, there was a dose-related increase in [^H]-inositol 
phosphates formation in response to endothelin-1 (10'^ -10"^ M) in each group.
There was no statistical difference in the [^H]-inositol phosphates formation in 
response to endothelin-1 between each renal operated group and its normotensive 
counterpart.
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Table 6.1. Tissue weights and basal [^H]-inositol phosphates ([^H]-IPs) formation in aortic (5 
thoracic & 4 abdominal) rings in each group of rabbits. (Mean ± S.D., n=6-8)
Category Control Gr. Choi. Gr. Ht. Gr. Ht-Chol. Gr.
Tissue weight (mg) 31.2±3.6 52.6±12.9* 40.4±7.2 56.8110.21
Basal [^H]-IPs/tissue weight 
(cpm/mg)
36.7±8.6 38.01:7.9 29.0±3.5 36.3±5.3
* p < 0.05 vs Control group.
Abbreviations for groups: Choi. Hypercholesterolemic; Ht. — Hypertensive;
Ht-Chol. — Hypertensive-Hypercholesterolemic
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Figure 6.3: Noradrenaline-stimulated [^H]-inositol phosphates formation in each 
group of rabbits 18 weeks after surgery and dietary manipulation.
(Mean ± S.D., n= 7-11. * p < 0.05 versus control group; # p < 0.05 Hypertensive 
group versus Hypertensive-Hypercholesterolemic group.)
□  Control group.
A  Hypercholesterolemic group.
A  Hypertensive group.
#  Hypertensive-Hypercholesterolemic group.
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Figure 6.4: Endothelin-1-stimulated [3H]-inositol phosphates formation in each 
group of rabbits 18 weeks after surgery and dietary manipulation.
(Mean ± S.D., n= 6-10. # p < 0.05 Hypertensive group versus Hypertensive- 
Hypercholesterolemic group.)
□  Control group.
A  Hypercholesterolemic group.
♦  Hypertensive group.
#  Hypertensive-Hypercholesterolemic group.
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The stimulation tended to be lower in each cholesterol-fed group than its normal- 
diet counterpart, but the difference reached significance only for the hypertensive 
group vs the hypertensive-hypercholesterolemic group at 10“^  & 10'^ M endothelin- 
1.
6.4. Discussion
Our results show that there was no difference in the basal [J H ]-inositol 
phosphates formation in the aorta from any experimental group as compared to the 
control group, suggesting that neither perinephritis hypertension nor 0.3% 
cholesterol diet for 18 weeks had any effect on the basal metabolism of aortic 
membrane phosphoinositides. No difference in the basal phosphoinositide hydrolysis 
was also observed in aorta from 1-, 2 -, or 6 -week perinephritis hypertensive rabbits 
versus their proper controls (Nixon et al, 1990).
The greater tissue weights in the two cholesterol-fed groups as compared to the 
control group were echoed in the picture of severe fatty depositions in the aorta of 
these two groups visualized by Sudan Red staining. (See Colour Plates 1 to 8)
Our results also showed that there was a dose-related increase in [^H]-inositol 
phosphates formation in response to noradrenaline and endothelin-1 in each group of 
rabbits. Severe hypercholesterolemia (> 25 mmol/L at 18th week of study) tended to 
attenuate the [^H]-inositol phosphates formation in response to noradrenaline as well 
as endothelin-1. However, hypertension (30-40 mmHg above normal at the 18th
'i
week of study) tended to increase [^H J-inositol phosphates form ation by 
noradrenaline, but not endothelin-1. The divergent picture of [^H]-inositol 
phosphates formation by noradrenaline and by endothelin-1 in perinephritis 
hypertension has also been shown by Nixon et al (1990) when earlier stages of 
hypertension were examined (1 to 6  weeks after renal operation as compared to 18 
weeks in this study). Nixon et al observed no difference in endothelin-1-stimulated
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[JH]-inositol phosphates formation between hypertensive and normotensive rabbits, 
whereas noradrenaline-stimulated [JH]-inositol phosphates formation was higher in 
hypertensive rabbits, especially at 2 weeks after renal operation. One explanation for 
this difference between endothelin-1 and noradrenaline is that, although both 
stimulate phosphoinositide hydrolysis, their receptor-coupling processes for the 
hydrolysis of phosphatidylinositol 4,5-bisphosphates may not be the same. In other 
words, noradrenaline and endothelin -1 may act via different isoenzymes of 
phospholipase C or transducer G proteins, and perinephritis hypertension might have 
differential effects on these phospholipase C isoenzymes or transducer G proteins. 
Ashkenazi et al (1989) reported that functionally distinct G proteins selectively 
coupled different receptors to phosphoinositide hydrolysis in the same cell. Different 
patterns of second messenger mobilization from the phosphoinositide messenger 
system by different agonists have also been shown in vascular smooth muscle cells 
(Kawahara et al,1988; Haller et al, 1990). Similarly, Zhu et al (1990) found that 
among agonists capable of stimulating phosphoinositide hydrolysis, some caused 
significantly greater phosphoinositide hydrolysis in fibroblasts from spontaneously 
hypertensive rats than in Wistar-Kyoto rats, while others caused a similar degree of 
stimulation in the two groups.
Enhanced noradrenaline-stimulated [JH]-inositol phosphates formation in aorta 
or arteries from secondary hypertensive animals has also been reported by others, 
mostly using the model of deoxycorticosterone-acetate-salt hypertensive rats (Jones 
et al, 1988; Eid & de Champlain, 1988; Takata et al, 1989; de Champlain et al,
1989). However, while de Champlain et al (1989) found a significantly greater 
stimulation of phosphoinositide hydrolysis by both noradrenaline and endothelin-1 
in mesenteric arteries from deoxycorticosterone-acetate-salt hypertensive rats, in this 
study and that of Nixon et al (1990) a greater stimulation by noradrenaline, but not 
endothelin-1 , in aorta from perinephritis hypertensive rabbits was observed. 
Differences in species, mode of hypertension, and tissue location may contribute to
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this difference, as reviewed in the Introduction Section of this chapter.
The attenuation of agonist-induced [J H]-inositol phosphates formation in 
hypercholesterolemic rabbits was surprising. However there are a few possible 
explanations:
(1) Hypercholesterolemia induced atherosclerotic lesions in the rabbit aorta, such 
that there was an increased structural barrier to agonists approaching receptor sites in 
the cell membrane. Indeed, the tissue weights of aortic rings from cholesterol-fed 
groups were 40-70% higher than their normal-diet counterparts. However, the [%!]- 
inositol uptake of the aortic muscle cells appeared to be un-impaired, since there was 
no decrease in basal [JH]-inositol phosphates formation in the cholesterol-fed 
groups. It is not known how much the fatty depositions contributed to the 40-70% 
increase in aortic weights from cholesterol-fed groups. It would be interesting to 
measure the dry weight of the aortic tissue (we only measured wet weight) and also 
extract the lipid from the aortic tissue in order to calculate the "fatty component" and 
compare this with the "smooth muscle cells and connective tissue content" of the 
vessels. More detailed knowledge of the changes in tissue composition of vessels 
from the hypercholesterolemic animals would provide further insights into the 
mechanisms behind the biochemical abnormalities observed.
(2) Hypercholesterolemia may alter some part of the receptor-coupling apparatus of 
the phosphoinositide messenger system in the aortic muscle membrane, such that the 
phosphoinositide messenger system became less responsive to agonist challenge. 
Alteration of membrane calcium channels by cholesterol enrichment of the cell 
membrane has been reported in rabbit arterial smooth muscle (Bialecki & Tulenko,
1989). Changes in adrenergic receptor number in aorta or myocardium from 
"cholesterol-fed" rabbits has also been observed (Nanda & Henry, 1982; Tsuji et al, 
1987). A decrease in receptor number could lead to decreased receptor activation 
and stimulation of phosphoinositide hydrolysis.
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In our study, hypercholesterolemia and hypertension had opposing effects on the 
agonist-stimulated [H]-inositol phosphates formation, with hypercholesterolemia 
attenuating, and hypertension augmenting or not changing, the hydrolysis of 
phosphatidylinositol 4,5-bisphosphates. Although smooth muscle proliferation is a 
common essential feature of both hypertension and atherosclerosis, there are also 
important differences between these two pathologenetic processes:
(1) The main pathological changes inflicted by hypertension are in the "medial" 
layer of the artery, whereas those inflicted by hypercholesterolemia are in the 
"intimal" layer (Mulvany & Simonsen, 1989).
(2) Hypercholesterolemia can cause pervasive lipid deposition intracellularly or 
extracellularly in the artery, while hypertension alone rarely causes lipid deposition 
without the concurrence of hypercholesterolemia (Chobanian, 1990).
These differences in pathogenesis of hypercholesterolemia and hypertension may 
contribute to the discrepancies in effects on the agonist-stimulated [JH]-inositol 
phosphates formation in our hypertensive and hypercholesterolemic rabbits.
Thus, although hypercholesterolemia and hypertension may have additive effects 
on the extent of atherosclerotic lesion development (McGill et al, 1985), their 
respective effects on the agonist-stimulated phosphoinositide hydrolysis were not 
additive in our study. The assumption of synergism between hypertension and 
hypercholesterolemia on the pathogenesis of vascular lesions deserves qualification 
and further investigation.
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CHAPTER 7 
GENERAL DISCUSSION AND CONCLUSION
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Chapter 7. General Discussion and Conclusion
Both hypertension and hypercholesterolemia are important risk factors for 
cardiovascular disease. The aim of this study was to investigate potential sites of 
interaction between these two pathogenetic processes.
In the course of the study, the following observations were made:
1. The imposition of perinephritis hypertension in New Zealand white rabbits caused 
an increase of about 40 mmHg in mean arterial pressure in the operated rabbits, 
which stabilized after 6-7 weeks. The feeding of 0.3% cholesterol diet induced a 
continual rise in plasma cholesterol in the rabbits, which reached 30 mmol/L after 4 
months. Perinephritis hypertension did not change the plasma cholesterol profile in 
the rabbit, and 0.3% cholesterol feeding did not have any effect on mean arterial 
pressure.
2. After 18-weeks cholesterol feeding, heavy fatty deposition on the aortic intimal 
surfaces was observed in the treated rabbits by the Sudan Red staining technique. 
This was echoed in the significantly greater tissue weight in the aorta from both 
cholesterol-fed groups than the control group. In contrast, there was little or no 
Sudan Red staining in either the hypertensive or the control group. The fatty 
depositions appeared to have no effect on mortality.
3. In contrast to 0.3% cholesterol feeding, perinephritis hypertension was a 
significant risk factor for cardiovascular deaths in the course of a 4-month study, as 
there were significantly greater numbers of cardiovascular deaths in both the 
hypertensive and the hypertensive-hypercholesterolemic groups versus the control 
group, but no significant difference between the hypercholesterolemic and the 
control group, or between the hypertensive-hypercholesterolem ic and the
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hypertensive group. Nevertheless, when the hypertensive-hypercholesterolemic group 
was compared to the hypertensive group, 0.3% cholesterol feeding tended to 
enhance the cardiovascular deaths in these hypertensive animals, although this was 
not statistically significant with the sample size used.
4. The imposition of perinephritis hypertension enhanced the in vivo pressor 
responses to noradrenaline, angiotensin II, and endothelin-1, as well as the depressor 
responses to acetylcholine, isoproterenol, and nitroprusside at 2-3, 6-7, and 13-16 
weeks of study. The differences tended to increase with the duration of hypertension 
for the pressor responses, but not for the depressor responses. The patterns of 
changes in the duration of hypertension differed from one pressor agonist to another, 
suggesting that the structural thickening in the vessel wall was not the sole 
explanation for enhanced vascular reactivity. Similar conclusions held for the 
depressor agonists. In contrast, the imposition of 0.3% cholesterol diet had no effect 
on the in vivo vascular reactivity at any time point of the study. The difference in 
vascular reactivity changes between hypertension and hypercholesterolemia could be 
partly  due to the d ifferen t p red ilection  sites for the two disease states, as 
experimental hypertension induces pathological changes in the resistance as well as 
conduit vessels, and hence changes in pressor and depressor responses. Experimental 
hypercho lestero lem ia, on the o ther hand, induces patho log ical changes 
predominantly in the aorta, and thus may not affect the pressor and depressor 
responses which are determined mainly by the resistance vessels rather than the 
aorta.
5. Neither perinephritis hypertension nor 0.3% cholesterol feeding caused any
9 4 -changes in the basal platelet [Ca'*' at the 17th week of study. However, 
measurement of the basal platelet [Ca^+]^  may not be a good model for the vascular
180
smooth muscle cells in the disease states. Other parameters of platelet activity, such
9  +as aggregation, adhesion, or [Ca^ changes in response to agonist stimulation, 
could be studied to clarify this matter in relation to the disease states.
6 . Perinephritis hypertension tended to enhance the noradrenaline-stimulated, but not 
the endothelin-1-stimulated phosphoinositide hydrolysis in the rabbit aorta, while
0.3% cholesterol feeding tended to decrease both noradrenaline- and endothelin-1- 
stim ulated, phosphoinositide hydrolysis, at the 18th week of study. Thus, 
hypertension and hypercholesterolemia tended to oppose, rather than augment, each 
other in terms of phosphoinositide hydrolysis stimulation. The discrepant picture of 
noradrenaline- vs endothelin- stimulated phosphoinositide hydrolysis in perinephritis 
hypertensive rabbits suggests that, although both agonists can stim ulate 
phosphoinositide hydrolysis, their receptor-coupling processes may not be the same. 
It remains to be studied whether noradrenaline and endothelin may act via different 
isoenzymes of phospholipase C or transducer G proteins; perinephritis hypertension 
might have differential effects on these phospholipase C isoenzymes or transducer G 
proteins. Although only the aorta was investigated in our study, it would be 
interesting to investigate the phosphoinositide hydrolysis in other vessels, such as 
the resistance arterioles, to see whether either disease state causes more distinct 
changes in phosphoinositide metabolism in these vessels.
a
There was no difference in the basal rH]-inositol phosphates formation between 
any experimental group and the control group, suggesting that neither perinephritis 
hypertension nor 0.3% cholesterol feeding for 18 weeks altered the basal 
phosphoinositide metabolism in rabbit aorta.
7. Overall, perinephritis hypertension caused increases in cardiovascular deaths, in 
the pressor as well as depressor responses, and the noradrenaline-stimulated 
phosphoinositide hydrolysis. In contrast, 0.3% cholesterol feeding with consequent
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hypercholesterolemia decreased the agonist-stimulated phosphoinositide hydrolysis, 
but had little effect on all other parameters.
Overall, no evidence of interactions was observed in any of the parameters 
examined between perinephritis hypertension and 0.3% cholesterol feeding. 
Questions remain whether sites of interaction, if any, could exist in other vascular 
beds such as coronary or cerebral vessels, which are the predilection sites for 
cardiovascular events. Moreover, we only studied one of the second messenger 
systems, i.e., the phosphoinositide messenger system. Further investigation in these 
animals into the other messenger systems such as the cAMP and cGMP systems in 
these disease states could be useful, as it has been reported that these second 
m essenger system s can be perturbed  in o ther m odels o f hypertension or 
hypercholesterolemia.
8 . There is much evidence that the endothelium-dependent relaxation in conduit and 
resistance arteries is im paired in disease states such as hypertension and 
atherosclerosis. However, we were unable to show any impairment in responses to 
acetylcholine in rabbits with perinephritis hypertension. Recently, it has been 
suggested that enhanced "endothelium-dependent contraction" may be involved in 
the functional impairment of the vascular endothelium in these disease states. Since 
the discovery of endothelin-1, one of the endothelium-derived contracting factors, 
and later on, reports of hypertensive patients with "endothelin-secreting tumours", 
and increased plasma concentrations of endothelin-1 in patients with essential 
hypertension and vasospastic diseases, it has been speculated that endothelin-1 might 
be one of the keys to these pathologically vasotonic states. Our work on endothelin-1 
showed that intravenous injection of endothelin-1 caused a greater pressor response 
in vivo in the perinephritis hypertensive rabbits as compared to the control rabbits, in 
line with other reports of increased pressor responses in various models of
182
hypertension. The mechanisms and significance of these observations in the 
pathophysiology of hypertension remains to be clarified.
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APPENDIX: Publications and presentations containing the work undertaken for this 
thesis.
1. Huang Y-T, Hamilton CA, & Reid JL. Endothelin stimulates phosphatidylinositol 
hydrolysis in rat vascular smooth muscles. J Hypertens 1989; 7: 703-705.
2. Huang Y-T, Hamilton CA, & Reid JL. Endothelin stimulates phosphatidyl inositol 
hydrolysis in rat aorta. Br J Pharmacol 1989; 97 (Proc Suppl): 530P.
3. Huang YT, Hamilton CA, Howie CA, & Reid JL. Responses to endothelin in 
hypertensive rabbits. Br J Pharmacol 1990; 101 (Proc Suppl): 509P.
4. Huang YT, Hamilton CA, & Reid JL. "Endothelin stimulates phosphatidylinositol 
hydrolysis in rat aorta." —presented as a poster (No. 57) in the main programme of the 
Fourth European Meeting on Hypertension, Milan, Italy, 1989.
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